Aryl-phenyl-sulfonamide-phenylene compounds and their use by University of Aberdeen.Medical Sciences et al.
1 11111 11111111 11 IIIIII IIIII 11111 11111 11111 11111 11111 11111 11111 11111 11111 111111 1111 1111 1111 
US 20110190302Al 
(19) United States
(12) Patent Application Publication
Greig et al. 
(10) Pub. No.: US 2011/0190302 Al
(43) Pub. Date: Aug. 4, 2011 
(54) ARYL-PHENYL-SULFONAMIDE-
PHENYLENE COMPOUNDS AND THEIR USE
(75) Inventors: Iain Robert Greig, Aberdeenshire 
(GB); Rose Mary Sheridan, 
Northchurch (GB); Raymond 
Fisher, High Peak (GB); Matthew 
John Tozer, High Peak (GB); Juha 
Andrew Clase, High Peak (GB); 
Andrew Smith, High Peak (GB); 
Andrew Robert Tuffnell, High 
Peak (GB); Robert Jurgen Van 't 
Hof, Lothian (GB) 
(73) 
(21) 
(22) 
(86) 
Assignee: 
Appl. No.: 
PCTFiled: 
PCTNo.: 
§ 371 (c)(l),
PIMCO 2664 LIMITED, London 
(GB) 
13 /063,950 
Sep.18,2009 
PCT /GB2009/002223 
(2), ( 4) Date: Mar. 1 5, 2011 
Related U.S. Application Data 
(60) Provisional application No. 61/098,275, filed on Sep.
19, 2008.
(30) Foreign Application Priority Data
Sep. 19, 2008 (GB) ................................... 0817208.2 
Publication Classification 
(51) Int. Cl.
A61K 31/5375
C07C 311/21
C07D 303/36
C07D 295/135
(2006.01) 
(2006.01) 
(2006.01) 
(2006.01) 
C07C 255/58 (2006.01) 
C07D 263/14 (2006.01) 
A61K 31/18 (2006.01) 
A61K 31/245 (2006.01) 
A61K 31/196 (2006.01) 
A61K 31/336 (2006.01) 
A61K 31/421 (2006.01) 
A61P 29/00 (2006.01) 
A61P 19/02 (2006.01) 
A61P 17/06 (2006.01) 
A61P 11100 (2006.01) 
A61P 9/10 (2006.01) 
A61P 35/00 (2006.01) 
A61P 35/02 (2006.01) 
A61P 19/08 (2006.01) 
A61P 19/10 (2006.01) 
(52) U.S. Cl . .......... 514/239.5; 564/92; 560/12; 562/430; 
(57) 
549/551; 544/159; 558/413; 548/232; 514/604; 
514/535; 514/562; 514/475; 514/602; 514/376 
AB STRACT 
The present invention pertains generally to the field of thera­
peutic compounds, and more specifically to certain aryl-phe­
nyl-sulfouamido-phenylene eompounds of the following for­
mula (I) ( collectively referred to herein as "APSAP 
compounds"). The present invention also pertains to phamia­
ceutical compositions comprising such compounds, and the 
use of such compounds and compositions, both in vitro and in 
viva, in treatment, for example, of inflammation and/or joint 
destruction and/or bone loss; of disorders mediated by exces­
sive and/or inappropriate and/or prolonged activation of the 
immune system; of inflammatory and autoimmune disorders, 
for example, rheumatoid arthritis, psoriasis, psoriatic arthri­
tis, chronic obstructive pulmonary disease (COPD), athero­
sclerosis, inflammatory bowel disease, ankylosing spondyli­
tis, and the like; of disorders associated with bone loss, such 
as bone loss associated with excessive osteoclast activity in 
rhemnatoid arthritis, osteoporosis, cancer-associated bone 
disease, Paget's disease and the like, etc.; and of cancer, such 
as a haematological malignancy, a solid tumour, etc. 
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ARYL-PHENYL-SULFONAMIDE-PHENYLENE 
COMPOUNDS AND THEIR USE 
RELATED APPLICATIONS 
(0001] This application is related to U.S. provisional patent 
application No. 61/098,275 filed 19 Sep. 2008 and United 
Kingdom patent application number 0817208.2 filed 19 Sep. 
2008, the contents of both of which are incorporated herein by 
reference in their entirety. 
TECHNICAL FIELD 
[0002] The present invention pertains generally to the field 
of therapeutic compounds, and more specifically to certain 
aryl-phenyl-sulfonamido-phenylene compounds ( collec­
tively referred to herein as "APSAP compounds"). The 
present invention also pertains to pharmaceutical composi­
tions comprising such compounds, and the use of such com­
pounds and compositions, both in vitro and in vivo, in treat­
ment, for example, of inflanllllation and/or joint destruction 
and/or bone loss; of disorders mediated by excessive and/or 
inappropriate and/or prolonged activation of the immune sys­
tem; of inflammatory and autoimmune disorders, for 
example, rheumatoid arthritis, psoriasis, psoriatic arthritis, 
chronic obstructive pulmonary disease (COPD), atheroscle­
rosis, inflammatory bowel disease, ankylosing spondylitis, 
and the like; of disorders associated with bone loss, such as 
bone loss associated with excessive osteoclast activity in 
rheumatoid arthritis, osteoporosis, cancer-associated bone 
disease, Paget's disease and the like, etc.; and of cancer, such 
as a haematological malignancy, a solid tumour, etc. 
BACKGROUND 
[0003] A number of patents and publications are cited 
herein in order to more fully describe and disclose the inven­
tion and the state of the art to which the invention pertains. 
Each of these references is incorporated herein by reference 
in its entirety into the present disclosure, to the same extent as 
if each individual reference was specifically and individually 
indicated to be incorporated by reference. 
[0004] Throughout this specification, including the claims 
which follow, unless the context requires otherwise, the word 
"comprise," and variations such as "comprises" and "com­
prising," will be understood to imply the inclusion of a stated 
integer or step or group of integers or steps but not the exclu­
sion of any other integer or step or group of integers or steps. 
[0005] It must be noted that, as used in the specification and 
the appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a pharmaceutical 
carrier" includes mixtures of two or more such carriers, and 
the like. 
(0006] Ranges are often expressed herein as from "about" 
one particular value, and/or to "about" another particular 
value. When such a range is expressed, another embodiment 
includes from the one particular value and/or to the other 
particular value. Similarly, when values are expressed as 
approximations, by the use of the antecedent "about," it will 
be understood that the particular value fom1s another embodi­
ment. 
[0007] This disclosure includes information that may be 
usefol in understanding the present invention. It is not an 
admission that any of the infomiation provided herein is prior 
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art or relevant to the presently claimed invention, or that any 
publication specifically or implicitly referenced is prior art. 
Rheumatoid Arthritis 
[0008] Rheumatoid arthritis (RA) is a chronic inflamma­
tory disease characterised by painfol swelling, stiffness, loss 
of movement and the destruction of cartilage and bone. RA is 
characterised by an inflanllllation of the synovial lining of 
multiple joints and commonly affects the joints of the wrist 
and hands and may also affect the elbows, shoulders, hips, 
neck and knees; the ultimate hallmark of RA is joint destruc­
tion. RA is a common disease, estimated to affect up to 1 % of 
adults in the developed world, with women more than twice 
as likely to be affected and over 30% of patients likely to 
become severely disabled within 20 years (see , e.g., Feld­
mann et al., 2006). RA is one of the most important causes of 
disability in the western world and is associated with a sig­
nificant reduction in quality of life as well as increased mor­
tality if left untreated. The disease can start at any age, with 
individuals aged between 40 and 70 most commonly affected. 
[0009] The exact cause of RA remains unclear, but is highly 
complex and may involve the combination of a number of 
factors which lead to the development of autoantibodies, 
formation of immune complexes, production of pro-inflam­
matory cytokines, angiogenesis and eventual bone and carti­
lage loss (see, e.g., Klareskog et al, 2006; Ziff et al, 1990; 
Weissmmm et al, 2006; Firestein et al, 2005). These factors 
include an abnonnal immune response caused by reduced self 
tolerance or a biological trigger such as reaction to environ­
mental factors, infectious agents, or hormonal stimulus (see, 
e.g., Klareskog et al, 2006); antibodies to the Fe fragment of
IgG, known as rheumatoid factor, are present in 60-80% of
adults with RA (see, e.g., Weissmallll et al, 2006) but it is not
known whether this factor is responsible for initiating the
inflmnmatory cascade or is generated at a later stage and
propagates the process (see, e.g., Weissmam1 et al, 2006);
there is also a notable genetic predisposition to the disease, as
shown by the presence of HLA-DR4 m1tibody in 70% of
patients (see, e.g., Klareskog et al, 2006).
(0010] At the cellular level, development of RA usually
commences with I-cells infiltrating the synovial membrane
lining the affected joint; this then leads to the activation of
macrophages, monocytes mid synovial fibroblasts (see, e.g.,
Firestein, 1996) by way of cell-cell contact and release of
various cytokines, including TNFa and IL-1 (see, e.g., Feld­
mmm, 1996). Activation of these cells leads to the overpro­
duction of a range of pro-inflmmnatory cytokines, of which
the most important are TNFa, IL-1 and IL-6 (see, e.g., Bren­
nmi et al, 1996; Mclmies et al, 2005). These pro-inflammatory
cytokines are then instrumental in orchestrating several com­
plex signal transduction cascades, including the NFKB,
MAPK and Jak/STAT pathways (see, e.g., Firestein et al,
1999) which lead to the induction of genes coding for various
products that propagate the inflammatory response and also
promote tissue destruction. These products include tissue­
degrading enzymes such as collagenases, matrix metallopro­
teases, cathepsins, and other pro-inflammatory factors such
as selectins, integrins, leukotrienes, prostaglandins, chemok­
ines, and other cytokines. Furthermore, TNF a mid IL-1 also
induce RANKL expression.
[0011] RANKL is an essential factor for the generation of
osteoclasts (see, e.g., Tanaka et al, 2003; Roodman, 2006),
and upregulated RANKL-production leads to increased
osteoclast differentiation mid ultimately bone destruction
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(see, e.g., Tanaka et al, 2003; Roodman, 2006). The inflam­
matory response leads to the accumulation of many leuko­
cytes and immune factor populations within the affected joint 
and also to hyperplasia of the Type-A and Type-B synovio­
cytes (see, e.g., Firestein et al, 2005), leading to thickening 
and vascularisation of the synovium into a destrnctive and 
aggressive tissue known as a pannus. The pannus contains 
both osteoclasts, which destroy bone, and metalloproteases, 
which continue the destrnction of cartilage. 
Treatment of Rheumatoid Arthritis 
[0012] Early therapies for RA focussed on controlling the 
symptoms of the disease, mainly by reduction of inflamma­
tion, rather than retarding disease progression. These drugs 
included NSAIDs such as aspirin, diclofenac and naproxen 
and, until recently, the COX-2 selective drngs Celebrex® and 
Vioxx® were also widely used. Inflammation was further 
controlled by glucocorticoids, and their combination with 
NSAIDs provided reasonably effective short-tenn control of 
the inflammation. More recently, a more aggressive approach 
to treating RA has been introduced starting at disease onset, 
using so-called disease-modifying anti-rheumatic drugs 
(DMARDs), which act to slow or even prevent disease pro­
gression. These include a number of older drugs, including 
gold salts; sulfasalazine; antimalarials such as hydroxychlo­
roquine; D-penicillamine; immunosuppressants such as 
mycophenolic acid, azathioprine, cyclosporineA, tacrolimus 
and sirolimus; minocycline; leflunomide; and most impor­
tantly, methotrexate (see, e.g., Smolen et al, 2003). 
[0013] Methotrexate is now the gold-standard therapy for 
clinical trial comparisons, and is generally used in combina­
tion with newer therapies. It is effective in most patients but, 
in common with all of the above agents, has significant gas­
trointestinal side effects, which lead to roughly 50% of 
patients eventually having to cease treatment with methotr­
exate (see, e.g., Mount et al, 2005). A further drawback of 
these older DMARDs is the length of time taken for the drug 
to start acting, ranging from weeks with methoxtrexate, to 
months with gold salts. Whilst full remissions only occur in 
about a quarter of patients, for those showing no effect it is not 
generally possible to stop therapy without suffering the risk of 
a more violent disease rebound (see, e.g., Smolen et al, 2003). 
In recent years, the treatment of RA has been revolutionised 
by the advent of biological agents which target specific 
inflallllllatory pathways. The first and most important of these 
are the anti-tumour necrosis factor (anti-TNF) agents (see, 
e.g., Elliott et al, 1994 ).
The Role of TNFa in RA 
[0014] As discussed above, the TNF superfamily of recep­
tors and ligands plays a key role in the causation of inflam­
mation and associated local and systemic bone loss. TNFa 
production within the joint may in fact play the pivotal role in 
orchestrating the production of other factors which leads to 
the persistence of inflallllllation and tissue damage (see, e.g., 
Feldmam1 et al, 2001; Brennan et al, 1999; Brennan, 1992). 
The importance ofTNF a in RA is highlighted by the finding 
that antibodies blocking TNFa can prevent inflanunation in 
animal models of RA, and that anti-TNF a therapy is currently 
the most effective treatment for RA (see, e.g., Elliott et al, 
1994; Feldmam1 et al, 1994; Joosten et al 1996, Klareskog et 
al, 2006). However, there is evidence that there are some 
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TNF a-independent effects of IL-1 in RA, most notably bone 
destrnction (see, e.g., van den Berg et al, 1999; van den Berg 
et al, 2002). 
[0015] TNF a is a cytokine that effects many different func­
tions, including the alteration of tissue remodelling, changes 
to the pem1eability of the epithelial cell barrier, activation of 
macrophages, up-regulation of adhesion molecules, recruit­
ment of other illllllune response effoctors and, most impor­
tantly in R,A, it instigates the signalling cascade which leads 
to the activation of the transcription factors NFKB and AP-1 
(see, e.g., Liu, 2005; Baud et al, 1999). Binding ofTNFa and 
IL-1 to their respective receptors leads to the recruitment of 
downstream signal transducers called TRAFs. Further 
kinases are recruited by the TRAFs, and the resulting kinase 
complex activates the MAP-kinase pathway, ultimately lead­
ing to activation of AP-1, and the phosphorylation of IKB 
kinase. IKB is the inhibitor ofNFKB, which acts by preventing 
translocation ofNFKB to the nucleus. Phosphorylation of IKB 
by IKB kinase leads to degradation of IKB. Once IKB has been 
degraded, NFKB migrates to the nucleus, where it promotes 
transcription of anti-apoptotic genes, which promote survival 
of T and B-cells, thereby prolonging the inunune response. 
This prolongation of the inflammatory response is central to 
the chronic nature of RA. The importance ofNFKB activation 
is demonstrated by the fact that inhibition ofNFKB activity by 
inhibitory peptides can prevent arthritis in animal models of 
RA (see, e.g., Jimi et al, 2004). 
Anti-TNFa Therapy 
[0016] Anti-TNFn therapy represents the market-leading 
therapies for Ri\., and is performed either with neutralising 
antibodies such as infliximab (Remicade® J&J and Schering 
Plough) and adalimumab (Humira®, Abbott) or decoy recep­
tors such as etanercept (Enbrel® Amgen and Wyeth), both 
which represent validated and highly effective treatments for 
RA. Anti-TNFn biologicals are already licensed for RA, 
Crohn's disease, and psoriasis. A number of other inflamma­
tory and autoimmune disorders are also being investigated as 
potential targets. Other approaches to blocking the action of 
TNFn include the pegylated anti-TNFn fragment certoli­
zumab (Cimzia®, UCB); inhibition of proximal signalling 
intermediates such as MAP kinase; interference with the syn­
thesis of TNFa via inhibition of TNFa converting enzyme 
(TACE); and inhibition of the metalloproteases responsible 
for cleaving TNFn from the cell surface (see, e.g., Smolen et 
al, 2003; Mount et al, 2005). 
Other Inliibitors ofNFKB Activation 
[0017] As described above, the binding of IL-1 and 
RANKL to their receptors also initiates a signalling cascade, 
which eventually leads to the activation ofNFKB and subse­
quent inflallllllatory response. The efficacy of inhibitors of 
these ligands has been validated by the use of the IL-1 recep­
tor antagonist anakinra (Kineret® Amgen) for the treatment 
of RA, and the completion of clinical trials for the mono­
clonal antibody against RANKL AMG-162 (Denosumab® 
Amgen) for osteoporosis (it is also in clinical trials for RA and 
psoriasis). 
Other Collllllon Inflallllllatory Diseases Mediated by TNFa 
[0018] There are several other common inflanunatory dis­
eases in which TNF n has been shown to play a major role and 
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in which TNFa inhibitors have found therapeutic use. These 
include inflammatory bowel disease (IBD) and psoriasis. 
(0019] IBD is an inflanuuatory disorder of the gut affecting 
about 0.25% of the population in the western world, of which 
the two main forms are: ulcerative colitis (UC), in which the 
lining of the colon becomes inflamed and ulcerated; and 
Crohn's disease (CD), which can occur anywhere within the 
gastrointestinal tract, but most often the ileum, and com­
monly involves inflammation of the entire gut wall. Common 
symptoms ofIBD are bloody diarrhoea and abdominal pain. 
(0020] Psoriasis is an inflanuuatory response of the skin 
affecting 1-3% of the population in the western world. The 
disease is characterised by raised, red, scaly plaques on the 
skin, which may be itchy and also cause significant psycho­
logical distress by their unsightly nature. A further complica­
tion of psoriasis is the development of psoriatic arthritis, an 
inflammatory arthritis of the joints, in up to 40% of patients, 
which develops on average 10 years after the first symptoms 
of skin disease are seen (see, e.g., Gottlieb, 2005). 
(0021] As with RA, the aetiology ofIBD and psoriasis are 
unknown and may involve a complex combination of infec­
tious agents, environmental, and genetic factors, generating 
an inappropriate and prolonged inflanuuatory response. 
(0022] Treatment ofIBD and psoriasis has followed a simi­
lar pattern to that of RA, with the past use of immunoregula­
tory agents such as NSAIDs, methotrexate, cyclosporine, 
steroids, and antimetabolites such as 6-mercaptopurine for 
IBD (see, e.g., Korzenik et al, 2006) and methotrexate and 
cyclosporine for psoriasis (see, e.g., Gottlieb, 2005). The 
treatment of both has been revolutionised by the advent of 
biological agents, in particular those which block TNF a sig­
nalling. Etanercept is licensed for the treatment of psoriasis 
and psoriatic arthritis; both infliximab and adalimumab are 
licensed for psoriatic arthritis, IBD, and psoriasis. 
Cancer 
(0023] There is growing evidence that activation ofNFKB 
can play a major role in the promotion and progression ofboth 
haematological malignancies, such as myeloma and lympho­
mas, and solid tumours. such as breast, prostate and lung 
cancer (see, e.g., Baud and Karin, 2009). There is also rising 
awareness of the role and importance of inflammation in 
cancer and in the development of resistance to radiotherapy 
and to chemotherapeutic agents, and it has been suggested 
that inflanuuation is in fact one of the basic hallmarks of 
cancer (see, e.g., Mantovani, 2009). Improving the efficacy of 
anti-cancer treatments by prevention of NFKB activation is 
therefore a promising strategy to augment existing therapeu­
tic regimes and is currently under investigation, most notably 
for the treatment of multiple myeloma. 
(0024] Defects in the normal apoptotic pathways are also 
implicated in the development and progression of tumour cell 
growth. Apoptosis (progranuued cell death) plays a key role 
in the removal of abnormal cells; defects in the signalling 
cascades, which would normally lead to its induction, play a 
key role in oncogenesis. Radiotherapy and many chemothera­
peutic agents act by causing cellular damage, which would 
normally induce apoptosis; defects in the pathway will there­
fore also reduce the effectiveness of such agents. The most 
important effector molecules in the signalling pathway lead­
ing to apoptosis are known as the caspases, which may be 
triggered by a number of stimuli, including TNF a binding to 
its receptor. Mutations in the genes which encode for the 
caspases have been found in a number of tumour types, 
3 
Aug. 4, 2011 
including gastric, breast, renal cell and cervical cancers as 
well as commonly in I-cell lymphoblastic lymphoma and 
basal cell ameloblastomas (see, e.g., Philchenkov et al., 
2004). Compounds which activate caspases, and thus sensi­
tise cells to apoptosis, would be highly effective as cancer 
therapies either as single agents or in enhancing the effective­
ness of existing cancer chemotherapy and radiotherapy. 
Common Bone Diseases 
(0025] Osteoporosis is a common disease characterised by 
reduced bone density, deterioration of bone tissue, and an 
increased risk of fracture. Many factors contribute to the 
pathogenesis of osteoporosis including poor diet, lack of 
exercise, smoking, and excessive alcohol intake. Osteoporo­
sis may also arise in association with inflammatory diseases 
such as rheumatoid arthritis, endocrine diseases such as thy­
rotoxicosis, and with certain drug treatments such as treat­
ment with glucocorticoids. However one of the most impor­
tant factors in the pathogenesis of osteoporosis is heredity. 
(0026] Paget's disease of bone is a conn11on condition of 
unknown cause, characterised by increased bone turnover 
and disorganised bone remodelling, with areas of increased 
osteoclastic and osteoblast activity. Although Pagetic bone is 
often denser than normal, the abnormal architecture causes 
the bone to be mechanically weak, resulting in bone defor­
mity and increased susceptibility to pathological fracture. 
[0027] Many types of cancer affect bone. Cancer-associ­
ated bone disease can be manifest by the occurrence ofhyper­
calcaemia or the development of osteolytic and/or osteoscle­
rotic metastases. Increased osteoclastic bone resorption plays 
a key role in the pathogenesis of both conditions. Whilst 
almost any cancer can be complicated by bone metastases, the 
most common sources are multiple myeloma, breast carci­
noma, and prostate carcinoma. The most common tumours 
associated with hypercalcaemia are multiple myeloma, breast 
carcinoma, and lung carcinoma. 
[0028] RANKL signalling has been shown to play a major 
role in osteoclast over-activity and a consequent increase in 
bone loss (see, e.g., Tanaka et al, 2003; Roodman, 2006). The 
use of drugs which affect this pathway has been validated by 
the completion of clinical trials of the monoclonal antibody 
against RANKL AMG-162 (Denosumab® Amgen) for the 
treatment of osteoporosis/multiple myeloma. 
(0029] As described previously, bone loss also plays a 
major role in the pathophysiology of rheumatoid arthritis and 
drugs which prevent activation of the signalling pathways 
described (e.g. TNFa blockers) are also able to prevent this 
bone loss. 
Agents that Prevent Inflammation and/or Bone Loss 
(0030] The inventors have identified a new class of com­
pounds which, for example. prevent inflannnation and/or 
bone loss, and thus may be used in the treatment of diseases 
with an inflammatory or autoinuuune component, including. 
for example, rheumatoid arthritis, inflann11atory bowel dis­
ease, psoriasis, and psoriatic arthritis; diseases which involve 
bone loss, including, for example, bone loss associated with 
rheumatoid arthritis, osteoporosis, Paget's disease of bone, 
and multiple myeloma; as well as cancer associated with 
activation of NFKB, with aberrant NFKB signaling, or with 
inflammation, including haematological malignancies such 
as multiple myeloma, leukaemia, T-cell lymphoblastic lym­
phoma, and other lymphoma (e.g., non-Hodgkin Lym­
phoma), and solid tumours such as cancer of the bladder, 
breast cancer (female and/or male), colon cancer, kidney 
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cancer, lung cancer, pancreatic cancer, prostate cancer, brain 
cancer, skin cancer, thyroid cancer, and melanoma; and can­
cer associated with the inactivation or impainnent of caspase­
mediated cell death, such as gastric cancer, breast cancer, 
renal cancer, cervical cancer, and basal cell ameloblastomas. 
(0031] Without wishing to be bound by any particular 
theory, the inventors believe that this action may be via a 
mechanism that involves blocking TNFa and/or IL-1 and/or 
RANKL-signalling. 
Biphenyl Sulfonamides 
(0032] Greig et al., 2004 and Greig et al., 2006 describe a 
class ofbiphenyl alkyl sulfonamides as anti-resorptive agents 
for the treatment of bone diseases, including, for example, 
2',4'-difluoro-biphenyl-4-sulfonic acid (5-hydroxy-pentyl)­
amide (ABD248) and 2',4'-difluoro-biphenyl-4-sulfonic acid 
( 4-hydroxy-butyl)-aniide (ABD256) (shown below). 
F-0--o+� OH 
0 
F 
ABD248 
F 
0 
II H 
II-N�OH
0 
ABD256 
No. 
[0033] Greig et al., 2008 (not yet published), describes a 
class of biphenyl all,"Yl sulfonamides, as anti-resorptive 
agents for the treatment of bone diseases including, for 
example, 2',4'-difluoro-biphenyl-4-sulfonic acid (3-hy­
droxymethy 1-pheny 1 )-amide ( ABD4 56), 2' ,4 '-difluoro-bi­
pheny 1-4-sulfonic acid ( 4-hydroxymethyl-phenyl)-amide 
(ABD466), and 2',4'-difluoro-biphenyl-4-sulfonic acid [3-(2-
hydroxy-ethyl)-phenyl]-amide (ABD628), shown below. 
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(0034] It appears that compounds of the following formu­
lae may be known: 
Strncture Registry No. 
1022865-56-9 
313 23 8-50-5 
[0035] The present inventors have identified a new a class 
of aryl sulfonamides. as defined herein, that have surprising 
and unexpected properties. 
(0036] The present inventors have identified a new a class 
of aryl sulfonan1ides, as defined herein, that have, inter alia, 
one or more surprising and unexpected properties. 
[0037] Without wishing to be bound to any particular 
theory, the inventors believe that the new compounds have 
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been protected against the major route of metabolism acting 
upon the previous biphenyl aryl sulfonamides (specifically, 
oxidation of the terminal alcohol to give a carboxylic acid) by 
the addition of a suitable blocking group in this region. In 
addition to the resulting substantial improvement in meta­
bolic stability, these blocking groups have also been selected 
to provide a further substantial enhancement in the aqueous 
solubility of the compounds. If a dmg is to show oral activity, 
it must first be solvated, to permit absorption from the gas­
trointestinal tract. S econd, the dmg must be sufficiently resis­
tant to first pass metabolism by metabolic enzymes contained 
within the liver so as to be able to enter the circulation and 
permit sufficient quantities to reach the biological target. 
Third, the dmg must be sufficiently potent against the bio­
logical target to give the desired therapeutic effect. 
(0038] The optimization of pharmacokinetic properties 
( action of the body on the dmg) of a dmg is a developmental 
barrier of equal challenge as compared to the optimization of 
pharmacodynamic properties (action of the dmg on the 
body). By improving both solubility and stability, with little 
or no loss of potency against the biological target, the new 
compounds disclosed herein show substantial improvements 
in their properties as oral therapeutic agents, as compared to 
previous compounds identified above. The new compmmds 
combine the characteristics required of orally active agents 
for the treatment of inflall1lllatory diseases and/or for the 
treatment of bone loss. 
SUMMARY OF THE INVENTION 
(0039] One aspect of the invention pertains to certain aryl­
phenyl-sulfonamido-phenylene compounds (for conve­
nience, collectively referred to herein as "APSAP com­
pollllds"), as described herein. 
(0040] Another aspect of the invention pertains to a com­
position (e.g., a pharmaceutical composition) comprising an 
APSAP compound, as described herein, and a pharmaceuti­
cally acceptable carrier or diluent. 
(0041] Another aspect of the invention pertains to method 
of preparing a composition ( e.g., a phamiaceutical composi­
tion) comprising the step of admixing anAPSAP compolllld, 
as described herein, and a pharmaceutically acceptable car­
rier or diluent. 
(0042] Another aspect of the invention pertains to a method 
of inhibiting an inflanunatory response, in vitro or in viva, 
comprising contacting an inunune system component with an 
effective amount of an APSAP compound, as described 
herein. 
(0043] Another aspect of the invention pertains to a method 
of inhibiting cellular and/or molecular pathways leading to 
joint destmction, in vitro or in viva, comprising contacting 
cells associated with an inunlllle response with a therapeuti­
cally-effective amount of anAPSAP compound, as described 
herein. 
(0044] Another aspect of the invention pertains to a method 
of inhibiting osteoclast survival, formation, and/ or activity, in 
vitro or in viva, comprising contacting an osteoclast with an 
effective amount of an APSAP compound, as described 
herein. 
(0045] Another aspect of the invention pertains to a method 
of inhibiting bone resorption, in vitro or in viva, comprising 
contacting cells in the bone microenvirmunent with a thera­
peutically-effective amount of an APSAP compound, as 
described herein. 
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(0046] Another aspect of the present invention pertains to a 
method of treatment comprising administering to a subject in 
need of treatment a therapeutically-effective amount of an 
APSAP compolllld, as described herein, preferably in the 
form of a phannaceutical composition. 
(0047] Another aspect of the present invention pertains to 
anAPSAP compolllld as described herein for use in a method 
of treatment of the human or animal body by therapy. 
(0048] Another aspect of the present invention pertains to 
use of an APSAP compound, as described herein, in the 
manufacture of a medicament for use in treatment. 
(0049] In one embodiment, the treatment is treatment of 
inflammation and/or joint destrnction and/or bone loss. 
(0050] In one embodiment, the treatment is treatment of 
disorders mediated by excessive and/or inappropriate and/or 
prolonged activation of the ill1lllune system. 
(0051] In one embodiment, the treatment is treatment of 
inflammatory and autoill1llltme disorders, for example, rheu­
matoid arthritis, psoriasis, psoriatic arthritis, chronic obstrnc­
tive pulmonary disease (COPD), atherosclerosis, inflall1llla­
tory bowel disease, ankylosing spondylitis, and the like. 
(0052] In one embodiment, the treatment is treatment of 
inflammatory and autoinuntme disorders, for example, rheu­
matoid arthritis, psoriasis, psoriatic arthritis, inflammatory 
bowel disease, ankylosing spondylitis, and the like. 
(0053] In one embodiment, the treatment is treatment of 
disorders associated with bone loss, such as bone loss asso­
ciated with excessive osteoclast activation in rheumatoid 
arthritis; osteoporosis; cancer-associated bone disease; Pag­
et's disease; and the like. 
(0054] In one embodiment, the treatment is treatment of a 
haematological malignancy, e.g., multiple myeloma, leu­
kaemia, or lymphoma ( e.g., non-Hodgkin Lymphoma), e.g., a 
haematological malignancy, multiple myeloma, leukaemia, 
or lymphoma (e.g., non-Hodgkin Lymphoma) associated 
with activation of NFKB, with aberrant NFKB signalling, or 
with inflanunation, e.g., alone, or in combination with, and to 
augment the efficacy of, radiotherapy or chemotherapy. 
(0055] In one embodiment, the treatment is treatment of a 
solid tlllllour cancer, e.g., cancer of the bladder, breast cancer 
(female and/or male), colon cancer, kidney cancer, lung can­
cer, pancreatic cancer, prostate cancer, brain cancer, skin 
cancer, thyroid cancer, or melanoma, e.g., a solid tumour 
cancer, cancer of the bladder, breast cancer (female and/or 
male), colon cancer, kidney cancer, lung cancer, pancreatic 
cancer, prostate cancer, brain cancer, skin cancer, thyroid 
cancer, and melanoma associated with activation of NFKB, 
with aberrant NFKB signalling, or with inflanunation, e.g., 
alone, or in combination with, and to augment the efficacy of, 
radiotherapy or chemotherapy. 
(0056] In one embodiment, the treatment is treatment of a 
haematological malignancy, e.g., T-cell lymphoblastic lym­
phoma, mantle cell lymphoma, or acute lymphoblastic leu­
kemia, e.g., a haematological malignancy, T-cell lymphoblas­
tic lymphoma, mantle cell lymphoma, or acute lymphoblastic 
leukemia associated with inactivation or impairment of 
caspase induction or with aberrant caspase signalling, e.g., 
alone or in combination with, and to augment the efficacy of, 
radiotherapy or chemotherapy. 
(0057] In one embodiment, the treatment is treatment of a 
solid tumour cancer, e.g., renal cell carcinoma, breast cancer 
(female and/or male), gastric cancer, prostate cancer, colon 
cancer, or basal cell ameloblastoma, e.g., a solid tumour 
cancer, e.g., renal cell carcinoma, breast cancer (female and/ 
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or male), gastric cancer, prostate cancer, colon cancer, or 
basal cell ameloblastoma associated with inactivation or 
impairment of caspase induction or with aberrant caspase 
signalling, e.g., alone, or in combination with, and to augment 
the efficacy of, radiotherapy or chemotherapy. 
[0058] In one embodiment, the treatment is part of treat­
ment by combination therapy, e.g., in combination with, and 
to augment the efficacy of, radiotherapy or chemotherapy. 
[0059] Another aspect of the present invention pertains to a 
kit comprising (a) anAPSAP compound, as described herein, 
preferably provided as a phannaceutical composition and in a 
suitable container and/or with suitable packaging; and (b) 
instructions for use, for example, written instructions on how 
to administer the compound. 
[0060] Another aspect of the present invention pertains to 
anAPSAP compound obtainable by a method of synthesis as 
described herein, or a method comprising a method of syn­
thesis as described herein. 
[0061] Another aspect of the present invention pertains to 
an APSAP compound obtained by a method of synthesis as 
described herein, or a method comprising a method of syn­
thesis as described herein. 
[0062] Another aspect of the present invention pertains to 
novel intem1ediates, as described herein, which are suitable 
for use in the methods of synthesis described herein. 
[0063] Another aspect of the present invention pertains to 
the use of such novel intermediates, as described herein, in the 
methods of synthesis described herein. 
[0064] As will be appreciated by one of skill in the art, 
features and preferred embodiments of one aspect of the 
invention will also pertain to other aspect of the invention. 
BRI EF DESCRIPTION OF THE DRAWIN GS 
[0065] FIG. l is a graph showing mean plasma concentra­
tion (ng/mL) of theAPSAP compmmdABD789 C•) after oral 
administration (1 mg/kg) to a rat model. 
[0066] FIG. 2 is a graph showing mean plasma concentra­
tion (ng/mL) of the APSAP compound ABD789 C•) after 
intravenous administration ( 1 mg/kg) to a rat model. 
[0067] FIG. 3 is a graph showing mean plasma concentra­
tion (�tg/mL) of the reference compound ABD455 C•) after 
oral administration 2.5 mg/kg to a rat model. 
[0068] FIG. 4 is a graph showing mean plasma concentra­
tion (µg/mL) of the reference compound ABD455 C•) after 
intravenous administration 2.5 mg/kg to a rat model 
DETAIL ED DESCRIPTION OF THE INVEN TION 
C ompounds 
[0069] T he compounds of the present invention are struc­
turally related to 1-(aryl)-phenyl- 4-sulfonic acid (3-substi­
tuted-phenyl)amide: 
0 --0- 11 H 
Ary! �-N
o-
0 f ' R. 
3 
[0070] One aspect of the present invention pertains to com­
pounds of the following formula, and phamiaceutically 
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acceptable salts, hydrates, and solvates thereof ( collectively 
referred to herein as "aryl-phenyl-sulfonamido-phenylene" 
or "APSAP compounds"): 
wherein: 
[0071] -A is independently: 
[0072] -Ar is independently phenyl, pyridinyl, or pyri­
midinyl; and 
[0073] p is independently an integer from Oto 3; 
and wherein: 
[0074] q is independently an integer from Oto 3; 
and wherein: 
[0075] is independently -H or saturated ali-
phatic C 1_4alkyl; 
and wherein: 
[0076] -R 81 is independently-Hor saturated aliphatic
C 1_4alkyl; 
[0077] is independently-Hor saturated aliphatic 
C 1_4alkyl; 
[0078] R83 is independently Hor saturated aliphatic 
C 1_4alkyl; 
[0079] -R 84 is independently-Hor saturated aliphatic 
C 1_4alkyl; 
and wherein -Q is independently selected from: 
wherein: 
[0080] each independently-Hor -R cN; 
[0081 J each is independently-Hor -R cN; 
[0082] each -R 0v is independently saturated aliphatic
C 1_4alkyl; 
[0083] or: 
[0084] - NR 1NR 2N is independently azetidino, pyrroli­
dino, imidazolidino, pyrazolidino, piperidino, piper­
azino, morpholino, thiomorpholino, azepino, or diaz-
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epino, each optionally substituted with one or more 
groups independently selected from saturated aliphatic 
C 1 _4 alk"Y 1; 
[0085] -R iA is independently-H, -R
e, or -RF; and 
[0086] is independently Re, or RF; 
[0087] or -R1A and -R2A together form a saturated 
aliphatic C2_4alk')'lene group; 
[0088] -R3A is independently-Re, -RF, or-RJ; and 
[0089] -R4A is independently-H, -Re, or -RF; 
[0090] or and together form a saturated 
aliphatic C2_4alkylene group; 
[0091] -R5A is independently . and 
[0092] -R6A is independently , or-RF; 
[0093] or -R5A and -R6·4 together form a saturated
aliphatic C2_4alkylene group; 
[0094] -R1B is independently-H,-Re, or-RF; and 
[0095] Rw is independently H, Re, or RF; 
[0096] or -R1B and -R2B together form a saturated 
aliphatic C2_4alkylene group; 
[0097] R3B is independently H. Re, RF, OH, 
or-OR0· and 
[0098] is independently -Re, or -RF; 
[0099] or R3B and R4B together fom1 a saturated 
aliphatic C2_4alk')'lene group; 
[0100] -R5B is independently-H, -Re, or-RF; and 
[0101] -R 6B is independently -H. -Re. or -RF;
[0102] or -R5B and -R6B together form a saturated 
aliphatic C2_4alkylene group; 
[0103] each -Re is independently saturated aliphatic 
C 1_4alkyl; 
[0104] each -RF is independently saturated aliphatic 
C 1_4fluoroalkyl; 
[0105] -R0 is independently saturated aliphatic 
C 1_4alkyl; 
[0106] -RJ is independently -NH2, -NHR
JN1, 
-NR=1 2, or -NR
=2R=3;
[0107] each -R=1 is independently -RJ1, -RJ2 -
OH, -RJ2-D-RJ1; 
[0108] each -RJ1 is independently saturated aliphatic 
C 1_4alkyl; 
[0109] each is independently saturated ali-
phatic C2_4alkylene; 
[0110] -NRJ1\'2RJ1\'3 is independently azetidino, pyrro­
lidino, imidazolidino, pyrazolidino, piperidino, piper­
azino, morpholino. thiomorpholino, azepino, or diaz­
epino, each optionally substituted with one or more 
groups independently selected from saturated aliphatic 
C 1_4alk')'l; 
and wherein each -Rx is independently: 
[0111] --Cl, -Br, -I, 
[0112] 
[0113] OH, OR>.:"', 
[0114] -SH, -SRxx, 
[0115] -OCF 3 , -SCF 3,
[0116] -NH2, -NHR
xx, -NRx\, -NR17Rzz, 
[0117] --C(=O)RxY, -DC(=O)Rrr, 
[0118] --C(=O)OH, -C(=O)ORxx, 
[0119] --C(=O)NH2, --C(=O)NHR
>.:"', -C(=O) 
NRrr,, --C(=O)NRyyRzz, 
[0120] - DC(=O)NH2, -DC(=O)NHR
xx, -DC 
(=0)NRxx2, -OC(=O)NR
n·Rzz, 
[0121] -NHC(=O)Rxx, -NRxxC(=O)Rxx, 
[0122] -NHC(=O)ORxx, -NRxxC(=O)ORxY, 
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[0123] -NHC(=O)NH2, -NHC(=O)NHR
xx, 
-NHC( =O)NR·rr2, -NHC(=O)NR 
rrRzz,
[0124] -NRXXC(=O)NH2, -NR
XXC(=O)NHR>.:Y,
-NRxxC(=O)NR
xx
2, -NR
xxC(=O)NR 
yyRzz,
[0125] --CN 
[0126] -N02, 
[0127] -S(=0hNH2, -S(=0)2NHR
rr, -S(=O) 
2NR
xx
2
, -S(=0) 2NR
rrRzz, 
[0128] -S(=O)Rx\-S(=0)2R·
rr, -0S(=0)2R
x¥, 
-S(=0)20H, or -S(=0)20R
x¥;
[0129] wherein: 
[0130] each -R= is independently saturated aliphatic 
C 1_6alk"Yl, phenyl, or benzyl, wherein said phenyl and 
benzyl are optionally substituted with one or more 
groups selected from: -F, --Cl, -Br, -I, --CF3, 
-DCF3, -R
xrr, -DH, -ORxrr, or -SR=·,
wherein each -R= is independently saturated ali­
phatic C 1_4alkyl; and
[0131] each-NR rrRzz is independently azetidino, pyr­
rolidino, imidazolidino, pyrazolidino, piperidino, piper­
azino, morpholino, thiomorpholino, azepino, or diaz­
epino, each optionally substituted with one or more 
groups independently selected from saturated aliphatic 
C 1_4alkyl. 
The Group -A 
[0132] In one embodiment, -A is independently: 
[0133] In one embodiment, -Ar is independently phenyl, 
pyridinyl, or pyrimidinyl. 
[0134] In one embodiment, -Ar is independently phenyl. 
[0135] In one embodiment, -Ar is independently pyridi­
nyl. 
[0136] In one embodiment, -Ar is independently pyridin-
2-yl.
[0137] In one embodiment, -Ar is independently pyridin-
3-yl.
[0138] In one embodiment, -Ar is independently pyridin-
4-yl.
pyridin-2-yl pyridin-3-yl pyridin-4-yl 
[0139] In one embodiment, -Ar is independently pyrim­
idinyl. 
[0140] In one embodiment, -Ar is independently pyrimi­
din-2-yl. 
[0141] In one embodiment, -Ar is independently pyrimi­
din-4-yl. 
[0142] In one embodiment, -Ar is independently pyrimi­
din-5-yl. 
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pyrimidin-2-yl pyrirnidin-4-yl pyrirnidin-5-yl 
Substituents on --Ar 
(0143] In one embodiment, p is independently an integer 
from Oto 3. 
[0144] In one embodiment, p is independently an integer 
from 1 to 3. 
[0145] In one embodiment, p is independently 0. 
(0146] In one embodiment, p is independently 1. 
(0147] In one embodiment, p is independently 2. 
(0148] In one embodiment, p is independently 3. 
The Group -A: Phenyl and Pyridinyl 
(0149] In one embodiment, -A is independently: 
wherein: 
(0150] =W---- is - CH= or and ----Y= is 
--CH= or --CRY ; or 
(0151] =W---- is --CH= or ----CRw and ----Y= is 
or 
(0152] =W---- is ----N= and ----Y= is --CH= or 
[0153] ----Rw is independently saturated aliphatic 
C1_4alkyl;
(0154] ----RY is independently saturated aliphatic 
C1_4alkyl;
[0155] --Rn is independently----H or 
(0156] is independently----H or 
(0157] ----Rx4 is independently ----H or ----R"45; 
[0158] is independently 
(0159] is independently , and 
[0160] is independently----Rx. 
(0161] In one embodiment, -A is independently: 
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(0162] In one embodiment, -A is independently: 
(0163] In one embodiment, -A is independently: 
The Group -A: Phenyl and Pyridinyl: the Groups =W----and 
----Y= 
(0164] In one embodiment, =W---- is --CH= or 
--CR w and ----Y = is - CH= or 
[ 0165] In one embodiment, = W---- is - CH= and ---- Y = 
is - CH=, as in, for example: 
[0166] In one embodiment, =W---- is --CH= or 
--CR w and ----Y = is ----N=. 
(0167] In one embodiment, = W----is --CH= and ----Y = 
is as in, for example: 
(0168] In one embodiment. = W---- is ----N= and ----Y = is 
--CH= or 
US 2011/0190302 Al 
(0169] In one embodiment, = W- is -N= and -Y = is 
-CH=, as in, for example:
(0170] In one embodiment. -R w, if present, is indepen­
dently saturated aliphatic C 1_4alkyl. 
(0171] In one embodiment, -R w, if present, is indepen­
dently -Me . 
(0172] In one embodiment, -R r, if present, is indepen­
dently saturated aliphatic C 1_4alkyl . 
(0173] In one embodiment, , if present, is indepen-
dently -Me . 
The Group -A: Phenyl: Rx2 and Rx4 
(0174] In one embodiment, -A is independently: 
wherein: 
(0175] -Rn is independently-Hor -Rns . 
(0176] -R"4 is independently-Hor 
(0177] -Rx:zs is independently-R"; and 
(0178] -Rx4s is independently -Rx. 
The Group -R12 
(0179] In one embodiment, , if present, is indepen-
dently -H or -R:12s . 
(0180] In one embodiment, -Rx:z, if present, is indepen­
dently -R'"2s.
(0181] In one embodiment, -Rx:z, if present, is indepen­
dently-H. 
The Group 
(0182] In one embodiment, -RD, if present, is indepen­
dently -H or -RX3s. 
[0183] In one embodiment, , if present, is indepen-
dently -R-1.ss . 
(0184] In one embodiment, -R-1.3 , if present, is indepen­
dently-H. 
The Group -Rx4 
(0185] In one embodiment, -Rx4, if present. is indepen­
dently-Hor 
(0186] In one embodiment, -Rx4, if present, is indepen­
dently 
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(0187] In one embodiment, -Rx4, if present, is indepen­
dently -H. 
Leading Phenylene Group 
(0188] For the avoidance of doubt, the leading phenylene 
group is the phenylene group that links the group -A, on the 
left, with the group -S(=0)2N(RsN)(DQ), on the right. 
(0189] And so, in one embodiment, the leading phenylene 
group is: 
M 
]Ky q 
(0190] In one embodiment, q is independently an integer 
from Oto 3. 
(0191] In one embodiment, q is independently an integer 
from 1 to 3. 
(0192] In one embodiment, q is independently 0. 
(0193] In one embodiment, q is independently 1. 
(0194] In one embodiment, q is independently 2. 
(0195] In one embodiment, the leading phenylene group is: 
wherein: 
(0196] is independently-Hor -Rx· and 
[0197] -Rxc2 is independently-Hor 
[0198] In one embodiment: 
[0199] -R'c1 is independently-Hor -R'; and
(0200] is independently 
or: 
(0201] 
[0202] 
-Rxci is independently -H; and 
is independently -H or 
or: 
(0203] is independently and 
[0204] -Rxc2 is independently-H. 
[0205] In one embodiment: 
[0206] is independently-H; and 
(0207] -Rxc2 is independently-Hor -R'. 
[0208] In one embodiment: 
(0209] -Rxci is independently-Hor -Rx ; and 
(0210] is independently-H. 
(0211] In one embodiment: 
(0212] -Rxci is independently-H; and 
[0213] is independently H. 
The Group -Rx 
(0214] In one embodiment, each -Rx, if present, is inde­
pendently: 
(0215] 
[0216] 
(0217] 
(0218] 
(0219] 
' 
-OH,-ORxx,
-SRxx,
--OCF3, 
-I,
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(0220] -NH2, -NHR"'Y, -NRx\, -NR rrR22, 
(0221] ----C(=O)RXY,---0C(=O)RXY, 
(0222] ----C(=O)OH, -C(=O)OR=, 
(0223] ----C(=O)NH 2, ----C(=O)NHR=, NRi::\. C(=O)NRYYR22• 
(0224] -OC(=O)NH2, -OC(=O)NHRn, -DC (=0)NRn2, ---OC(=O)NR rrR22, 
(0225] -NHC(=O)Rn, -NRnC(=O)Rn, 
(0226] -NHC(=O)ORxx, -NRxxC(=O)ORxx, 
(0227] -NHC(=O)NH2, -NHC(=O)NHR,n,-NHC(=O)NRx\, -NHC(=O)NR rrR22,
(0228] -NR,nC(=O)NH2• -NRnC(=O)NHRxY,-NR=C(=O)NR=2, -NR=C(=O)NR rrR22,
(0229] ----CN, 
(0230] -N02, 
(0231] -S(=0\NH2, -S(=0)2NHRn, -S(=O)
2NRx\, -S(=0) 2NRYYR22, 
(0232] -S(=O)Rx:<,-S(=0)2Rx:Y, -OS(=0)2R=,-S(=0) 20H, or-S(=0)20Rn;
(0233] wherein: 
(0234] each is independently saturated aliphatic 
C1_6alkyl, phenyl, or benzyl, wherein said phenyl and benzyl are optionally substituted with one or more 
groups selected from: -Cl, -Br, -I, -CF 3, ---OCF,, -R= -OH, -OR=, or -sR=, 
wherei1i each is independently saturated ali­
phatic C1_4alkyl; and 
(0235] each-NR 11'R22 is independently azetidino, pyr­
rolidino, imidazolidino, pyrazolidino, piperidino, piper­
azino, morpholino, thiomorpholino, azepino, or diaz­
epino, each optionally substituted with one or more 
groups independently selected from saturated aliphatic 
C1_4alkyl. 
(0236] In one embodiment, each , if present, is inde-
pendently: 
(0237] 
(0238] , XY (0239] -OH, -OR , 
(0240] -SRn,
[0241] -OCF3, 
[0242] -NH2, -NHRxx, 2, -NR11,R22,
(0243] ----C(=O)Rxx, -0C(=O)R1x, 
(0244] ----C(=O)OH, -C(=O)OR=, 
(0245] ----C(=O)NH 2, ----C(=O)NHR,n, -C(=O) NRx\, ----C(=O)NRYrR22,
[0246] ----CN, 
[0247] -N02, 
[0248] -01=1J1o1,�n,. -S(=0)2NHR"'<, -S(=O) 
2NR"'\, or -S(=0\NRrrR22. 
(0249] In one embodiment, each -RY if present, is inde­
pendently -Br, -I, , -OH, , 
-SRn, -CF3, ---OCI\, -SCI\, -C(=O)R·tx, ----CN, or-N02 . 
(0250] In one embodiment, each -RY, if present, is inde­
pendently -Br, -I, -R,n, -OH, ---ORx<,
-SR':x, ----CF3, ---OCF3, -SCF3, ----CN, or-N02. 
[0251] In one embodiment, each-Rx, if present, is inde­
pendently -F, -Cl, -Br, -I, -R=, -OH, -OR=,
-SR=, or-N02 • 
(0252] In one embodiment, each -Rx, if present, is inde­
pendently -F, -Br. -I, -R=, -OR=, -SRx:\ 
or 
[0253] In one embodiment, each-R=, if present, is inde­
pendently saturated aliphatic C1_6alkyl, phenyl, or benzyl. 
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(0254] In one embodiment, each-R,n, if present, is inde­
pendently saturated aliphatic C1_6alkyl. 
[0255] In one embodiment, each-R,n, if present, is inde­
pendently saturated aliphatic C1_4alk-yl. 
[0256] In one embodiment, each -NR YYR22, if present, is 
independently pyrrolidino, imidazolidino, pyrazolidino, pip­
eridino, piperazino, or morpholino, each optionally substi­
tuted with one or more groups independently selected from 
saturated aliphatic C1_4alkyl. 
(0257] In one embodiment, each -NR YYR22, if present, is 
independently pyrrolidino, piperidino, piperazino, or mor­
pholino, each optionally substituted with one or more groups 
independently selected from saturated aliphatic C1_4alk-yl. 
Substituents on the Leading Phenylene Group 
(0258] In one embodiment, the leading phenylene group is: 
wherein: 
[0259] -Rxci is independently-H or -Rxcc; and 
[0260] -Rxc2 is independently-H or -Rxcc; 
wherein each -Ryce is independently: 
102611 -F, -Rxccc, ---ORxccc,
wherein each is independently saturated aliphatic
C1_4alkyl. 
[0262] In one embodiment: 
or: 
(0263] -Rxci is independently-H or -Rxcc; and 
[0264] -Rxc2 is independently -H;
(0265] -Rm is independently-H; and 
(0266] -RYcl is independently-H or -Rxcc; 
or: 
(0267] -Rxci is independently and 
[0268] -Rxc2 is independently -H.
[0269] In one embodiment: 
(0270] -Rxci is independently-H; and 
(0271] is independently-H or 
(0272] In one embodiment: 
[0273] -Rxci is independently-H or -Rxcc; and 
(0274] -RYc2 is independently-II. 
[0275] In one embodiment: 
[0276] is independently and 
[0277] -RYc2 is independently -H. 
[0278] In one embodiment, each , if present, is 
independently -F, -Cl, or -Rxccc. 
[0279] In one embodiment, each -Rxcc, if present, is 
independently -Rxccc. 
[0280] In one embodiment, each -Rxccc, if present, is 
independently -Me, -nPr, or -iPr. 
[0281] In one embodiment, each -Rxccc, if present, is 
independently -Me or -Et. 
The Group 
[0282] In one embodiment, -RJr'2s, if present, is indepen­
dently 
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(0283] In one embodiment, , if present, is indepen­dently -F, --Cl, -Br, -I, -RxA ---ORxA, -SRYA,or wherein each is independently saturated aliphatic C1_4alkyl. 
(0284] In one embodiment, dently -Br, -OCF3 '
if present, is indepen­' -ORxA, or 
[0285] In one embodiment, , if present, is indepen-dently -F, --Cl, -Br, -I, --Cl\, or ---OCI\.
(0286] In one embodiment, -Rx2s, if present, is indepen-dently or 
(0287] In one embodiment, dently -F or -Cl.
[0288] In one embodiment, dently-F.
, if present, is indepen-
, if present, is indepen-
(0289] In one embodiment, -Rx2s, if present, is indepen­dently Cl.
The Group -RDs 
(0290] In one embodiment, -Rns, if present, is indepen­dently -Rx. 
(0291] In one embodiment, , if present, is indepen­dently -F, --Cl, -Br, -I, -RxA, ---ORYA, -SRxA, or -OCF 3, wherein each -RXA is independentlysaturated aliphatic C1_4alkyl. 
[0292] In one embodiment, -RDs if present, is indepen­dently -Br, , -ORxA, or -OCF3 '
(0293] In one embodiment, , if present, is indepen-dently -F, --Cl, -Br, -I, ----CF3, or---OCF3. 
(0294] In one embodiment, -R'ns, if present, is indepen-dently or 
(0295] In one embodiment, -RX3s, if present, is indepen­dently -F or -Cl.
[0296] In one embodiment, , if present, is indepen-dently -F.
(0297] In one embodiment, -R'ns, if present, is indepen­dently --Cl.
The Group 
(0298] In one embodiment, , if present, is indepen-dently -Rx. 
[0299] In one embodiment, , if present, is indepen­dently -F, --Cl, -Br, -I, -RxA, ---ORxA, -SRxA, or -OCF 3, wherein each -RXA is independentlysaturated aliphatic C1_4alkyl. 
(0300] In one embodiment, -RY4s if present, is indepen­dently -F, -Br, -I, , ---ORxA, or -OCF3• 
(0301] In one embodiment, -Rx4s, if present, is indepen-dently or 
[0302] , if present, is indepen-dently 
(0303] In one embodiment, -RY4s, if present, is indepen­dently -F or -Cl. 
(0304] In one embodiment, -Rx4s, if present, is indepen­dently -F. 
(0305] In one embodiment, -RY4s, if present, is indepen­dently --Cl. 
[0306] In one embodiment, -RY2s and-Rx4s, if present,are each independently -F. 
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(0307] In one embodiment, -R't:2s and-Rx4s, if present, are each independently -Cl. The Group -RxA
[0308] In one embodiment, each-RxA , if present, is inde­pendently saturated aliphatic C1_4alkyl. 
(0309] In one embodiment, each-RxA , if present, is inde­pendently -Me or -Et. 
(031 OJ In one embodiment, each -RxA , if present, is inde­pendently -Me. TheGroup -Q 
(0311] In one embodiment, -Q is independently selected from: 
rA f 4 rA rB rB IR!N 
r-C-C-OH r-C-OH r-C-C-N 
I I I I I \ R4A R2A R6A R4B R2B R2N
r-
r
B 
l
1N 
r-
TI l
!N 
C-N S-N 
I ' II ' R6B R2N O R2N 
[0312] In one embodiment, -Q is independently selected from: 
r-
r r 
r-
r
B rB IRIN 
C-C-OH C-C-N 
I I I I \ , R4A R2A R4B R2B R"N
(0313] In one embodiment, -Q is independently selected from: 
r-
r r 
r-
r
A 
C-C-OH C-OH. 
I I I R4A R2A R6A 
(0314] In one embodiment, -Q is independently: 
r-
r r 
C-C-OH. 
i4A i2A 
(0315] In one embodiment, -Q is independently: 
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(0316] In one embodiment, -Q is independently selected 
from: 
(0317] In one embodiment, -Q is independently: 
(0318] In one embodiment, -Q is independently: 
(0319] In one embodiment, -Q is independently: 
r-0 R!N 
II ; . 
S-NM \2N 
(0320] For the avoidance of doubt, where no stereochem­
istry is indicated, all possible conformations are encom­
passed. 
(0321] For example, the group described as -CH(Me)OH 
or as any of the following: 
H-OH 
Me 
r-H r-Me 
t-Me 
t-
OH 
OH H 
L
OH 
L
OH 
d-Me rf-H
H 
Me 
encompasses both stereoisomers: 
kH HH ,, ,,,,, Me OH. OH Me 
The Groups -R IN and -R 2N
(0322] In one embodiment: 
r-Me 
t-
H 
OH 
(0323] each -R IN, if present, is independently -H or 
-RCN; 
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[0324] each , if present, is independently -H or 
-RcN; and 
[0325] each , if present, is independently satu-
rated aliphatic C 1_4alkyl; 
[0326] or: 
[0327] -NR1NR21v-, if present, is independently azeti­
dino, pyrrolidino, imidazolidino, pyrazolidino, piperi­
dino, piperazino, morpholino, thiomorpholino, azepino, 
or diazepino, each optionally substituted with one or 
more groups independently selected from saturated ali­
phatic C 1_4alkyl. 
(0328] In one embodiment: 
(0329] each-R1N, if present, is independently-H or 
-RcN; and 
(0330] each , if present, is independently -II or 
-RCN_
(0331] In one embodiment: 
[0332] each -R IN, if present, is independently -H or 
-RcN; and 
(0333] each-R2N, if present, is independently-II. 
[0334] In one embodiment: 
(0335] each -R 1N, if present, is independently -R cN; 
and 
(0336] each , if present, is independently -II. 
(0337] In one embodiment: 
(0338] each -R 1N, if present, is independently 
and 
[0339] each -R2N, if present, is independently -R cv_ 
[0340] In one embodiment: 
[ 0341] each -R 1N, if present, is independently-H; and
(0342] each-R21v-, if present, is independently-II. 
(0343] In one embodiment, -NR 1NR 2N, if present, is inde­
pendently azetidino, pyrrolidino, imidazolidino, pyrazoli­
dino, piperidino, piperazino, morpholino, thiomorpholino, 
azepino, or diazepino, each optionally substituted with one or 
more groups independently selected from saturated aliphatic 
C 1_4alkyl. 
[0344] In one embodiment, -NR 1NR2N, if present, is inde­
pendently piperidino. piperazino, or morpholino. each 
optionally substituted with one or more groups independently 
selected from saturated aliphatic C 1_4alkyl. 
(0345] In one embodiment, -NR 1NR 2,v, if present, is inde­
pendently morpholino. 
(0346] In one embodiment, each-R cv, if present, is inde­
pendently -Me or -Et. 
[0347] In one embodiment, each-R cv, if present, is inde­
pendently -Me. 
(0348] In one embodiment, -NR 1NR 2N, if present, is inde­
pendently -NH2, -NIIMe, -NMe2, -NHEt, -NEt2, 
pyrrolidino, or morpholino. 
(0349] In one embodiment, -NR1NR2,v, if present, is inde­
pendently -NH2, -NIIMe, -NMe2, or morpholino. 
The Groups -RIA and -R 2A 
[0350] In one embodiment: 
(0351] -R1A, if present, is independently-H,-Rc, or 
-RF; and 
(0352] -R2A, if present, is independently-H,-Rc, or 
-RF; 
(0353] or -R1A and-R2,\ if present, together form a 
saturated aliphatic C2_4alkylene group. 
[0354] In one embodiment: 
(0355] -RIA, if present, is independently-II, -R c, or 
-RF; and 
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(0356] , if present, is independently-H, , or 
-RF.
(0357] In one embodiment: 
(0358] -RIA, if present, is independently-H or-Re; 
and 
(0359] -R2A, if present, is independently-H or-R
e. 
(0360] In one embodiment: 
(0361] , if present, is independently-H or-Re; 
and 
(0362] , if present, is independently -H. 
(0363] In one embodiment: 
(0364] -RIA if present, is independently-Re; and 
(0365] . if present, is independently -H. 
(0366] In one embodiment: 
(0367] -RIA, if present, is independently-Re; and 
(0368] , if present, is independently-Re. 
(0369] In one embodiment: 
(0370] -RIA if present, is independently -H; and 
(0371] , if present, is independently -H. 
(0372] In one embodiment, -R1A and -R2A, if present, 
together form a saturated aliphatic C 2_4alk")'lene group. 
(0373] In one embodiment, -RIA and -R2A, if present, 
together fonn �A1-,L11,--, ---,__,_,:1?,A1,,L11,- -, or 
(0374] In one embodiment, -RIA and-R2A, if present, 
together form -,�u,,<.J11,- -. 
The Groups -R3A and -R4A 
(0375] In one embodiment: 
(0376] -R3A, if present, is independently-Re, -RF,
or-RJ; and 
(0377] , if present, is independently-H, , or 
-RF;
(0378] or -R3A and -R4A , if present, together form a 
saturated aliphatic C 2_4alkylene group. 
(0379] In one embodiment: 
(0380] , if present, is independently-Re or -RJ; 
and 
(0381] , if present, is independently -H or-Re. 
(0382] In one embodiment: 
[0383] -R3A if present, is independently-R'; and 
[0384] , if present, is independently-H or-Re. 
(0385] In one embodiment: 
(0386] -R3A if present, is independently -RJ; and 
(0387] , if present, is independently -H. 
(0388] In one embodiment: 
(0389] -R3A, if present, is independently -RJ; and 
[0390] -R4A, if present, is independently-Re. 
(0391] In one embodiment: 
(0392] -R3A if present. is independently-Re; and 
(0393] , if present, is independently-H 
(0394] In one embodiment: 
[0395] -R3A, if present, is independently-Re; and 
[0396] -R4A, if present, is independently -H. 
(0397] In one embodiment: 
(0398] -R3A if present, is independently-Re· and 
(0399] , if present, is independently 
(0400] In one embodiment, -R3A and -R4A, if present, 
together form a saturated aliphatic C 2_4alkylene group. 
(0401] In one embodiment, -R3A and -R4A, if present, 
together fonn ----CH2CH2-, ----CH2CH2CH2-, or 
-CH2CH2CH2CH2-. 
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The Groups -RsA and-R 6A 
(0403] In one embodiment: 
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and -R4A, if present, 
[ 0404] -RsA, if present, is independently-Re or-RF;
and 
[0405] -R6A, if present, is independently-H,-Re, or 
-RF·
[0406] 'or R6A and R6A , if present, together form a 
saturated aliphatic C 2_4alkylene group. 
[0407] In one embodiment: 
[ 0408] -RSA. if present.is independently-Re or -RF;
and 
[ 0409] -R GA, if present, is independently-H, -Re, or 
-RF.
(0410] In one embodiment: 
(0411] -RsA if present, is independently-Re; and 
(0412] , if present, is independently-H or-Re_ 
[0413] In one embodiment: 
[0414] if present, is independently-Re; and 
[0415] , if present, is independently -H. 
(0416] In one embodiment: 
[0417] -RsA, if present, is independently-Re; and 
[0418] -R 6A, if present, is independently-Re.
[0419] In one embodiment: 
[0420] -R5A if present, is independently-RF; and 
(0421] , if present, is independently -H. 
[0422] In one embodiment, -RsA and -R6A, if present, 
together form a saturated aliphatic C 2_4alkylene group. 
(0423] In one embodiment, -RsA and -R6A, if present, 
together form -----<Al,,\Jll,- -, - -'-_, Jllo\Jll, Lll?- -, or 
----CH2CH2CH2CH2-. 
(0424] In one embodiment, -R5A and -R6A, if present, 
together form ----CH2CH2-. 
The Groups -RIB and -R 2B 
[0425] In one embodiment: 
[0426] -R1B, if present, is independently-H,-Re, or 
-RF; and 
[0427] -R2B, if present, is independently-H,-Re, or 
-RF;
[0428] or -R1B and-R2B, if present, together form a 
saturated aliphatic C 2_4alkylene group. 
[0429] In one embodiment: 
[ 043 0] -R !B, if present, is independently -H, , or 
-RF; and
[ 0431] -R 2B, if present, is independently-H, -Re, or 
-RF.
[0432] In one embodiment: 
[0433] -RIB, if present, is independently-II or-Re; 
and 
[0434] -R2B, if present, is independently-H or-Re. 
[0435] In one embodiment: 
[0436] RIB, if present, is independently H or Re; 
and 
(0437] , if present, is independently -H. 
[0438] In one embodiment: 
[0439] -R w, if present, is independently -H; and 
[0440] -R2B, if present, is independently-Re. 
[0441] In one embodiment: 
[0442] -R1B if present, is independently-Re· and 
(0443] , if present, is independently 
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(0444] In one embodiment: 
(0445] -RIB, if present, is independently -H; and 
(0446] -R2B, if present, is independently-H. 
(0447] In one embodiment, -R1B and -R2B, if present, 
together form a saturated aliphatic C2_4alkylene group. 
(0448] In one embodiment, -R1B and-R2B, if present, 
together form �H2CH2-, �H2CH2CH2-, or 
-CH2CH2CII2CH2-. 
(0449] In one embodiment, -R1B and , if present, 
together form -CH2CH2-. 
The Groups -R3B and -R4B 
(0450] In one embodiment: 
[0451] -R3B, if present, is independently -II, -Re, 
-RF,-OH, or-OR0; and
(0452] -R4B, if present, is independently-H, -Re, or 
-RF;
(0453] or -R3B and -R4B, if present, together form a 
saturated aliphatic C2_4alkylene group. 
(0454] In one embodiment: 
[0455] -R3B, if present, is independently -II, -Re, 
-RF. -OH, or-OR0; and
(0456] -R4B, if present, is independently-II, -Re, or 
-RF.
(0457] In one embodiment: 
(0458] -R3B, if present, is independently -H, -OH, 
or-OR0· and 
(0459] -R4B, if present, is independently-II or-Re. 
(0460] In one embodiment: 
(0461] -R3B, if present, is independently -OH or 
-OR0; and
(0462] -R4B, if present, is independently-H or-Re. 
(0463] In one embodiment: 
(0464] -R3B, if present, is independently -OH or 
-OR0; and
(0465] -R4B, if present, is independently -H. 
(0466] In one embodiment: 
(0467] -R3B, if present, is independently-OH; and 
(0468] -R4B, if present, is independently -H. 
[0469] In one embodiment: 
(0470] -R3B, if present, is independently-II or-Re; 
and 
(0471] -R4B, if present, is independently-II or-Re. 
(0472] In one embodiment: 
(0473] -R3B, if present, is independently-II or-Re; 
and 
(0474] -R4B, if present, is independently-H. 
(0475] In one embodiment: 
[0476] -R3B, if present, is independently -II; and 
(0477] -R4B, if present, is independently-Re. 
[0478] In one embodiment: 
[0479] R3B, if present, is independently Re; and 
(0480] -R4B, if present, is independently-Re. 
(0481] In one embodiment: 
(0482] , if present, is independently and 
(0483] -R4B, if present, is independently-H. 
(0484] In one embodiment, -R3B and -R4B, if present, 
together form a saturated aliphatic C2_4alkylene group. 
(0485] In one embodiment, -R3B and -R4B, if present, 
together fonn �II2CII2-, �II2CII2CII2-, or 
-CII2CH2CII2CII2-. 
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(0486] In one embodiment, -R3B and -R4B, if present, 
together form �H2CH2-. 
The Groups -R5B and-R 6B 
(0487] In one embodiment: 
[ 0488] -R5B, if present, is independently-H, -Re, or 
-RF· and 
[0489] ' -R 6B, if present, is independently-H, -Re, or
-RF·
[0490] ' or R5B and R 6B, if present, together form a 
saturated aliphatic C2_4alkylene group. 
[0491] In one embodiment: 
[ 0492] -R sB. if present, is independently -H. -Re, or 
-RF· and 
(0493] ' -R 6B, if present, is independently-H, -Re, or
-RF.
(0494] In one embodiment: 
(0495] -R5B, if present, is independently-II or-Re; 
and 
(0496] -R6B, if present, is independently-II or-Re. 
(0497] In one embodiment: 
[0498] -R5B, if present, is independently-H or-Re; 
and 
[0499] -R 6B, if present, is independently -H.
[0500] In one embodiment: 
[0501] , if present, is independently -H; and
(0502] -R 68, if present, is independently-Re.
[0503] In one embodiment: 
(0504] -R5B, if present, is independently-Re; and 
[0505] -R 6B, if present, is independently-Re.
(0506] In one embodiment: 
[0507] -R5B, if present, is independently -H; and 
(0508] -R 6B, if present, is independently -II.
[0509] In one embodiment, -R5B and -R6B, if present, 
together form a saturated aliphatic C2_4alkylene group. 
[0510] In one embodiment, -R5B and -R6B, if present, 
together form �H2CH2-, -CH2CH2CH2-, or 
�II2CH2CH2CII2-. 
(0511] In one embodiment, -R5B and -R6B, if present, 
together form �II2CH2-. 
The Group -R 0 
(0512] In one embodiment, -R 0, if present, is indepen­
dently saturated aliphatic C1 _4alh.')'l. 
(0513] In one embodiment, -R 0, if present, is indepen­
dently -Me or -Et. 
(0514] In one embodiment, -R 0, if present, is indepen­
dently -Me. 
The Group 
[0515] In one embodiment, each-Re, if present, is inde­
pendently saturated aliphatic C1 _4alkyl. 
[0516] In one embodiment, each Re, if present, is inde­
pendently -Me or -Et. 
[0517] In one embodiment, each-Re, if present, is inde­
pendently -Me. 
The Group -RF 
[0518] In one embodiment. each -RF, if present, is inde­
pendently saturated aliphatic C1 _4fluoroalkyl. 
[0519] In one embodiment, each -RF, if present, is inde-
pendently -,�"''-"' or �H2CII2F. 
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(0520] In one embodiment, each -RF, if present, is inde­
pendently -CF 3 • 
The Group -RJ 
(0521] In one embodiment, , if present, is indepen-
dently -NHRIN1, -NRJN1 ,. or -NRJN2RJN3 . 
[0522] In one embodiment, -RJ,�if present, is indepen-
dently -NHRIN1, or-NRIN12. 
(0523] In one embodiment, -RJ, if present, is indepen­
dently NH2 or NHRIN1. 
(0524] In one embodiment, -RJ, if present, is indepen­
dently -NH2 . 
(0525] In one embodiment, -RJ, if present, is indepen­
dently NHRJN1. 
(0526] In one embodiment, -RJ, if present, is indepen­
dently -NRIN1 2. 
(0527] In one embodiment, RJ, if present, is indepen­
dently -NR'N2RJN3 . 
(0528] In one embodiment: 
(0529] each -RJN1, if present, is independently 
-Rn--O H, -Rn--O-RJ1; 
(0530] each-Rn , if present, is independently saturated 
aliphatic C1_4alkyl; and 
(0531] each-Rn-, if present, is independently satu-
rated aliphatic C2_4alkylene. 
(0532] In one embodiment, each-RJN1, if present, is inde­
pendently -RJ1. 
(0533] In one embodiment, each -RJJ , if present, is inde­
pendently saturated aliphatic C1_4alkyl. 
[0534] In one embodiment, each -RJJ , if present, is inde­
pendently -Me, -Et, or -iPr. 
[0535] In one embodiment, each -RJ , if present, is inde­
pendently -Me or -Et. 
[0536] In one embodiment, each -RJ , if present, is inde­
pendently -Me. 
(0537] In one embodiment, each -Rn-, if present, is 
independently saturated aliphatic C2_4alkylene. 
(0538] In one embodiment, each -Rn-, if present, is 
independently -\_JU,vu,- or -CH2CH2CH2-· 
(0539] In one embodiment, each -Rn-, if present, is 
independently -,�u-,v,,,- -. 
(0540] In one embodiment, each RJN1, if present, is inde­
pendently saturated aliphatic C1_4alkyl. 
(0541] In one embodiment, each-RJN1, if present, is inde­
pendently -Me, -Et, or -iPr. 
[0542] In one embodiment, each-RJN1, if present, is inde­
pendently -Me or -Et. 
(0543] In one embodiment, each-RJN1, if present, is inde­
pendently -Me. 
(0544] In one embodiment, -NRJN2RJN3, if present, is 
independently azetidino, pyrrolidino, imidazolidino, pyrazo­
lidino, piperidino, piperazino, morpholino, thiomorpholino, 
azepino, or diazepino, each optionally substituted with one or 
more groups independently selected from saturated aliphatic 
C1_4alkyl. 
[0545] In one embodiment, -NRJN2RJN3' if present, is 
independently piperidino, piperazino, or morpholino, each 
optionally substituted with one or more groups independently 
selected from saturated aliphatic C1_4alkyl. 
[0546] In one embodiment, -NRJN2RJN3, if present, is 
independently morpholino. 
[0547] In one embodiment, -RJ, if present, is indepen­
dently -NH2, -NHMe, -NMe2, -NHEt, -NEt2, -NH 
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(nPr), -N(nPr)2, -NH(iPr), -N(iPr)2, -NH 
(CH2CH20H), -NH(CH2CH20CH3), piperidino, 
piperazino, or morpholino. 
(0548] In one embodiment, -RJ, if present, is indepen­
dently-NH2, -NHMe, -NMe2, -NHEt, -NEt2, -NH 
(nPr), -N(nPr)2, -NH(iPr), -N(iPr)2, piperidino, piper­
azino, or morpholino. 
(0549] In one embodiment, -RJ, if present, is indepen-
dently -NHMe, -NMe2, or morpholino. 
(0550] In one embodiment, -RJ, if present. is indepen­
dently -NH2, -NHMe, or -NMe2 . 
The Group -Q: Some Preferred Embodiments 
[0551] In one embodiment, -Q is independently: 
[0552] ----CH(Me)OH, ----C(Me)20H, -CH(CF3)0H, 
-( cycloprop-1 J-di-yl)OH, 
(0553] ----CH(NH2)CH20H, ----CH(NHMe)CH20H, 
----CH(NMe2)CH20H, 
(0554] ----CH(NHEt)CH20H, -CH(NEt2)CH20H, 
(0555] ----CH(morpholino )CH20H, 
(0556] ----CH(NHCH2CH20H)CH20H, -CH 
(NHCH2CH20Me )CH20H, 
[0557] ----C(Me)(NH2)CH20H, 
(0558] ----CH2NH2, -CH2NHMe, -CH2NMe2, 
----CH2NHEt, ----CH2NEt2, 
(0559] ----CH2CH2NH2 , -CH2CH2NHMe, 
----CH2CH2NMe2, 
(0560] ----CH(OH)CH2NH2, ----CH(OH)CH2NHMe, 
----CH(OH)CH2NMe2, ----CH(OH)CHimorpholino ), 
[0561] -S(=0)2NH2, or-S(=O)i(pyrrolidino ). 
[0562] In one embodiment, -Q is independently: 
[0563] ----CH(Me)OH, ----C(Me)20H, -CH(CF3)0H, 
-( cycloprop-1,1-di-yl)OH, 
[0564] ----CH(NH2)CH20H, ----CH(NHMe)CH20H. 
----CH(NMe2)CH20H, ----CH(morpholino )CH20H, 
[0565] ----CH2NH2, ----CH2NHMe, -CH2NMe2, 
[0566] ----CH2CH2NH2, -CH2CH2NHMe,
----CH2CH2NMe2, 
[0567] ----CH(OH)CH2NH2, ----CH(OH)CH2NHMe, 
----CH(OH)CH2NMe2, ----CH(OH)CHimorpholino ), or 
(0568] -S(=0)2NH2 • 
(0569] In one embodiment, -Q is independently: 
(0570] ----CH(NH2)CH20H. ----CH(NHMe)CH20H, 
----CH(NMe2)CHpH, ----CH(NHEt)CH20H, -CH 
(NEt2)CH20H, ----CH(morpholino )CH20H, 
(0571] ----CH(OH)CH2NH2, ----CH(OH)CH2NHMe, 
----CH(OH)CH2NMe2, or-CH(OH)CH:i(morpholino ). 
(0572] In one embodiment, -Q is independently: 
(0573] ----CH(NH2)CH20H, ----CH(NHMe)CH20H, 
CH(NMe2)CH20H, CH(morpholino )CH20H, 
(0574] ----CH(OH)CH2NH2, ----CH(OH)CH2NHMe, 
----CH(OH)CH2NMe2, or-CH(OH)CHi(morpholino ). 
(0575] In one embodiment, -Q is independently----CH(Me) 
OH, -C(Me)20H, ----CH(CF3)0H, or -(cycloprop-1,1-di­
yl)OH. 
[0576] In one embodiment, -Q is independently -CH 
(NH2)CH20H, ----CH(NHMe)CH20H, -CH(NMe2) 
CH20H, ----CH(NHEt)CH20H, ----CH(NEt2)CH20H, or 
----CH(morpholino )CH20H. 
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(0577] In one embodiment, -Q is independently --CH 
( NH2 )CH20H, --CH(NHMe)CH20H, -CH(NMe2) 
CH20H, or --CH(morpholino )CH20H. 
(0578] In one embodiment, -Q is independently 
-CH2 NH2, --CI 2 NI Me, -CI 2 NMe2, --CH2 NHEt, or
-CI 2 NEt2• 
(0579] In one embodiment, -Q is independently 
-CI 2 NH2, -CI 2 NI Me, or -CI 2 NMe2 • 
(0580] In one embodiment, -Q is independently 
-CI 2 CI 2 NI 2, --CI 2 CI 2 NI Me, --CI 2 CI 2 NMe2, 
-CH2 CH2 NHEt, or -CH2 CH2 NEt2 • 
(0581] In one embodiment, -Q is independently 
-CI 2 CH2 NI 2, --CH2 CH2 NHMe, or -CI 2 CH2 NMe2• 
[0582] In one embodiment, -Q is independently CH(OII) 
CI 2 NI 2, -CI (OI )CI 2 NI Me, --CI (OI )CI 2 NMe2, 
-CH(OH)CHi (morpholino ). 
(0583] In one embodiment, -Q is independently S(=O) 
2 NI 2, or -S(=OMpyrrolidino ). 
(0584] In one embodiment, -Q is independently -S(=O) 
NI 2 • 
The Group-RsN 
(0585] In one embodiment, -R8N is independently-Hor 
saturated aliphatic C1_4all.,-yl. 
[0586] In one embodiment, is independently -H, 
-Me, or -Et .
(0587] In one embodiment, -RsN is independently -I .
(0588] In one embodiment, -Rs1 is independently-I  or 
saturated aliphatic C1_4alkyl. 
(0589] In one embodiment, -R'S'1 is independently-Hor 
-Me.
(0590] In one embodiment, -Rs1 is independently -H.
(0591] In one embodiment, is independently-Me.
(0592] In one embodiment, -R82 is independently-Hor
saturated aliphatic C1_4alkyl. 
(0593] In one embodiment, 
[0594] In one embodiment, 
saturated aliphatic C1_4alkyl . 
is independently -H. 
is independently -H or 
(0595] In one embodiment, -Rs3 is independently-I . 
(0596] In one embodiment, is independently-Hor 
saturated aliphatic C1_4alkyl. 
(0597] In one embodiment, -Rs4 is independently-I . 
(0598] In one embodiment: 
(0599] -R81 is independently-I  or saturated aliphatic 
C 1_4alk-yl ; 
(0600] is independently 
(0601] -R'S'3 is independently -H; and
(0602] -Rs4 is independently-I . 
(0603] In one embodiment: 
(0604] -Rs1 is independently-I  or -Me ;
(0605] -Rs2 is independently -H;
(0606] -R83 is independently -H; and 
(0607] -R84 is independently -H. 
(0608] In one embodiment: 
(0609] -R81 is independently-H; 
[0610] -R'S'2 is independently-I ; 
(0611] -R'S'3 is independently -H; and 
(0612] is independently -H. 
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Some Preferred Combinations-I 
(0613] In one preferred embodiment: 
[0614] -A is independently: 
[0615] -Q is independently: 
r-rr 
C-C-OH 
I I 
R4A R2A 
[0616] -R1A is independently-H; 
(0617] -R2A is independently-I ; 
Aug. 4, 2011 
[0618] is independently -RJ ; and 
[0619] -R4A is independently-H. 
[0620] In one preferred embodiment: 
[0621] -A is independently: 
(0622] -Q is independently: 
r-r r 
C-C-OH 
I I 
R4A R2A 
[0623] -R1A is independently-I ; 
(0624] is independently H; 
[0625] -R3A is independently-RJ ; 
(0626] -R4A is independently-H; 
[0627] -Rx2 is independently -F or -Cl ; 
[0628] -R'Y4 is independently-F or --Cl ; and 
[0629] -R8N is independently-Hor -Me. 
[0630] In other preferred embodiments, additionally, -RJ 
is independently -NH2, -NHMe, -NMe2, -NHEt. 
-NEt2, -NI (nPr), -N(nPr)2, -NI (iPr), -N(iPr)2, pip­
eridino, piperazino, or morpholino.
[0631] In other preferred embodiments, additionally, -RJ 
is independently-NH2, -NHMe, -NMe2, or morpholino. 
[0632] In other preferred embodiments, additionally, -RJ 
is independently-NH2, -NHMe, or -NMe2 • 
[0633] In other preferred embodiments, additionally, 
is independently -NHMe. 
[0634] In other preferred embodiments, additionally, 
-R·n is independently -F and-Rx4 is independently -F.
[0635] In other preferred embodiments, additionally,
-RsN is independently -H.
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(0636] For example, in one embodiment, the compound is 
selected from compounds of the following fonnula, and phar­
maceutically acceptable salts, hydrates, and solvates thereof: 
F 
F 
O 
-dRJ OH. 
II 
-
�-� \ j 
Some Preferred Combinations-2 
(0637] In one preferred embodiment: 
(0638] -A is independently: 
(0639] -Q is independently: 
(0640] -R1B is independently 
(0641] -Rw is independently-H; 
(0642] -R3B is independently-OH or -DR 0; and
(0643] -R4B is independently-H. 
(0644] In one preferred embodiment: 
(0645] -A is independently: 
(0646] -Q is independently: 
R3B RIB IN r- 1 I l 
C-C-N 
I I \ 
R4B R2B R2N 
(0647] -R18 is independently 
(0648] is independently 
(0649] -R3B is independently --OH; and 
(0650] is independently-H. 
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(0651] In one preferred embodiment: 
(0652] -A is independently: 
(0653] -Q is independently: 
RJB RIB IN r- 1 I l 
C-C-N 
I I \ 
R4B R2B R2N 
(0654] -R1B is independently-H; 
(0655] is independently 
Aug. 4, 2011 
(0656] -R3B is independently-OH; 
(0657] -R4B is independently 
(0658] each -R lN is independently-Hor -R c"!; and 
(0659] each -R 2N is independently -H or -R cN_ 
(0660] In one preferred embodiment: 
(0661] -A is independently: 
(0662] -Q is independently: 
R3B RIB IN r- 1 I l 
C-C-N 
I I \ 
R4B R2B R2N 
(0663] -R1B is independently 
(0664] -Rw is independently 
(0665] -R3B is independently-OH; 
(0666] is independently-H; 
[ 0667] each -R lN is independently -H or -R cN;
(0668] each -R 2N is independently -H or -R cN; 
(0669] -W\'2 is independently -F or -Cl ; 
(0670] is independently-F or and 
(0671] -R',N is independently-Hor-Me . 
(0672] In one preferred embodiment: 
(0673] -A is independently: 
US 2011/0190302 Al 
(0674] -Q is independently: 
(0675] -R1B is independently 
(0676] -R2B is independently-H; 
(0677] -R3B is independently-OH; 
(0678] -R4B is independently-H; 
(0679] each-R1N is independently-Hor -Me; 
[0680] each R2N is independently Hor -Me ; 
[0681] -R:r2 is independently-For -Cl; 
[0682] -R¥4 is independently -F or --Cl; and 
[0683] -R8N is independently-Hor -Me. 
Molecular W eight 
[0684] In one embodiment, the APSAP compound has a 
molecular weight of from 338 to 1200. 
(0685] In one embodiment, the bottom ofrange is 350, 375, 
400, 425, 450, 500. 
(0686] In one embodiment, the top of range is 1100, 1 OOO, 
900, 800, 700, or 600. 
(0687] In one embodiment, the range is from 375 to 700. 
Combinations 
(0688] It is appreciated that certain features of the inven­
tion, which are, for clarity, described in the context of separate 
18 
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embodiments, may also be provided in combination in a 
single embodiment. Conversely, various features of the 
invention, which are, for brevity, described in the context of a 
single embodiment, may also be provided separately or in any 
suitable sub-combination. All combinations of the embodi­
ments pertaining to the chemical groups represented by the 
variables (e.g., -A, , p, q, -R'
'N,
-Rs3, -Rs4, -Q, , -R2A, , -R4A,
-R6A -RIB -R2B, -R3B, -R4B, -RSB -R6B,-RlN
-NR1NR2N -Re RF -Ro 
-RJ1,'_
RJ2,
,
_N R'm2R'oo -R'.:\:¥ '_NRJTRzz,._RXi:'X: 
=W-, -Rw, ' ' ' ' R"'2s,
-RDs, , -Rx4 . etc.) are specifically embraced by 
the present invention and are disclosed herein just as if each 
and every combination was individually and explicitly dis­
closed, to the extent that such combinations embrace com­
pounds that are stable compounds (i.e., compounds that can 
be isolated, characterised, and tested for biological activity). 
In addition, all sub-combinations of the chemical groups 
listed in the embodiments describing such variables are also 
specifically embraced by the present invention and are dis­
closed herein just as if each and every such sub-combination 
of chemical groups was individually and explicitly disclosed 
herein. 
Specific Embodiments 
[0689] In one embodiment, the compounds are selected 
from compounds of the following fonnulae and phannaceu­
tically acceptable salts, hydrates, and solvates thereof: 
Structure 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
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-continued
Compolllld No. Structure 
ABD766 Cl 
CJ 
[0690] In one embodiment, the compounds are selected 
from compounds of the following formulae and pharmaceu­
tically acceptable salts, hydrates, and solvates thereof: 
CompolllldNo. 
ABD723 Cl 
Cl 
ABD724 Cl 
Cl 
ABD788 F 
F 
ABD829 F 
F 
ABD830 F 
F 
Structure 
0 
II H rNvf' 
0 
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0 
II H rNvNH, 
II H rNv�/
0 
II H �-N
v
� 
N� 
0 H 
# 
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Compound No. 
ABD831 
F 
ABD833 
ABD834 
ABD860 
ABD880 
ABD881 
ABD882 
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(0691] In one embodiment, the compounds are selected 
from compounds of the following formulae and pharmaceu­
tically acceptable salts, hydrates, and solvates thereof: 
CompoudNo. 
ABD782 F 
F 
ABD783 F 
F 
ABD784 F 
F 
ABD785 
F 
ABD832 F 
F 
Stmcture 
0 OH 
I H
��-N � NH2 
o 
# 
0 OH 
IIH
�
H 
r
N 
i : 
N, 
0 OH I IIH
� r
N 
i : 
N, 
II H H 
r
N
�
N' 
(0692] In one embodiment, the compounds are selected 
from compounds of the following fonnulae and phannaceu­
tically acceptable salts, hydrates, and solvates thereof: 
Compound No. Stmcture 
ABD789 
F 
Aug. 4, 2011 
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Compound No. 
ABD790 F 
F 
ABD791 F 
F 
ABD792 
F 
F 
ABD810 F 
F 
ABD811 F 
F 
ABD850 Cl 
Cl 
ABD851 F 
Cl 
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Compound No. 
ABD852 
ABD853 
ABD854 
ABD855 
ABD857 
ABD858 
F 
ABD859 
ABD862 
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Structure 
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Compolllld No. Structure 
ABD885 F 
F 
[0693] In one embodiment, the compounds are selected 
from compounds of the following formulae and pharmaceu­
tically acceptable salts, hydrates, and solvates thereof: 
CompolllldNo. 
ABD751 Cl 
Cl 
ABD758 Cl 
Cl 
ABD760 Cl 
F 
ABD805 Cl 
Cl 
ABD866 F 
F 
Strncture 
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Compound No. 
ABD867 
ABD869 
ABD870 
ABD871 
ABD872 
ABD873 
ABD874 
ABD875 
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Compolllld No. Structure 
ABD879 
Chirality 
[0694] In some embodiments (for example, according to 
the choices for -RIA and -R 2A; the choices for -R3A and 
-R4A · the choices for -R5A and -R6A; the choices for 
-R1B' and -Rw; the choices for -R3B and -R4B; the 
choices for -R sB and -R 6B), the compound may have one
or more chiral centres. 
[0695] The chiral centre, or each chiral centre, if more than 
one is present, is independently in the R-configuration or the 
S-configuration.
[0696] If no configuration is indicated, then both configu­
rations are encompassed.
Substantially Purified Forms 
[0697] One aspect of the present invention pertain.s toAPSAP compounds, as described herein, in substantially 
purified form and/or in a form substantially free from con­
taminants. 
[0698] In one embodiment, the substantially p�ified form 
is at least 50% by weight, e.g., at least 60% by weight, e.g., at 
least 70% by weight, e.g., at least 80% by weight, e.g., at least 
90% by weight, e.g., at least 95% by weight, e.g., at least 97% 
by weight, e.g., at least 98% by weight, e.g., at least 99% by 
weight. 
[0699] Unless specified, the substantially purified form 
refers to the compound in any stereo isomeric or enantiomeric 
form. For example, in one embodiment, the substantially 
purified form refers to a mixture of stereoisomers, .i.e., puri­fied with respect to other compmmds. In one embodiment, the 
substantially purified form refers to one stereoisomer, e.g., 
optically pure stereoisomer. In one embodiment, the substan­
tially purified form refers to a mixture of enantiomers. In one 
embodiment, the substantially purified form refers to an 
equimolar mixture of enantiomers (i.e., a racen�ic mixt�e, a racemate). In one embodiment, the substantially purified 
form refers to one enantiomer, e.g., optically pure enanti­
omer. 
[0700] In one embodiment, the contaminants represent no 
more than 50% by weight, e.g., no more than 40% by weight, 
e.g., no more than 30% by weight, e.g., no more than 20% by
weight, e.g., no more than 10% by weight, e.g., no more than
5% by weight, e.g., no more than 3% by weight, e.g., no more
than 2% by weight, e.g., no more than 1 % by weight.
[0701] Unless specified, the contaminants refer to other
compounds, that is, other than stereo isomers or enantiomers.
In one embodiment, the contaminants refer to other com­
pmmds and other stereoisomers. In one embodiment, tl�e 
contaminants refer to other compounds and the other enanti­
omer. 
[0702] In one embodiment, the substantially purified form 
is at least 60% optically pure (i.e., 60% of the compound, on 
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a molar basis, is the desired stereo isomer or enantiomer, and 
40% is the undesired stereoisomer or enantiomer), e.g., at 
least 70% optically pure, e.g., at least 80% optically pure, e.g., 
at least 90% optically pure, e.g., at least 95% optically pure, 
e.g., at least 97% optically pure, e.g., at least 98% optically
pure, e.g., at least 99% optically pure.
Isomers 
[0703] Certain compmmds may exist in one or more par­
ticular geometric, optical, enantiomeric, diasteriomeric, 
epimeric, atropic, stereoisomeric, tautomeric, confonna­
tional, or anomeric forms, including but not limited to, cis­
and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo­
and exo-forms; R -, S-, and meso-forms; D- and L-forms; 
d- and I-forms; ( +) and (-) forms; keto-, enol-, and enolate­
forms; syn- and anti-forms; synclinal- and anticlinal-fon:1s; 
a.- and �-forms; axial and equatorial forms; boat-, chatr-, 
twist-, envelope-, and halfchair-forms; and combinations 
thereof, hereinafter collectively referred to as "isomers" ( or 
"isomeric fonns"). 
[0704] Note that, except as discussed below for tautomeric 
forms, specifically excluded from the term "isomers," as used 
herein, are structural ( or constitutional) isomers (i.e., isomers 
which differ in the connections between atoms rather than 
merely by the position of atoms in space). For example, a 
reference to a methoxy group, -DCH3 , is not to be construed 
as a reference to its structural isomer, a hydroxymethy 1 group, 
--CH,OH. Similarly, a reference to ortho-chlorophenyl is 
not to\e construed as a reference to its structural isomer, 
meta-chlorophenyl. However, a reference to a class of struc­
tures may well include structurally isomeric forms falling 
within that class (e.g., C1_7alkyl includes n-propyl and iso­
propyl; butyl includes n-, iso-, sec-, and tert-butyl; methox­
yphenyl includes ortho-, meta-, and para-methoxyphenyl). 
[0705] The above exclusion does not pertain to tautomeric 
forms, for example, keto-, enol-, and enolate-forms, as in, for 
example, the following tautomeric pairs: keto/enol (illus­
trated below), imine/enamine, amide/imino alcohol, amidine/ 
amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hy­
droxyazo, and nitro/aci-nitro. 
i II° 
-c-c ....--
I \ 
keto 
\ ;°H \ t 
c=c c=c 
I \ I \ 
enol enolate 
[0706] Note that specifically included in the term "isomer" 
are compounds with one or more isotopic substitutions. For 
US 2011/0190302 Al 
example, H may be in any isotopic form, including 1 H, 2H 
(D), and 3H (T); C may be in any isotopic fonn, including 12C, 
13C, and 14C; 0 may be in any isotopic fonn, including 160 
and 180; and the like. 
[0707] Unless otherwise specified, a reference to a particu­
lar compound includes all such isomeric fonns, including 
mixtures ( e.g., racemic mixtures) thereof. Methods for the 
preparation ( e.g., asymmetric synthesis) and separation ( e.g., 
fractional crystallisation and chromatographic means) of 
such isomeric forms are either known in the art or are readily 
obtained by adapting the methods taught herein, or known 
methods, in a known mallller. 
Salts 
[0708] It may be convenient or desirable to prepare, purify, 
and/or handle a corresponding salt of the compound, for 
example, a pharmaceutically-acceptable salt. Examples of 
pharmaceutically acceptable salts are discussed in Berge et 
al., 1977, "Pharmaceutically Acceptable Salts," J Phann.
Sci., Vol. 66, pp. 1-19. 
[0709] For example, if the compound is anionic, or has a 
functional group which may be anionic ( e.g., -COOH may 
be -COO-), then a salt may be formed with a suitable cation. 
Examples of suitable inorganic cations include, but are not 
limited to, alkali metal ions such as Na+ and K+, alkaline earth 
cations such as Ca2+ and Mg2+, and other cations such asAi+3 . 
Examples of suitable organic cations include, but are not 
limited to, arllll1onium ion (i.e., NH4 
+) and substituted ammo­
nium ions ( e.g., NH3R
+, NH2R2 
+, NHR3 
+, NR4 
+). Examples 
of some suitable substituted ammonium ions are those 
derived from: ethylamine, diethylamine, dicyclohexylamine, 
triethylamine, butylamine, ethylenediamine, ethanolamine, 
diethanolamine, piperizine, benzylamine, phenylbenzy­
lamine, choline, meglumine, and tromethamine, as well as 
amino acids, such as lysine and arginine. An example of a 
common quaternary arllll10nium ion is N(CH3 )4 
+. 
[0710] If the compound is cationic, or has a functional 
group which may be cationic ( e.g., -NH2 may be -NH3 
+), 
then a salt may be formed with a suitable anion. Examples of 
suitable inorganic anions include, but are not limited to, those 
derived from the following inorganic acids: hydrochloric, 
hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, 
phosphoric, and phosphorous. 
[0711] Examples of suitable organic anions include, but are 
not limited to, those derived from the following organic acids: 
2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, cam­
phorsulfonic, cimrnmic, citric, edetic, ethanedisulfonic,
ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic,
glycolic, hydroxymaleic, hydroxynaphthalene carboxylic,
isethionic, lactic, lactobionic, !auric, maleic, malic, methane­
sulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic,
phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic,
stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and
valeric. Examples of suitable polymeric organic anions
include, but are not limited to, those derived from the follow­
ing polymeric acids: tallllic acid, carboxymethyl cellulose.
[0712] Unless otherwise specified, a reference to a particu­
lar compound also includes salt forms thereof.
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Solvates and Hydrates 
(0713] It may be convenient or desirable to prepare, purify, 
and/or handle a corresponding solvate of the compound. The 
tenn "solvate" is used herein in the conventional sense to refer 
to a complex of solute (e.g., compound, salt of compound) 
and solvent. If the solvent is water, the solvate may be con­
veniently referred to as a hydrate, for example, a mono­
hydrate, a di-hydrate, a tri-hydrate, etc. 
(0714] Unless otherwise specified, a reference to a particu­
lar compound also includes solvate and hydrate forms 
thereof. 
Chemical Synthesis 
[0715] Methods for the chemical synthesis ofAPSAP com­
pounds of the present invention are described herein. These 
and/or other well-known methods may be modified and/or 
adapted in known ways in order to facilitate the synthesis of 
additional APSAP compounds of the present invention. 
[ 0716] In one approach, an appropriate bipheny I compound 
is prepared from a boronic acid and bromobenzene via a 
Suzuki coupling, for example, as described by O'Brien et al., 
2000. The biphenyl is sulfonylated using chlorosulfonic acid 
to give the corresponding sulfonic acid. The acid is then 
reacted with thionyl chloride to give the corresponding aryl 
sulfonyl chloride. Finally the sulfonyl chloride is coupled 
with ai1 ai11ine to give the corresponding sulfonamide. An 
exainple of such a method is shown in the following scheme. 
Cl 
Cl c=) ( -v- OH B,-O 
Cl 
c,-0-0
1. C!3SOH 2. SOCl2 
Cl 
c,-0-0-J-c, 
0 
0 i .,.NMe2 H,NUS · r i I o ' 
[ 0717] In another approach, the sulfonamide can be formed 
first, from a suitable bromobenzene sulfonyl chloride and 
amine ai1d the biphenyl compound then prepared by similar 
Suzuki methodology. An example of such a method is shown 
in the following scheme. 
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(0718] In another approach, the carboxylic acid can be 
replaced by an amide, by chlorination of the acid followed by 
coupling with the desired amine. For example the acid can be 
chlorinated by reflux with thionyl chloride or oxalyl chloride 
in a solvent such as toluene or DCM, followed by coupling 
with ammonia or methylamine in a solvent such as THF. An 
example of such a method is shown in the following scheme. 
ri._Cl /\ 0 0 
c1---<J-V-J-M'lf 
0H
-0-0-
Cl O 0 Cl �-�v g ,. I Cl 
� -OD-Cl O 0 Cl �-�v g ,. I NH2 
� -0-0-Cl O 0 
II Cl S-� g 'Ci'"Thk 
(0719] In another approach, the amide is reduced to the 
corresponding amine by reaetion with a suitable reducing 
agent. For example, the amide can be reduced by lithium 
aluminium hydride in a solvent such as THF. An example of 
such a method is shown in the following scheme. 
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(0720] In another approach, the amino group is prepared by 
reduction of the corresponding cyanophenyl derivative, for 
example, with a reducing agent such as lithium aluminium 
hydride in a solvent such as THF. An example of such a 
method is shown in the following scheme. 
F 
,-0-0-J-c, 0 
0 
II H 
F 
r
N
umr, 
(0721] In another approach, further substitutions may be 
made on a benzyl alcohol, by nucleophilic attack on an 
acetophenone derivative. This may be done, for example, 
with a reducing agent such as sodium borohydride in a solvent 
such as methanol, or with a Grignard reagent such as methyl 
magnesium bromide, in a solvent such as THF. An example of 
such a method is shown in the following scheme. 
F 
F-0-0-1-CI 0 
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[0722] In another approach, further substitutions may be 
made on a benzyl alcohol, by nucleophilic attack on a car­
boxylic ester derivative and subsequent cyclisation. This may 
be done, for example, with a Grignard reagent such as ethyl 
magnesium bromide in a solvent such as THF, followed by 
cyclisation with a reagent such as titanium isopropoxide 
(Sharpless epoxidation) in a solvent such as THF. An example 
of such a method is shown in the following scheme. 
F 
,-0-0-1-c, 
0 
F -00� H 0 
F S-N i '(r'oM,
F 
F 
[0723] In another approach, the benzyl alcohol can be 
selectively oxidised to give the aldehyde, and then further 
substituted by reaction with an appropriate nucleophile. For 
example, the aldehyde can be prepared by oxidation of the 
benzyl alcohol with Dess-Martin periodinane (1,1,1-triac­
etoxy-l, l-dihydro-1,2-benzoiododoxol-3-(IH)-one) in a sol­
vent such as DCM, and then reacted with (trifluoromethyl) 
trimethyl silane to give a trifluoromethyl substituted benzyl 
alcohol. An example of such a method is shown in the fol­
lowing scheme. 
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[0724] In another approach, a range of amino-substituted 
benzyl alcohols and hydroxyl-substituted benzylamines can 
be prepared by nucleophilic attack on an epoxide. For 
example, the epoxide can be prepared from the corresponding 
alkene by reaction with a peroxide, such as m-chloroperoxy­
benzoic acid, in a solvent such as DCM. The epoxide can then 
be further reacted with an amine, for example ammonia, 
methylamine or ethylamine, in a solvent such as methanol. 
This methodology gives a mixture of ring-opening positions 
and two different regioisomers, which can be separated by 
column chromatography or HPLC. An example of such a 
method is shown in the following scheme. 
F 
,-0-0-1-c, 
0 
F
-0--0-� H F S-Nv � � I � ' 
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[0725] In another approach, the separate stereoisomers 
generated by such a reaction as shown above in Scheme 9 can 
be prepared directly using chiral starting materials, for 
example (R) or (S)-methyl phenylglycine. A nitro group can 
be introduced, by reaction with nitric acid, and then hydro­
genated to give the desired aniline, which may then be 
coupled with an appropriately substituted phenylsulfonyl 
chloride as previously described. Then finally, the methyl 
ester can be reduced and the an1ide hydrolysed, to give the 
free alcohol and amine respectively. An example of such a 
method is shown in the following scheme. 
H1pJ1cnylsullonyl chloride 
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[0726] In another approach, a methyl group can be intro­
duced onto the primary amine, by use of the desired chiral 
phenyloxazolidinone starting material. Reduction of the car­
bonyl leads to ring opening and the formation of an N-methyl 
derivative whilst retaining chirality. The required aromatic 
amine can again be introduced by nitration and reduction as 
described in Scheme 10, whilst the aliphatic amine is pro­
tected by re-cyclisation. Coupling with the required biphe­
ny lsulfony 1 chloride and ring opening can then be used to give 
the final N-methyl derivative. For example, (R)-4-phenylox­
azolidin-2-one can be reduced with LiAIH4, nitrated with 
HNO/H2S04, protected as a cyclic intem1ediate by reaction 
with carbonyl diimidazole, reduced and coupled as described 
in Scheme 10 and finally hydrolysed with LiOH to give the 
free alcohol and amine. An example of such a method is 
shown in the following scheme. 
LiAlH.; -
2. H2 Pd/C
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[0727] In another approach, a range of groups can be 
attached to the amine by protection of the alcohol and aro­
matic amines and addition of a suitable leaving group, which 
may be displaced by the desired amine. For example, the 
aromatic amine can be protected with a carboxybenzyl, the 
alcohol with a tertiary butyl silyl, and the aliphatic amine 
protected from over-reaction by protection with a tertiary­
butyloxycarbonyl group. An example of such a method is 
shown in the following scheme. 
roN� 
U tc
1. 2. TBSCl 
NaOAc -
NaBJ¼ -
Pd/C 
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[0728] In another approach, the biphenyl sulfonamide 
group can be replaced by a heteroaryl-phenyl sulfonamide 
motif by preparation of any of the above compounds as a 
bromophenyl sulfonamide derivative, preparation of the 
boronic acid or boronate, and subsequent Suzuki coupling 
with a substituted pyridyl bromide at a suitable stage of the 
reaction pathway. For example, bromobenzene sulfonamide 
compounds can be prepared from the vinyl benzene, 
acetophenone, benzoate, cyanobenzene, and benzyl alcohol 
compounds described in the above schemes. These can then 
be reacted with bis(pinacolato )di boron to give the required 
borane, which can then be coupled with an appropriate het­
erocyclic bromide using Suzuki coupling. Examples of such 
methods are shown in the following schemes. 
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[0729] In another approach, a range of substituents can be 
introduced onto the phenyl rings, by use of the appropriate 
starting material. For example, a substituted aniline can be 
reacted with a substituted bromobenzene sulfonyl chloride, 
which may in turn be coupled with the required boronic acid, 
to give the desired final substitution pattern. An example of 
such a method is shown in the following scheme. 
0 Br-Q-' �-Cl 
_ II 
0 
Et 
Br-Q-' �-�vMe 
_ M 1 
"¾ NMe2 
Et # 
Cl 
Compositions 
[0730] One aspect of the present invention pertains to a 
composition (e.g., a pharmaceutical composition) compris­
ing an APSAP compound, as described herein, and a phar­
maceutically acceptable carrier, diluent, or excipient. 
[0731] Another aspect of the present invention pertains to a 
method of preparing a composition ( e.g., a pharmaceutical 
composition) comprising admixing anAPSAP compound, as 
described herein, and a pharmaceutically acceptable carrier, 
diluent, or excipient. 
Uses 
[0732] The APSAP compounds described herein are 
believed to be anti-inflammatory agents, which may act by 
blockade or modification of pro-inflammatory signalling 
pathways (for example those mediated by TNFa. signalling 
and NFKB or AP-1 activation) and thus may prevent inflam­
mation or suppress autoimmune responses or offer protection 
against joint destruction and other effects of chronic inflam­
matory disease. 
DCM/pyridine 
[0733] The APSAP compounds described herein are also 
believed to be anti-resorptive agents, which may act by block­
ade or modification of pathways that lead to excessive osteo­
clast activity (for example those mediated by RANKL, 
TNF a, and IL-1 signalling and NFKB activation) and thereby 
protect against the bone loss seen in osteoporosis and many 
chronic inflammatory conditions. 
[0734] Thus, the APSAP compounds described herein are 
believed to be useful in the treatment of inflammation and/or 
joint destruction and/or bone loss. 
[0735] Thus, the APSAP compounds described herein are 
believed to be useful in the treatment of disorders mediated by 
excessive and/or inappropriate and/or prolonged activation of 
the immune system. 
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(0736] Thus, the APSAP compounds described herein are 
believed to be useful in the treatment of, inflammatory and 
autoinuuune disorders, for example, rheumatoid arthritis, 
psoriasis, psoriatic arthritis, chronic obstructive pulmonary 
disease (COPD), atherosclerosis, inflammatory bowel dis­
ease, ank-ylosing spondylitis, and the like. 
(0737] Thus, the APSAP compounds described herein are 
believed to be useful in the treatment of disorders associated 
with bone loss, such as bone loss associated with excessive 
osteoclast activation in rheumatoid arthritis, osteoporosis, 
cancer-associated bone disease, Paget's disease and the like. 
(0738] Thus, the APSAP compounds described herein are 
believed to be useful in the treatment of haematological 
malignancies, e.g., multiple myeloma, leukaemia, or lym­
phoma ( e.g., non-Hodgkin Lymphoma), e.g., haematological 
malignancies, multiple myeloma, leukaemia, or lymphoma 
( e.g., non-Hodgkin Lymphoma) associated with activation of 
NFKB, with aberrant NFKB signalling, or with inflanuuation. 
(0739] Thus, the APSAP compounds described herein are 
believed to be useful in the treatment of solid tumour cancers, 
e.g., cancer of the bladder, breast cancer (female and/or
male), colon cancer, kidney cancer, lung cancer, pancreatic
cancer, prostate cancer, brain cancer, skin cancer, thyroid
cancer, or melanoma, e.g., solid tumour cancers, cancer ofthe
bladder, breast cancer (female and/or male), colon cancer,
kidney cancer, lung cancer, pancreatic cancer, prostate can­
cer, brain cancer, skin cancer, thyroid cancer, and melanoma
associated with activation of NFKB, with aberrant NFKB
signalling, or with inflanuuation.
(0740] Thus, the APSAP compounds described herein are
believed to be useful in the treatment of a haematological
malignancy, e.g., I-cell lymphoblastic lymphoma, mantle
cell lymphoma, or acute lymphoblastic leukemia, e.g., a hae­
matological malignancy, I-cell lymphoblastic lymphoma,
mantle cell lymphoma, or acute lymphoblastic leukemia
associated with inactivation or impaim1ent of caspase induc­
tion or with aberrant caspase signalling, e.g., alone, or in
combination with, and to augment the efficacy of, radio­
therapy or chemotherapy.
(0741] Thus, the APSAP compounds described herein are
believed to be useful in the treatment of a solid tumour cancer,
e.g., renal cell carcinoma, breast cancer (female and/or male),
gastric cancer, prostate eaneer, colon eaneer or basal eell
ameloblastoma, e.g., a solid tumour cancer, e.g., renal cell
carcinoma, breast cancer (female and/or male), gastric can­
cer, prostate cancer, colon cancer, or basal cell ameloblas­
toma associated with inactivation or impairment of caspase
induction or with aberrant caspase signalling, e.g., alone or in
combination with, and to augment the efficacy of, radio­
therapy or chemotherapy.
Use in Methods oflnhibition 
[0742] One aspect of the invention pertains to a method of 
inhibiting an inflallllllatory response, in vitro or in viva, com­
prising contacting an inuuune system component with an 
effective amount of an APSAP compound, as described 
herein. 
(0743] One aspect of the invention pertains to a method of 
inhibiting cellular and/or molecular pathways leading to joint 
destruction, in vitro or in vivo, comprising contacting cells 
associated with an immune response with a therapeutically­
effective amount of an APSAP compound, as described 
herein. 
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(0744] One aspect of the invention pertains to a method of 
inhibiting osteoclast survival, formation, and/or activity, in 
vitro or in viva, comprising contacting an osteoclast with an 
effective an10unt of an APSAP compmmd, as described 
herein. 
(0745] One aspect of the invention pertains to a method of 
inhibiting bone resorption, in vitro or in viva, comprising 
contacting cells in the bone microenvironment with a thera­
peutically-effective amount of an APSAP compound, as 
described herein. 
(0746] The term "immune system component," as used 
herein, relates to, but is not restricted to, cells such as mac­
rophages, I-cells, B-cells, NK-cells, monocytes, neutrophils, 
dendritic cells, lymphocytes, leukocytes, granulocytes, anti­
gen-presenting cells, and other cells of the haematopoietic 
lineage including osteoclasts. 
(0747] The tem1 "cells in the bone microenvironment," as 
used herein, pertains to cells such as osteoblasts, osteoclasts, 
osteocytes, and bone marrow stromal cells, which are located 
in close proximity to bone ( e.g., within one hundred 
micrometers of the bone surface). 
Use in Methods of Therapy 
(0748] Another aspect of the present invention pertains to 
an APSAP compound, as described herein, for use in a 
method of treatment of the human or animal body by therapy. 
Use in the Manufacture of Medicaments 
(0749] Another aspect of the present invention pertains to 
use of an APSAP compound, as described herein, in the 
manufacture of a medicament for use in treatment. 
(0750] In one embodiment, the medicament comprises the 
APSAP compound. 
Methods of Treatment 
(0751] Another aspect of the present invention pertains to a 
method of treatment comprising administering to a patient in 
need of treatment a therapeutically effective amount of an 
APSAP compound, as described herein, preferably in the 
form of a pharmaceutical composition. 
Diseases and Disorders 
(0752] In one embodiment, the treatment is treatment of an 
inflammatory disorder or an autoinuuune disorder. 
(0753] In one embodiment, the treatment is treatment of a 
disorder associated with inflallllllation and/or activation of 
the immune system. 
(0754] In one embodiment, the treatment is treatment of a 
disorder mediated by excessive and/or inappropriate and/or 
prolonged activation of the immune system. 
(0755] In one embodiment, the treatment is treatment of 
inflammation. 
[0756] In one embodiment, the treatment is treatment of a 
disorder associated with inflammation or activation of the 
innnune system. 
(0757] In one embodiment, the treatment is treatment of 
rheumatoid arthritis. 
(0758] In one embodiment, the treatment is treatment of 
psoriasis. 
[0759] In one embodiment, the treatment is treatment of 
psoriatic arthritis. 
[0760] In one embodiment, the treatment is treatment of 
chronic obstructive pulmonary disease (COPD). 
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(0761] In one embodiment, the treatment is treatment of 
atherosclerosis. 
(0762] In one embodiment, the treatment is treatment of 
ankylosing spondylitis. 
(0763] In one embodiment, the treatment is treatment of 
inflammatory bowel disease. 
(0764] In one embodiment, the treatment is prevention of 
an immune response leading to organ or graft rejection fol­
lowing transplant. 
(0765] In one embodiment, the treatment is treatment of a 
tumour which over expresses TNFa, IL-1, RANKL, or 
NFKB, or in which inhibition of TNFa, IL-1, RANKL, or 
NFKB facilitates or improves the action of cytotoxic tmnou­
ricidal agents. 
(0766] In one embodiment, the treatment is treatment of a 
haematological malignancy, e.g., multiple myeloma, leu­
kaemia, or lymphoma ( e.g., non-Hodgkin Lymphoma), e.g., a 
haematological malignancy, multiple myeloma, leukaemia, 
or lymphoma (e.g., non-Hodgkin Lymphoma) associated 
with activation of NFKB, with aberrant NFKB signalling, or 
with inflammation, e.g., alone, or in combination with, and to 
augment the efficacy of, radiotherapy or chemotherapy. 
(0767] In one embodiment, the treatment is treatment of a 
solid tlllllour cancer, e.g., cancer of the bladder, breast cancer 
(female and/or male), colon cancer, kidney cancer, lung can­
cer, pancreatic cancer, prostate cancer, brain cancer, skin 
cancer, thyroid cancer, or melanoma, e.g., a solid tlllllour 
cancer, cancer of the bladder, breast cancer (female and/or 
male), colon cancer, kidney cancer, lung cancer, pancreatic 
cancer, prostate cancer, brain cancer, skin cancer, thyroid 
cancer, and melanoma associated with activation of NFKB, 
with aberrant NFKB signalling, or with infla111111ation, e.g., 
alone, or in combination with, and to augment the efficacy of, 
radiotherapy or chemotherapy. 
(0768] In one embodiment, the treatment is treatment of a 
haematological malignancy, e.g., T-cell lymphoblastic lym­
phoma, mantle cell lymphoma, or acute lymphoblastic leu­
kemia, e.g., a haematological malignancy, T-cell lymphoblas­
tic lymphoma, mantle cell lymphoma, or acute lymphoblastic 
leukemia associated with inactivation or impairment of 
caspase induction or with aberrant caspase signalling, e.g., 
alone or in combination with, and to augment the efficacy of, 
radiotherapy or chemotherapy. 
(0769] In one embodiment, the treatment is treatment of a 
solid tmnour cancer, e.g., renal cell carcinoma, breast cancer 
(female and/or male), gastric cancer, prostate cancer, colon 
cancer, or basal cell ameloblastoma, e.g., a solid tmnour 
cancer, e.g., renal cell carcinoma, breast cancer (female and/ 
or male), gastric cancer, prostate cancer, colon cancer, or 
basal cell ameloblastoma associated with inactivation or 
impairment of caspase induction or with aberrant caspase 
signalling, e.g., alone, or in combination with, and to augn1ent 
the efficacy of� radiotherapy or chemotherapy. 
(0770] In one embodiment, the treatment is part of treat­
ment by combination therapy, e.g., in combination with, and 
to augment the efficacy of, radiotherapy or chemotherapy. 
(0771] In one embodiment, the treatment is treatment of a 
disease or disorder selected from: diseases having an inflam­
matory or autoi111111une component, including asthma, athero­
sclerosis, allergic diseases, such as atopy, allergic rhinitis, 
atopic dennatitis, anaphylaxis, allergic bronchopulmonary 
aspergillosis, and hypersensitivity pneumonitis (pigeon 
breeders disease, farmer's lung disease, humidifier lung dis­
ease, malt workers' lung disease); allergies, including flea 
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allergy dermatitis in mammals such as domestic animals, e.g., 
dogs and cats, contact allergens including mosquito bites or 
other insect sting allergies, poison ivy, poison oak, poison 
slUllac, or other skin allergens; autoimmune disorders, 
including, but not limited to, type I diabetes and associated 
complications, multiple sclerosis, arthritis, systemic lupus 
erythematosus, autoimmune (Hasimoto's) thyroiditis, 
autoinnnune liver diseases such as hepatitis and primary bil­
iary cirrhosis, hyperthyroidism (Graves' disease; thyrotoxi­
cosis ), insulin-resistant diabetes, autoinnnune adrenal insuf­
ficiency (Addison's disease), autoinnnune oophoritis, 
autoinnnune orchitis, autoinnnune hemolytic anemia, parox­
ysmal cold hemoglobinuria, Behcet's disease, autoinnnune 
thrombocytopenia, autoimmune neutropenia, pernicious ane­
mia, pure red cell anemia, autoinnnune coagulopathies, 
myasthenia gravis, experimental allergic encephalomyelitis, 
autoimmune polyneuritis, pemphigus and other bullous dis­
eases, rhemnatic carditis, Goodpasture's syndrome, postcar­
diotomy syndrome, Sjogren's syndrome, polymyositis, der­
matomyositis, and scleroderma; disease states resulting from 
inappropriate inflammation, either local or systemic, for 
example, irritable or inflannnatory bowel syndrome (Maz­
zucchelli et al., 1996, J Pathol., Vol. 178, p. 201), skin dis­
eases such as lichen planus, delayed type hypersensitivity, 
chronic pulmonary infla111111ation, e.g., pulmonary alveolitis 
and pulmonary granuloma, gingival inflannnation or other 
periodontal disease, and osseous inflammation associated 
with lesions of endodontic origin (Volejnikova et al., 1997, 
Am. J Pathol., Vol. 150, p. 1711), hypersensitivity lung dis­
eases such as hypersensitivity pneumonitis (Sugiyama et al., 
1995, Eur. Respir. J., Vol. 8, p. 1084), and inflammation 
related to histamine release from basophils (Dvorak et al., 
1996, J Allergy Clin. Immunol., Vol. 98, p. 355), such as hay 
fever, histamine release from mast cells (Galli et al., 1989, 
Ciba Foundation Symposium, Vol. 147, p. 53), or mast cell 
tumours, types of type 1 hypersensitivity reactions (anaphy­
laxis, skin allergy, hives, gout, allergic rhinitis, and allergic 
gastroenteritis); ulcerative colitis or Crohn's disease; TNFn 
induced polycystic kidney disease (Xiaogang Li et al., 2008, 
Nature Medicine, Vol. 14(8), p. 863); or Cryopyrin-Associ­
ated Periodic Syndromes, including Muckle-Wells Syn­
drome. 
(0772] In one embodiment, the treatment is treatment of a 
disorder mediated by osteoclasts. 
(0773] In one embodiment, the treatment is treatment of a 
disorder characterised by excessive bone resorption. 
(0774] In one embodiment, the treatment is treatment of 
bone loss. 
(0775] In one embodiment, the treatment is treatment of 
bone loss associated with inflammation. 
(0776] In one embodiment, the treatment is treatment of 
bone loss not associated with inflammation. 
(0777] In one embodiment, the treatment is treatment of 
bone loss associated with excessive osteoclast activation. 
(0778] In one embodiment, the treatment is treatment of 
joint destrnction. 
(0779] In one embodiment, the treatment is treatment of 
joint destrnction associated with infla111111ation. 
(0780] In one embodiment, the treatment is treatment of 
joint destrnction associated with excessive osteoclast activa­
tion. 
(0781] In one embodiment, the treatment is treatment of 
bone loss associated with rheumatoid arthritis, osteoporosis, 
cancer-associated bone disease, or Paget's disease of bone. 
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(0782] In one embodiment, the treatment is treatment of 
rheumatoid arthritis, osteoporosis, cancer-associated bone 
disease, or Paget's disease of bone. 
(0783] In one embodiment, the treatment is treatment of 
neoplasia of bones, whether as a primary tumour or as 
metastases, including but not limited to, osteosarcoma and 
osteoma (Zheng et al., 1998, J. Cell Biochem., Vol. 70, p. 121) 
and cancer-associated bone disease ( e.g., hypercalcaemia of 
malignancy, bone metastases, osteolytic bone metastases, 
multiple myeloma, breast carcinoma). 
(0784] In one embodiment, the treatment is treatment of 
hypercalcaemia caused by conditions associated with 
increased bone resorption, including, but not limited to: vita­
min D intoxication, primary or tertiary hyperparathyroidism, 
immobilisation, and sarcoidosis. 
(0785] In one embodiment, the treatment is treatment of 
aseptic loosening of prosthetic implants ( e.g., artificial joints, 
e.g., knees, hips, etc., can loosen due to osteoclast activity
driven by local inflammation) (see, e.g., Childs, L. M., et al.,
2001, Journal of Bone and Mineral Research, Vol. 16, No. 2,
pp. 338-347).
(0786] In one embodiment, the treatment is treatment of 
osteopetrosis, osteoarthritis, or ectopic bone formation. 
Treatment 
(0787] The tem1 "treatment," as used herein in the context 
of treating a condition, pertains generally to treatment and 
therapy, whether of a human or an animal ( e.g., in veterinary 
applications), in which some desired therapeutic effect is 
achieved, for example, the inhibition of the progress of the 
condition, and includes a reduction in the rate of progress, a 
halt in the rate of progress, alleviatiation of symptoms of the 
condition, amelioration of the condition, and cure of the con­
dition. Treatment as a prophylactic measure (i.e., prophy­
laxis) is also included. For example, use with patients who 
have not yet developed the condition, but who are at risk of 
developing the condition, is encompassed by the term "treat­
ment." 
(0788] For example, use with perimenopausal women who 
may not yet have osteoporosis, but who are at risk of 
osteoporosis, is encompassed by the term "treatment." 
(0789] The term "therapeutically-effective amount," as 
used herein, pertains to that amount of a compound, or a 
material, composition or dosage form comprising a com­
pound, which is effective for producing some desired thera­
peutic effect, commensurate with a reasonable benefit/risk 
ratio. when administered in accordance with a desired treat­
ment regimen. 
(0790] The term "treatment" includes combination treat­
ments and therapies, in which two or more treatments or 
therapies are combined, for example, sequentially or simul­
taneously. Examples of treatments and therapies include, but 
are not limited to, chemotherapy ( the administration of active 
agents, including, e.g., drugs, antibodies ( e.g., as in imn1tmo­
therapy), prodrugs ( e.g., as in photodynamic therapy, 
GDEPT, ADEPT, etc.); surgery; radiation therapy; and gene 
therapy. 
Other Uses 
(0791] The APSAP compounds described herein may also 
be used as cell culture additives to inhibit immune cell func-
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tion, for example, to inhibit the survival, formation, and/or 
activity of macrophages, I-cells, or other cells involved in the 
inunune response. 
(0792] The APSAP compounds, as described herein, may 
also be used as cell culture additives, for example, to inhibit 
osteoclasts, for exan1ple, to inhibit the survival, formation, 
and/or activity of osteoclasts. 
(0793] The APSAP compounds described herein may also 
be used as part of an in vitro assay, for example, in order to 
determine whether a candidate host is likely to benefit from 
treatment with the compound in question. 
(0794] The APSAP compounds described herein may also 
be used as a standard, for example, in an assay, in order to 
identify other active compounds, other osteoclast inhibitors, 
etc. 
Kits 
(0795] One aspect of the invention pertains to a kit com­
prising (a) an APSAP compound as described herein, or a 
composition comprising an APSAP compound as described 
herein, e.g., preferably provided in a suitable container and/or 
with suitable packaging; and (b) instructions for use, e.g., 
written instructions on how to administer the compound or 
composition. 
(0796] The written instructions may also include a list of 
indications for which the APSAP compound is a suitable 
treatment. 
Routes of Administration 
(0797] The APSAP compound or pharmaceutical compo­
sition comprising the APSAP compound may be adminis­
tered to a subject by any convenient route of administration, 
whether systemically/peripherally or topically (i.e., at the site 
of desired action). 
(0798] Routes of administration include, but are not limited 
to, oral (e.g., by ingestion); buccal; sublingual; transdermal 
(including, e.g., by a patch, plaster, etc.); transmucosal (in­
cluding, e.g., by a patch, plaster, etc.); intranasal (e.g., by 
nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by 
inhalation or insuffiation therapy using, e.g., via an aerosol, 
e.g., through the mouth or nose); rectal (e.g., by suppository
or enema); vaginal (e.g., by pessary); parenteral, for example,
by injection, including subcutaneous, intradermal, intramus­
cular, intravenous, intraarterial, intracardiac, intrathecal,
intraspinal, intracapsular, subcapsular, intraorbital, intraperi­
toneal, intratracheal, subcuticular, intraarticular, subarach­
noid, and intrasternal; by implant of a depot or reservoir, for
example, subcutaneously or intramuscularly.
The Subject/Patient 
(0799] The subject/patient may be a chordate, a vertebrate, 
a mammal, a placental manu11al, a marsupial ( e.g., kangaroo, 
wombat), a rodent (e.g., a gninea pig, a hamster, a rat, a 
mouse), murine ( e.g., a mouse), a lagomorph ( e.g., a rabbit), 
avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), 
equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a 
sheep), bovine ( e.g., a cow), a primate, simian ( e.g., a monkey 
or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., 
gorilla, chimpanzee, orangutang, gibbon), or a human. 
(0800] Furthennore, the subject/patient may be any of its 
forms of development, for example, a foetus. 
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(0801] In one preferred embodiment, the subject/patient is 
a human. 
Formulations 
(0802] While it is possible for theAPSAP compound to be 
administered alone, it is preferable to present it as a phamia­
ceutical fommlation ( e.g., composition, preparation, medica­
ment) comprising at least one APSAP compound, as 
described herein, together with one or more other phamia­
ceutically acceptable ingredients well known to those skilled 
in the art, including, but not limited to, pharmaceutically 
acceptable carriers, diluents, excipients, adjuvants, fillers, 
buffers, preservatives, anti-oxidants, lubricants, stabilisers, 
solubilisers, surfactants ( e.g., wetting agents), masking 
agents, colouring agents, flavouring agents, and sweetening 
agents. The formulation may further comprise other active 
agents, for example, other therapeutic or prophylactic agents. 
[0803] Thus, the present invention further provides phar­
maceutical compositions, as defined above, and methods of 
making a pharmaceutical composition comprising admixing 
at least one APSAP compound, as described herein, together 
with one or more other pharmaceutically acceptable ingredi­
ents well known to those skilled in the art, e.g., carriers, 
diluents, excipients, etc. If formulated as discrete units ( e.g., 
tablets, etc.), each unit contains a predetennined amount 
(dosage) of the compound. 
[0804] The term "pharmaceutically acceptable," as used 
herein, pertains to compounds, ingredients, materials, com­
positions, dosage fom1s, etc., which are, within the scope of 
sound medical judgment, suitable for use in contact with the 
tissues of the subject in question ( e.g., human) without exces­
sive toxicity, irritation, allergic response, or other problem or 
complication, collll11ensurate with a reasonable benefit/risk 
ratio. Each carrier, diluent, excipient, etc. must also be 
"acceptable" in the sense of being compatible with the other 
ingredients of the fommlation. 
(0805] Suitable carriers, diluents, excipients, etc. can be 
found in standard pharmaceutical texts, for example, Rem­
ington's Pharmaceutical Sciences, 18th edition, Mack Pub­
lishing Company, Easton, Pa., 1990; and Handbook of Phar­
maceutical Excipients, 5th edition, 2005. 
(0806] The fommlations may be prepared by any methods 
well known in the art of pharmacy. Such methods include the 
step of bringing into association the compound with a carrier 
which constitutes one or more accessory ingredients. In gen­
eral, the formulations are prepared by uniformly and inti­
mately bringing into association the compmmd with carriers 
(e.g., liquid carriers, finely divided solid carrier, etc.), and 
then shaping the product, if necessary. 
(0807] The formulation may be prepared to provide for 
rapid or slow release; inunediate, delayed, timed, or sustained 
release; or a combination thereof. 
(0808] Formulations may suitably be in the form of liquids, 
solutions (e.g., aqueous, non-aqueous), suspensions (e.g., 
aqueous, non-aqueous), emulsions (e.g., oil-in-water, water­
in-oil), elixirs, syrups, electuaries, mouthwashes, drops, tab­
lets (including, e.g., coated tablets), granules, powders, losen­
ges, pastilles, capsules (including, e.g., hard and soft gelatin 
capsules), cachets, pills, ampoules, boluses, suppositories, 
pessaries, tinctures, gels, pastes, ointments, creams, lotions, 
oils, foams, sprays, mists, or aerosols. 
(0809] Formulations may suitably be provided as a patch, 
adhesive plaster, bandage, dressing, or the like which is 
impregnated with one or more compmmds and optionally one 
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or more other pharmaceutically acceptable ingredients, 
including, for example, penetration, pem1eation, and absorp­
tion enhancers. Formulations may also suitably be provided 
in the form of a depot or reservoir. 
(0810] The compound may be dissolved in, suspended in, 
or admixed with one or more other pharmaceutically accept­
able ingredients. The compound may be presented in a lipo­
some or other microparticulate which is designed to target the 
compound, for example, to blood components or one or more 
organs. 
(0811] Formulations suitable for oral administration (e.g., 
by ingestion) include liquids, solutions (e.g., aqueous, non­
aqueous), suspensions (e.g., aqueous, non-aqueous), emul­
sions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electu­
aries, tablets, granules, powders, capsules, cachets, pills, 
ampoules, boluses. 
(0812] Formulations suitable for buccal administration 
include mouthwashes, losenges, pastilles, as well as patches, 
adhesive plasters, depots, and reservoirs. Losenges typically 
comprise the compound in a flavored basis, usually sucrose 
and acacia or tragacanth. Pastilles typically comprise the 
compound in an inert matrix, such as gelatin and glycerin, or 
sucrose and acacia. Mouthwashes typically comprise the 
compound in a suitable liquid carrier. 
(0813] Formulations suitable for sublingual administration 
include tablets, losenges, pastilles, capsules, and pills. 
(0814] Formulations suitable for oral transmucosal admin­
istration include liquids, solutions (e.g., aqueous, non-aque­
ous), suspensions (e.g., aqueous, non-aqueous), emulsions 
(e.g., oil-in-water, water-in-oil), mouthwashes, losenges, 
pastilles, as well as patches, adhesive plasters, depots, and 
reservoirs. 
[0815] Formulations suitable for non-oral transmucosal 
administration include liquids, solutions ( e.g., aqueous, non­
aqueous ), suspensions (e.g., aqueous, non-aqueous), emul­
sions ( e.g., oil-in-water, water-in-oil), suppositories, pes­
saries, gels, pastes, ointments, creams, lotions, oils, as well as 
patches, adhesive plasters, depots, and reservoirs. 
[0816] Formulations suitable for transdermal administra­
tion include gels, pastes, ointments, creams, lotions, and oils, 
as well as patches, adhesive plasters, bandages, dressings, 
depots, and reservoirs. 
(0817] Tablets may be made by conventional means, e.g., 
compression or moulding, optionally with one or more acces­
sory ingredients. Compressed tablets may be prepared by 
compressing in a suitable machine the compound in a free­
flowing form such as a powder or granules, optionally mixed 
with one or more binders ( e.g., povidone, gelatin, acacia, 
sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers 
or diluents ( e.g., lactose, microcrystalline cellulose, calcium 
hydrogen phosphate); lubricants (e.g., magnesium stearate, 
talc, silica); disintegrants ( e.g., sodium starch glycolate, 
cross-linked povidone, cross-linked sodium carboxymethyl 
cellulose); surface-active or dispersing or wetting agents 
( e.g., sodium lauryl sulfate ); preservatives ( e.g., methyl p-hy­
droxybenzoate, propyl p-hydroxybenzoate, sorbic acid); fla­
vours, flavour enhancing agents, and sweeteners. Moulded 
tablets may be made by moulding in a suitable machine a 
mixture of the powdered compound moistened with an inert 
liquid diluent. The tablets may optionally be coated or scored 
and may be fonnulated so as to provide slow or controlled 
release of the compound therein using, for example, hydrox­
ypropylmethyl cellulose in varying proportions to provide the 
desired release profile. Tablets may optionally be provided 
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with a coating, for example, to affect release, for example an 
enteric coating, to provide release in parts of the gut other than 
the stomach. 
[0818] Ointments are typically prepared from the com­
pound and a paraffinic or a water-miscible ointment base. 
[0819] Creams are typically prepared from the compound 
and an oil-in-water cream base. If desired, the aqueous phase 
of the cream base may include, for example, at least about 
30% w/w of a polyhydric alcohol, i.e., an alcohol having two 
or more hydroxyl groups such as propylene glycol, butane-I, 
3-dioL mam1itol, sorbitol, glycerol and polyethylene glycol
and mixtures thereof. The topical formulations may desirably
include a compound which enhances absorption or penetra­
tion of the compound through the skin or other affected areas.
Examples of such dermal penetration enhancers include dim­
ethylsulfoxide and related analogues.
[0820] Emulsions are typically prepared from the com­
pmmd and an oily phase, which may optionally comprise
merely an emulsifier ( otherwise known as an emulgent ), or it
may comprises a mixture of at least one emulsifier with a fat
or an oil or with both a fat and an oil. Preferably, a hydrophilic
emulsifier is included together with a lipophilic emulsifier
which acts as a stabiliser. It is also preferred to include both an
oil and a fat. Together, the emulsifier(s) with or without sta­
biliser( s) make up the so-called emulsifying wax, and the wax
together with the oil and/or fat make up the so-called emul­
sifying ointment base which forms the oily dispersed phase of
the cream formulations.
[0821] Suitable emulgents and emulsion stabilisers include
Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol,
glyceryl monostearate and sodilllll lauryl sulfate. The choice
of suitable oils or fats for the formulation is based on achiev­
ing the desired cosmetic properties, since the solubility of the
compound in most oils likely to be used in phannaceutical
emulsion formulations may be very low. Thus the cream
should preferably be a non-greasy, non-staining and washable
product with suitable consistency to avoid leakage from tubes
or other containers. Straight or branched chain. mono- or
dibasic alkyl esters such as di-isoadipate, isocetyl stearate,
propylene glycol diester of coconut fatty acids, isopropyl
myristate, decyl oleate, isopropyl palmitate, butyl stearate,
2-ethylhexyl palmitate or a blend of branched chain esters
known as Crodamol CAP may be used, the last three being
preferred esters. These may be used alone or in combination
depending on the properties required. Alternatively, high
melting point lipids such as white soft paraffin and/or liquid
paraffin or other mineral oils can be used.
[0822] Formulations suitable for intranasal administration,
where the carrier is a liquid, include, for example, nasal spray, 
nasal drops, or by aerosol administration by nebuliser,
include aqueous or oily solutions of the compmmd.
[0823] Formulations suitable for intranasal administration,
where the carrier is a solid, include, for example, those pre­
sented as a coarse powder having a particle size, for example,
in the range of about 20 to about 500 microns which is
administered in the manner in which snuff is taken, i.e., by
rapid inhalation through the nasal passage from a container of
the powder held close up to the nose.
[0824] Formulations suitable for pulmonary administration
( e.g., by inhalation or insuffiation therapy) include those pre­
sented as an aerosol spray from a pressurised pack, with the
use of a suitable propellant, such as dichlorodifluoromethane,
trichlorofluoromethane, dichoro-tetrafluoroethane, carbon
dioxide, or other suitable gases. 
38 
Aug. 4, 2011 
[0825] Formulations suitable for ocular administration 
include eye drops wherein the compound is dissolved or 
suspended in a suitable carrier, especially an aqueous solvent 
for the compound. 
[0826] Formulations suitable for rectal administration may 
be presented as a suppository with a suitable base comprising, 
for example, natural or hardened oils, waxes, fats, semi-liquid 
or liquid polyols, for example, cocoa butter or a salicylate; or 
as a solution or suspension for treatment by enema. 
[0827] Formulations suitable for vaginal administration 
may be presented as pessaries, tampons, creams, gels, pastes, 
foams or spray formulations containing in addition to the 
compound, such carriers as are known in the art to be appro­
priate. 
[0828] Formulations suitable for parenteral administration 
( e.g., by injection), include aqueous or non-aqueous, isotonic. 
pyrogen-free, sterile liquids (e.g., solutions, suspensions), in 
which the compound is dissolved, suspended, or otherwise 
provided ( e.g., in a liposome or other microparticulate ). Such 
liquids may additional contain other pharmaceutically 
acceptable ingredients, such as anti-oxidants, buffers, preser­
vatives, stabilisers, bacteriostats, suspending agents, thicken­
ing agents, and solutes which render the fonnulation isotonic 
with the blood ( or other relevant bodily fluid) of the intended 
recipient. Examples of excipients include, for example, 
water, alcohols, polyols, glycerol, vegetable oils, and the like. 
Examples of suitable isotonic carriers for use in such fornrn­
lations include Sodium Chloride Injection, Ringer's Solution, 
or Lactated Ringer's Injection. Typically, the concentration of 
the compound in the liquid is from about 1 ng/mL to about 
100 �tg/mL, for example from about 10 ng/mL to about 10 
µg/mL, for example from about 10 ng/mL to about 1 µg/mL. 
The formulations may be presented in unit-dose or multi-dose 
sealed containers, for example, ampoules and vials, and may 
be stored in a freeze-dried (lyophilised) condition requiring 
only the addition of the sterile liquid carrier, for example 
water for injections, inm1ediately prior to use. Extemporane­
ous injection solutions and suspensions may be prepared 
from sterile powders, granules, and tablets. 
Dosage 
[0829] It will be appreciated by one of skill in the art that 
appropriate dosages of the APSAP compounds, and compo­
sitions comprising the APSAP compounds, can vary from 
patient to patient. Determining the optimal dosage will gen­
erally involve the balancing of the level of therapeutic benefit 
against any risk or deleterious side effects. The selected dos­
age level will depend on a variety of factors including, but not 
limited to, the activity of the particular APSAP compound, 
the route of administration, the time of administration, the 
rate of excretion of theAPSAP compound, the duration of the 
treatment, other drugs, compounds, and/or materials used in 
combination, the severity of the condition, and the species, 
sex, age, weight, condition, general health, and prior medical 
history of the patient. The ammmt of APSAP compound and 
route of administration will ultimately be at the discretion of 
the physician, veterinarian, or clinician, although generally 
the dosage will be selected to achieve local concentrations at 
the site of action which achieve the desired effect without 
causing substantial harmfol or deleterious side-effects. 
[0830] Administration can be effected in one dose, continu­
ously or intern1ittently (e.g., in divided doses at appropriate 
intervals) throughout the course of treatment. Methods of 
determining the most effective means and dosage of admin-
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istration are well known to those of skill in the art and will 
vary with the formulation used for therapy, the purpose of the 
therapy, the target cell( s) being treated, and the subject being 
treated. Single or multiple administrations can be carried out 
with the dose level and pattern being selected by the treating 
physician, veterinarian, or clinician. 
[0831] In general, a suitable dose of the APSAP compound 
is in the range of about 10 �tg to about 250 mg (more typically 
about 100 µg to about 25 mg) per kilogran1 body weight of the 
subject per day. Where the compound is a salt, an ester, an 
amide, a prodrug, or the like, the amount administered is 
calculated on the basis of the parent compound and so the 
actual weight to be used is increased proportionately. 
EXAMPLES 
[0832] The following examples are provided solely to illus­
trate the present invention and are not intended to limit the 
scope of the invention, as described herein. 
Chemical Synthesis 
Synthesis 1 
N-(3-Acety lpheny 1 )-4-bromobenzenesulfonamide 
[0833] 
Br-0-' �-ijvO _ g 
1
� Me 
# 
[0834] Method A: 4'-Bromobenzene sulfonyl chloride (1.5 
g) and 3-aminoacetophenone (1.5 g) were dissolved in DCM
(50 mL) and pyridine (3 mL) was added. The mixture was
stirred overnight then poured into dilute HCI and extracted
with DCM. The organic phase was washed with water, dried
and evaporated to give a thick red oil, purified by column
chromatography ( ethyl acetate/petrol) and the title compound
obtained as a white powder.
Synthesis 2 
N-(3-Acetylphenyl)-2',4'-difluorobiphenyl-4-sul­
fonamide 
[0835] 
F 
F 
[0836] Method B: N-(3-Acetylphenyl)-4-bromobenzene­
sulfonamide (2 g) was dissolved in a mixture of toluene (20 
mL) and ethanol (20 mL ). 2,4-Difluorophenylboronic acid (2 
g)was added followed by 2 M Na2C03 (20 mL). The mixture
was stirred vigorously under N2 and (PPh3)4Pd (0.2 g) added.
The mixture was refluxed with stirring for 3 hours under an 
atmosphere ofN2 • The solvent was removed under vacuum,
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the residue dissolved in ethyl acetate and washed with water 
and saturated NaCl solution. After drying (Na2S04) the sol­
vent was evaporated and the brown residue purified by col­
Ulllll chromatography ( ethyl acetate/petrol) and the title com­
pound obtained as a crystalline white solid from ethyl acetate/ 
petrol. 13C NMR (250 MHz, DMSO-d6): 6 26.7, 104.7 (m),
112.2 (m), 118.5, 118.7, 123.2, 124.2, 126.8, 127.4, 129.7, 
132.1, 137.7, 138.2, 138.6, 138.7, 159.1 (dd, 1=250.0, 11.7
Hz), 162.3 (dd, 1=248.0, 11.7 Hz) and 197.3. 1H NMR (250
MHz, DMSO-d6): 6 2.48 (3H, s), 7.18 ( lH, t, 1=7.0 Hz),
7.31-7.41 (3H, m), 7.54-7.66 (3H, m), 7.70 (2H, d,J=9.2 Hz),
7.87 (2H, d, 1=8.2 Hz) and 10.67 ( lH, s).
Synthesis 3 
N-(3-Acety lpheny I )-4' -bromo bipheny 1-4-sulfona­
mide 
[0837] 
0 0 Br-0-0-' {I ' �-ijv _ _  g 
1
� Me 
# 
[0838] Using a method analogous to Method A, using 
4'-bromobiphenyl sulfonyl chloride (1.5 g) and 3-aminoac­
etophenone (1.5 g), the title compound was obtained as a 
white powder. 
Synthesis 4 
N-(3-Acetylphenyl)-2',4'-dichlorobiphenyl-4-sul­
fonaniide (ABD746) 
[0839] 
Cl 
Cl 
[0840] Method C: A solution ofN-(3-acetylphenyl)-4-bro­
mobenzenesulfonamide (350 mg, 1 nuuol) and 2,4-dichlo­
rophenylboronic acid (290 mg, 1.5 mmol) in dimethoxy­
ethane (5 mL) was stirred under nitrogen and 2 M Na2C03 
(1.5 mL) was added. The flask was flushed with nitrogen 
before Pd(dppf)Cl2 (36 mg, 0.05 mmol) was added and the 
flask was placed in an oil bath that had been pre-heated to 90°
C. and stirred for 1 hour. The mixture was cooled, poured into
water (50 mL) and extracted with ethyl acetate (3x25 mL). 
The extracts were washed with water (15 mL) and brine (15 
mL) and dried over MgS04• Evaporation of the solvents
afforded a brown solid which was purified by column chro­
matography on silica, eluting with hexane/acetone (2: 1) and 
the title compound obtained as a pale brown powder ( 400 
mg). 
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Synthesis 5 
2',4'-Dichloro-N-(3-(2 -hydroxypropan- 2 -yl)phenyl) 
biphenyl-4-sulfonamide (ABD707) 
[0841] 
Cl 
Cl 
TI HefMe .re 
S-N 
M I 
� OH 
# 
[0842] A solution of ABD746 (310 mg, 0.74 11111101) in 
anhydrous THF (10 mL) was cooled under nitrogen to 0° C. A
solution of 3 M methylmagnesium bromide in diethyl ether 
(615 µL, 1.84 11111101) was added by syringe and the solution 
was stirred at 0° C. for 1 hour. Saturated NH4Cl (5 mL) was
added at 0° C., the mixture diluted with water (5 mL) and
ethyl acetate (2 0 mL ), and the layers separated. The organic 
phase was washed with water (10 mL) and brine (10 mL) and 
dried over MgS04 . Evaporation of the solvents gave a yellow 
solid which was purified by column chromatography on 
silica, eluting with hexane/acetone (2: 1) to give the title com­
pound as an off-white solid (2 75 mg). 1H NMR (300 MHz,
DMSO-d6): 1\ 1.2 8  (6H, s), 4.95 (lH, s), 6.94 (lH, d, J=8 Hz), 
7.04-7.14 (2H, m), 7.16 (lH, s), 7.40 (lH, d, J=9 Hz), 7.50 
(lH, d, J=9 Hz), 7.57 (2H, d, J=8 Hz), 7.74 (lH, br s), 7.80 
(2H, d, J=8 Hz) and 10. 2 6  (lH, br s). MS, m/z: Calcd, 435. 
046. Found, 435.24 (M).
Synthesis 6 
2' ,4 '-Dichloro-N-(3-( 1-hydroxyethy l)pheny I) biphe­
nyl-4-sulfonamide (ABD708) 
[0843] 
Cl 
Cl 
[0844] A solution of ABD746 (70 mg, 0.17 mmol) in 
methanol (5 mL) was cooled under nitrogen to 0° C. and
NaBH4 (13 mg, 0.33 11111101) was added in one portion. The 
mixture was stirred for 16 hours, allowing the temperatnre to 
rise to room temperature. Evaporation of the solvent gave a 
pale brown solid, which was purified by column chromatog­
raphy on silica, eluting with hexane/acetone (2: 1 ). The result­
ing waxy yellow solid was triturated with diethyl ether and 
hexane and the title compound obtained as a white solid ( 40 
mg). 1H NMR (300 MHz, CDC1
3
): 1\ 1.43 (3H, d, J=6 Hz),
4.82 (lH, q, J=6 Hz), 6.79 (lH, br s), 6.95-7.40 (6H, m), 7.47 
(2H, d, J=8 Hz), 7.50 (lH, s) and 7.81 (2H, d, J=8 Hz). MS, 
m/z: Calcd, 42 1.031. Found, 42 1. 14 (M). 
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Synthesis 7 
2' ,4'-Dichloro-N-(3-(1-hydroxycyclopropyl)phenyl) 
biphenyl-4-sulfonamide (ABD709) 
[0845] 
Cl 
Cl 
[0846] A solution of methyl 3-(2',4'-dichlorobiphenyl-4-
ylsulfonamido)benzoate (500 mg, 1.03 mn10l) and titanium 
isopropoxide (61 µL, 0. 2 06 11111101) in anhydrous THF (10 
mL) was cooled under nitrogen to -10° C. A solution of3
Methylmagnesium iodide in THF (2 .4 mL, 7.2 11111101) was 
added by syringe and the solution was stirred at 0° C. for 1
hour, then at room temperature overnight. The mixture was 
diluted with water (5 mL) and ethyl acetate (2 0 mL) and 
filtered through Celite. The layers were separated. The 
organic phase was washed with water (10 mL) and brine (10 
mL) and dried over MgS04• Evaporation of the solvents gave
an orange gum which was purified by column chromatogra­
phy on silica, eluting with acetone/hexane (1:4) and the title 
compound obtained as a light yellow foam (100 mg). 1H
NMR (300 MHz, CDC13): 1\ 0.95-1.05 (2H, 111), 1. 2 0- 1.24 
(2H, 111), 6.90-7. 10 (3H, 111), 7.2 0-7.46 (3H, 111), 7.47-7.48 
(3H, m) and 7.83 (2H, d). MS, m/z: Calcd, 433.031. Fmmd, 
433.2 2 (M). 
Synthesis 8 
Ethyl 3-( 4-bromophenyl-4-ylsulfonamido )benzoate 
[0847] 
Br-0-' �-�do 
- M I 
� OEt 
# 
[0848] Using a method analogous to Method A, with 4-bro­
mophenyl sulfonylchloride and ethyl 3-amino-benzoate, the 
title compound was obtained as a white powder. 
Synthesis 9 
Ethyl 3-(2',4'-dichlorobiphenyl-4-yl sulfonamido) 
benzoate 
[0849] 
Cl 
Cl 
[0850] Using a method analogous to Method B, with ethyl-
5-( 4-bromophenyl-4-ylsulfonamido) benzoate and 2 ,4-
dichlorophenylboronic acid, the title compmmd was obtained 
as white crystals. 13C NMR (250 MHz, DMSO-d6): 1\ 14.1,
US 2011/0190302 Al 
61.0, 120.3, 12 4.5, 125.2 , 126.5, 126.9, 127.8, 129.9, 130.2 , 
130.8, 132 .2 , 133.1, 133.8, 137.1, 138.1, 138.9, 142 .0 and 
165.1. 1H NMR (250 MHz, DMSO-d6): o 1.2 7 (3H, t, J=7.3
Hz), 4.26 (2H, q, J=7.0 Hz), 7.39 (lH, d, J=7.9 Hz), 7.42 (lH,
d, J=7.3 Hz), 7.43 (lH, s), 7.50 ( lH. dd. J=8.2 . 1.9 Hz), 7.60
( lH, m), 7.62 (2H, d, J=8.2 Hz), 7.74 (2H, s), 7.86 (2H, d, 
J=8.5 Hz) and 10.70 (lH, s). MS, m/z: Calcd, 449.03. Found,
449.2 3 (M). 
Synthesis 10 
3-(2 ' ,4' -Dichlorobiphenyl-4-y lsulfonamido )benzoic 
acid 
[0851] 
Cl 
Cl 
[0852] Ethyl 3-(2 ',4'-dichlorobiphenyl-4-ylsulfonamido) 
benzoate (0.4 g) was dissolved in a mixtnre of THF (5 mL) 
and methanol (5 mL). 1 M NaOH (10 mL) was added and the 
mixture stirred for 3 hours at room temperature followed by 1 
hour at 50° C., by which stage a clear solution had fonned.
Concentrated HCl was added and the precipitate collected as 
a white solid. The solid was dissolved in ethyl acetate and 
dried with Na2S04. Evaporation gave the title compound as a
white solid, recrystallised from ethyl acetate/petrol. 13C 
NMR (250 MHz, DMSO-d6): o 12 2 .4, 12 4.1, 125.0, 126.3,
126.5, 127.7, 129.6, 130.4, 131.9, 132 .2 , 132.5, 133.8, 137.1, 
137.9, 138.9. 142.0 and 166.8. MS, m/z: Calcd, 420.99. 
Found, 42 1.2 2 (M). 
Synthesis 11 
3-(2 ',4'-Dichlorobiphenyl-4-ylsulfonamido)benzoyl 
chloride 
[0853] 
Cl 
Cl 
[0854] A suspension of 3-(2 ',4'-dichlorobiphenyl-4-ylsul­
fonamido )benzoic acid (1.50 g, 3.5611111101) in DCM (35 mL) 
was stirred at 0° C. and oxalyl chloride (340 µL, 3.9 mmol)
was added, followed by a catalytic amount ofDMF (<50 �tL). 
The mixtnre was allowed to warm to room temperatnre and 
stirred for two days, during which time the solid dissolved to 
form a light yellow clear solution. The mixtnre was evapo­
rated under reduced pressure and the residue was azeotroped 
with toluene (3 mL), then hexane (10 mL) and the title corn-
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poundobtained as a light brown, slightly gummy, solid (1.5 g) 
which was used without farther purification. 
Synthesis 12 
3-(2 ' ,4'-Dichlorobiphenyl-4-ylsulfonamido )-N,N­
dimethylbenzamide 
[0855] 
Cl 
Cl S N 
�H�
O 
f I: ( 
[0856] A solution of 2 M dimethylamine in THF (5 mL) 
was added to 3-(2 ',4'-dichlorobiphenyl-4-ylsulfonamido) 
benzoyl chloride (350 mg, 0.76 mmol) and the mixtnre was 
stirred at room temperatnre for 3 days. Satnrated anltllonium 
chloride (3 mL) was added and the solution acidified to pH 3 
with 2 M HCI. The mixture was extracted with EtOAc (3x5 
mL) and the organic layer was washed with brine (5 mL), 
dried over MgS04, filtered and evaporated to give a yellow 
glass. This was tritnrated with acetone and the title compound 
obtained as a white solid (130 mg). 
Synthesis 13 
2 '  ,4'-Dichloro-N-(3-( ( dimethylamino )methyl)phenyl) 
biphenyl-4-sulfonamide (ABD72 4) 
[0857] 
Cl 
0 
II H 
Cl 
r
N
l)
(
[0858] A solution of 3-(2 ',4'-dichlorobiphenyl-4-ylsul­
fonamido)-N.N-dimethylbenzamide (130 mg. 0.2 911111101) in 
THF ( 5 mL) was stirred at room temperature and 1 M borane 
in THF (1 .45 mL, 1 .45 11111101) was added. The solution was 
heated at 50° C. for 45 minutes. The mixtnre was then cooled
and saturated annnonium chloride (5 mL) was added. The 
mixture was further diluted with water (10 mL) and extracted 
with EtOAc (3x15 mL). The combined organic layers were 
dried over MgS04, filtered and evaporated. The residue was 
purified by column chromatography (Si02, 2 0% acetone/
hexane) and the title compound obtained as a light yellow 
glass (73 mg). 1H NMR (300 MHz, CDC1
3
): o 2 .49 (6H, s),
3.87 (2H, s), 6.69 (lH, br s), 7.05-7.35 (6H, m), 7.49-7.50 
(3H, m) and 7.81 (2H, d, J=9 Hz). MS, m/z: Calcd, 434.062 . 
Found, 434.17 (M). 
US 2011/0190302 Al 
Synthesis 14 
4-Bromo-N -(3-sulfamoy !phenyl )benzenesulfona­
mide (ABD751a) 
[0859] 
O O 0 -0- 11 H \/ 
Br S-N
v
s, 
M I 
"a: NH2 
# 
[0860] A solution of 4-bromobenzenesulfonyl chloride 
(1.34 g, 5.25 nunol), 3-aniinobenzenesulfonamide (860 mg, 
5.0 nunol) and DIPEA (1.29 g, 10 nunol) in THF (10 mL) was 
stirred overnight at room temperature. The solvent was then 
evaporated and the residue purified by chromatography on the 
SP4 (70 g Silica I solute II, 0-100% EtOAc/hexane) to and the 
title compound obtained as a white solid (395 mg). 
Synthesis 15 
2',4'-Dichloro-N-(3-sulfamoylphenyl)biphenyl-4-
sulfonamide (ABD751) 
[0861] 
Cl 
Cl 
[0862] Using a method analogous to Method C, using 
ABD75la and 2.4-dichlorobenzeneboronic acid the title 
compound was obtained as an off-white solid (170 mg). 1H 
NMR (300 MHz, DMSO-d6): 6 7.30 (lH, br d, J=7.5 Hz), 
7.34-7.54 (6H, m), 7.56-7.63 (3H, m), 7.73 (lH, d, J=2.5 Hz), 
7.86 (2H, d, J=8 Hz) and 10.78 (lH, br s). MS, m/z: Calcd, 
455.977. Found, 456.17 (M). 
Synthesis 16 
2',4'-Dichloro-N-(3-formylphenyl)biphenyl-4-sul­
fonamide 
[0863] 
Cl 
Cl 
[0864] A solution of 2',4'-dichloro-N-(3-(hydroxymethyl) 
phenyl)biphenyl-4-sulfonamide (340 mg, 0.83 nu11ol) in 
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DCM (10 mL) was stirred under argon at room temperature. 
Dess-Martin reagent (390 mg, 0.92 1111110!) was added in one 
portion and the mixture was stirred for an hour. The suspen­
sion was filtered through Celite, rinsing well with DCM. The 
filtrate was washed with 1 M Na2S203 (lOmL) and water (lO 
mL) and the DCM was dried over MgS04• The solvent was 
evaporated and the residue absorbed onto Si02 and purified 
by column chromatography (4x16 cm Si02, 25% acetone/ 
hexane) and the title compound obtained as a yellow waxy 
solid (280 mg). 
Synthesis 17 
2',4'-Dichloro-N-(3-(2,2,2-trifluoro-l-hydroxyethyl) 
phenyl)biphenyl-4-sulfonamide (ABD766) 
[0865] 
Cl 
Cl 
0 \;;F3 
II H 
r
N
vOH 
[0866] A solution of 2',4'-dichloro-N-(3-formylphenyl)bi­
phenyl-4-sulfonamide (133 mg, 0.33 1111110!) in dry THF (3 
mL) was stirred under argon. Trifluoromethyl)trimethylsi­
lane (58 µL) and 1 M TBAF in THF (33 �tL) were added by 
syringe and the solution was stirred at room temperature. 
TLC indicated very little reaction, so further (trifluorometh­
yl)trimethylsilane (240 µL) and 1 M TBAF in THF (350 µL) 
were added. Stirring was continued for a further two hours, 
when TLC indicated the formation of a more polar com­
pound. 1 M HCl ( 5 mL) was added and the mixture was stirred 
overnight. Diethyl ether (20 mL) was then added and the 
layers were separated. The aqueous phase was extracted with 
further diethyl ether (10 mL) and the combined extracts were 
dried (MgS04) and evaporated to afford a yellow gum (145 
mg) consisting of a mixture of unreacted starting material and 
the desired product by LCMS. This mixture was redissolved 
in THF (2 mL) and further (trifluoromethyl)trimethylsilane 
(500 µL) and l M TBAF in THF (350 µL) were added. After 
1 hour, the mixture was quenched and worked up as above. 
The crude product was purified by SP4 chromatography (20 g 
!solute II Silica colunu1, 0-30% acetone/hexane) gave a yel­
low gum (65 mg). This was triturated with ether and hexane
and the title compound obtained as a white powdery solid ( 43 
mg). 1H NMR (300 MHz, DMSO-d6): 6 5.05 (lH, quintet,
J=6 Hz), 6.78 (lH, d,J=6 Hz), 7.12 (2H, d, J=7 Hz), 7.20-7.28
(2H, m), 7.38 (lH, d, J=7 Hz), 7.49 (lH, dd, J=8 Hz, 2 Hz),
7.57 (2H, d, J=8 Hz), 7.76 (lH, d, J=2 Hz), 7.81 (2H, d, J=8
Hz) and 10.56 (lH, br s).
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Synthesis 18 
2' ,4 '-Difluoro bipheny lsulfony 1 chloride 
[0867] 
F 
0 
II 
F S-Cl 
II 
0 
[0868] 2,4-Difluorophenylboronic acid (15 g, 129 mmol) 
was added to a solution ofbromobenzene (19.8 g, 126 mmol) 
in DME (500 mL). To this was added a solution of sodium 
carbonate (55.8 g, 520 mmol) in water (260 mL ). The solution 
was degassed by bubbling argon through the mixture aud then 
stirred under argon. Pd( dppf)Cl2 (1.5 g, 2.1 nunol) was added 
and the flask was flushed with argon and heated at 90° C.
overnight. The mixture was then cooled to room temperature 
and water (150 mL) and ethyl acetate (500 mL) were added. 
The layers were separated and the organic layer washed with 
2 M NaOH (100 mL), water (100 mL) and brine (100 mL). 
The black ethyl acetate layer was dried over MgS04, charcoal 
was added, and the mixture was filtered through a short pad of 
silica. Evaporation of the solvents gave 2,4-difluorobiphenyl 
as a brown oil, which crystallised on standing (21.2 g). 
[0869] 2,4-Difluorobiphenyl (21.2 g, 111 nunol) was dis­
solved in chloroform (120 mL) and chlorosulfonic acid (12.5 
mL, 188 mmol) was added dropwise. The reagents were 
stirred overnight at room temperature. The reaction was con­
centrated in vacua and the residue was taken up into EtOAc 
(100 mL) and washed with water (3x25 mL). The organics 
were shaken with brine, whereupon a flocculent solid formed. 
This was filtered and washed with EtOAc and dried to give 
2',4'-difluorobiphenyl sulfonic acid as an off-white solid 
(12.1 g). 
[0870] 2',4'-Difluorobiphenyl-4-sulfonic acid (12.1 g, 47 
mmol) was suspended in thionyl chloride (100 mL). The 
mixture was heated at reflux for 30 minutes, when a catalytic 
amount of dry DMF was added and the reaction was heated at 
reflux for a further 4 hours. The reaction was then cooled and 
the thionyl chloride evaporated and the residue was then 
azeotroped with toluene (3xl0 mL). The resulting yellow/ 
orange gnm was taken up into EtOAc 250 mL) and washed 
with water (50 mL) and brine (50 mL), and dried over 
MgS04. Filtration and evaporation gave the title compound 
as a brown oil which crystallized on standing (11 g). 
Synthesis 19 
2',4'-Difluoro-N-(3-vinylphenyl)biphenyl-4-sulfona­
mide 
[0871] 
F 
0 
II H 
F rNu 
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[0872] 3-Amino styrene (1.36 g, 11.4 mmol) was added to 
a solution of 2' ,4'-difluorobiphenyl-4-sulphonyl chloride (3 .0 
g, 10.3 mmol) in DCM (25 mL) at 0° C. Pyridine (6.0 mL, 74
nunol) was then added aud the mixture was allowed to stir and 
warm to room temperature overnight. The reaction was par­
titioned between further DCM (100 mL) aud 2 M HCl (30 
mL ), stirred and separated. The DCM layer was washed with 
water (20 mL) and brine (20 mL) and dried over MgSO 4. The 
solvent was evaporated and the title compound obtained as au 
orange gum (3.46 g) which was used without further purifi­
cation. 
Synthesis 20 
2',4'-Difluoro-N-(3-(oxirau-2-yl)phenyl)biphenyl-4-
sulfonamide 
[0873] 
F 
F 
[0874] Dry meta-chloroperoxybenzoic acid (-85%, dried 
over KOH in a clean, dry, uncontaminated vacuum desiccator 
for at least 48 hours; 3.7 g, 21 mmol) was added to a solution 
of 2',4'-difluoro-N-(3-vinylphenyl)biphenyl-4-sulfonamide 
(1.16 g, 4.3 nm10 l) in dry DCM (30 mL) at 0
° C. The mixture
was allowed to wann to room temperature and stirred for 5 
hours. Water (30 mL) was added and the layers were sepa­
rated. The DCM layer was washed with 10% Na2S03 (30 
mL), saturated NaHC03 (30 mL), water (30 mL) and brine 
(30 mL) and dried over MgS04 . The solvent was evaporated 
and the title componnd obtained as au orange oil (1.16 g) 
which was used without further purification. 
Synthesis 21 
N-(3-(2-Amino-l -hydroxyethyl)phenyl)-2',4'-difluo­
robiphenyl-4-sulfonamide (ABD782) 
[0875] 
[0876] Method D: A solution of 2',4'-difluoro-N-(3-( oxi­
ran-2-yl)phenyl)biphenyl-4-sulfonamide (1.1 g, 2.84 11111101) 
in dry THF (10 mL) was added dropwise to a solution of 20% 
ammonia in methanol (20 mL) and the reaction was stirred 
overnight. The solvents were evaporated and the residue was 
azeotroped with toluene. The crude product was dissolved in 
methanol, loaded onto a 5 g SCX II cartridge which was 
eluted with methanol nntil clear aud then with 20% NH3 in 
methanol and the title compound obtained as a mixture of 
regioisomers (1:1 with ABD790) which were not further 
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separated. 1 H NMR (300 MHz, CDC13): o 2 .76 (0.5H, br s),
3.0 2 (0.5H, br s), 3.45 (0.5H, br s), 3.60 (0.5H, br s), 3.95 
(0.5H, br s ), 4.30 (2H, br s ), 4.60 (0.5H, br s ), 6.70-7 .60 (1 OH, 
m) and 7.80 (2H, br s).
Synthesis 2 2  
2 ',4'-Difluoro-N-(3-(1-hydroxy-2 -(methylamino) 
ethyl)phenyl)biphenyl-4-sulfonamide (ABD783) 
[0877] 
-0-0-F tH
�
O
H 
H 
F S N 
� 
N
'-... 
g I 
# 
[0878] Using a method analogous to Method D, using 2 '  ,4'­
difluoro-N-(3-( oxiran-2 -y !)phenyl )bipheny 1-4-sulfonamide 
and 33% methylamine in ethanol, a mixture of regioisomers 
was obtained. This solution was evaporated and the isomers 
were separated by flash chromatography (Si02, eluting with 
5% to 20% methanol/DCM, containing 0.1 % concentrated 
aqueous NH3), giving ABD789 as a light orange powder (165
mg). With further elution (increasing the polarity slowly to 
40% methanol/DCM) ABD783 was obtained as an orange 
gum, which was triturated with ether to give the title com­
pound as a light orange powder (330 mg). 1H NMR (400 
MHz, DMSO-d6): o 2.47 (3H, s), 2 .70-2 .76 (lH, t), 2.80-2.89
(lH, dd), 4.85 (lH, d, J=8 Hz), 6.95-7.1 5 (2H, m), 7.10-7. 25  
(3H, m), 7.40 (lH, t), 7.55-7.65 (lH, m), 7.66 (2H, d, J=8 Hz) 
and 7.84 (2H, d, J=8 Hz). MS, m/z: Calcd, 418.1 1 .  Found, 
418.28 (M). 
Synthesis 2 3
N-(3-(2 -(Dimethylamino )-1 -hydroxyethyl)phenyl)-
2 ',4'-difluorobiphenyl-4-sulfonamide (ABD784) 
[0879] -0-o-F 
o on 
I
F �-ij N 
g I � '
# 
[0880] Using a method analogous to Method D, using 2 ',4'­
difluoro-N-(3-( oxiran-2 -y !)phenyl )bipheny 1-4-sulfonamide 
and 33% dimethylamine in ethanol, a mixture of regioisomers 
was obtained. Reverse-phase HPLC was used to purify the 
mixture and the title compound was obtained as a pale orange 
powder. 1H NMR (300 MHz, CDC13): o 2 .70 (6H, s), 3.05-
3.1 0  (2H, m), 5.05 (lH, bd), 6.80-6.95 (2H, m), 7.00-7.2 2  
(3H, m), 7.2 5-7.35 (2H, m), 7.49 (2H, d, J=8 Hz) and 7.87 
(2H, d, J=8 Hz). 
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Synthesis 2 4  
2 '  ,4' -Difluoro-N-(3-(1-hydroxy-2 -morpholinoethyl) 
phenyl)biphenyl-4-sulfonamide (ABD785) 
[0881] 
[0882] Using a method analogous to Method D, using 2 ',4'­
difluoro-N-(3-( oxiran- 2 -yl )pheny 1 )bipheny 1-4-sulfonamide 
and 1 M morpholine in methanol, a mixture of regioisomers 
was obtained. Reverse-phase HPLC was used to purify the 
mixture and the title compound was obtained as a pale orange 
powder. 1H NMR (300 MHz, CDC13): o 2 . 20-2 .40 (3H, m),
2 .50- 2 .70 (2H, m), 3.60-3.80 (4H, m), 4.66 (lH, m), 6.85-7. 
00 (2H, m), 7.0 3-7.1 9  (3H, m), 7.2 0-7.30 (lH, m), 7. 30-7.40 
(lH, m). 7.57 (2H, d, J=8 Hz) and 7.91 (2H, d, J=8 Hz). MS. 
m/z: Calcd, 474. 14 2 .  Found, 474.56 (M). 
Synthesis 2 5  
N-(3-Cyanophenyl )-2 '  ,4' -difluoro bipheny 1-4-sulfona­
mide 
[0883] 
F 
0 
II H 
F rN
v
CN 
[0884] 2 ',4'-Difluorobiphenylsulfonyl chloride (260 mg, 
0.90 mmol) and 3-aminobenzonitrile (160 mg, 1 . 35 mmol) 
were stirred in DCM (10 mL) at room temperature. Pyridine 
(145 µL, 1 .80 mmol) was added by syringe and the mixture 
was stirred overnight. The solution was poured into EtOAc 
(50 mL) and washed with 1 MHCl (2xlOmL), water (lOmL) 
and brine (10 mL). The solvent was dried over MgS04 and 
evaporated to give an orange oil ( 450 mg). This was absorbed 
onto Si02 and purified by SP4 chromatography (2 0 g !solute 
II Si02 column, 0- 30% acetone/hexane) and the title com­
pound obtained as a yellow oil (330 mg). 
Synthesis 26  
N-(3-(Aminomethyl)phenyl)-2 ',4'-difluorobiphenyl-
4-sulfonamide (ABD788)
[0885] 
F 
0 
II H 
F rN
vNH, 
[0886] A solution of N-(3-cyanophenyl)-2 ',4'-difluorobi­
phenyl-4-sulfonamide in THF was cooled under argon to 0° 
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C. A solution of LiAIH4 in THF (2.67 mL) was added by
syringe and the mixture was stirred for an hour, after which
TLC indicated very little reaction. Further LiAIH4 in THF
(2.5 mL) was added and the mixture was allowed to warm to
room temperature and stirred for 3 days. The solution was
cooled to 0° C. and Na2S04.10H20 (500 mg) was added and
the mixture stirred vigorously for 30 minutes. MgS04 was 
added and the mixture was filtered and evaporated to give an 
off-white solid (135 mg). This was purified by on a 2 g SCX 
column, eluting with DCM/MeOH (1:1, 2x5 mL) and then 
NH/MeOH/DCM (20% 2 M NH/MeOH in DCM; 4x5 mL) 
to give a glassy solid. This was triturated with diethyl ether 
and the title compound obtained as an off-white powder ( 40 
mg). 1H NMR (400 MHz, DMSO-d6): o 3.65 (2H, s), 3.85
(2H, br s), 6.87 (lH, d, J=7.5 Hz), 6.92 (lH, d, J=7.5 Hz), 7.07 
(lH, t, J=7.5 Hz), 7.17 (lH, td, J=9 Hz, 3 Hz), 7.35 (lH, td, 
J=lO Hz, 3 Hz), 7.57 (lH, q, J=6.5 Hz), 7.62 (2H, d, J=8 Hz) 
and 7.82 (2H, d, J=8 Hz). MS, m/z: Calcd, 374.09. Folllld, 
374.30 (M). 
Synthesis 27 
2' ,4'-Difluoro-N-(3-(2-hydroxy-l -(methylamino) 
ethyl)phenyl)biphenyl-4-sulfonamide (ABD789) 
(0887] 
[0888] Using a method analogous to Method D, using 2' ,4'­
difluoro-N-(3-( oxiran-2-y !)phenyl )bipheny 1-4-sulfonamide 
and 33% methylamine in ethanol, the title compound was 
obtained as a light orange powder (165 mg) by flash chroma­
tography of mixture of regioisomers which gave ABD783. 1 H 
NMR (400 MHz, CDC13): o 2.10 (3H, s), 3.51 (lH, 111), 
3.60-3.6 2 (2H, m), 5.10 (3H, br s), 6.70-6.95 (3H, m), 7.10-
7.15 (4H, 111), 7.20-7.25 (lH, m), 7.34 (2H, d, J=8 Hz) and 
7.73 (2H, d, J=8 Hz). MS, m/z: Calcd, 418.11. Folllld, 418.09 
(M). 
Synthesis 28 
N-(3-(1-Amino-2-hydroxyethy l)pheny 1)-2', 4 '-difluo­
ro bipheny 1-4-sulfonamide (ABD790) 
(0889] 
[0890] Using a method analogous to Method D, the title 
compound was obtained as a mixture of regioisomers (1: 1 
with ABD782) which were not further separated. 1 H NMR 
(300 MHz, CDCIJ: o 2.76 (0.5H, br s), 3.02 (0.5H, br s), 3.45 
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(0.5H, br s), 3.60 (0.5H, br s), 3.95 (0.5H, br s), 4.30 (2H, br 
s), 4.60 (0.5H, br s), 6.70-7.60 (lOH, m) and 7.80 (2H, br s). 
Synthesis 29 
N-(3-(1-(Dimethylamino )-2-hydroxyethyl)phenyl)-
2' ,4'-difluorobiphenyl-4-sulfonamide (ABD79 l )  
(0891] 
(0892] Using a method analogous to Method D, using 2',4'­
difluoro-N-(3-(oxiran-2-yl)phenyl)biphenyl-4-sulfonamide 
and 33% dimethylamine in ethanol, a mixture of regioisomers 
was obtained. Reverse-phase HPLC was used to purify the 
mixture and the title compound was obtained as a pale orange 
powder from the mixture of isomers as gave ABD784. 1H 
NMR (300 MHz, CDC13): o 2.08 (6H, s), 3.40 (3H, m), 3.48 
(lH, 111), 3.62-3.64 (lH, 111), 6.87-6.96 (3H, 111), 7.04-7.12 
(2R 111), 7.20-7.25 (lH, 111), 7.33-7.40 (lH, m), 7.53 (2H, d, 
J=8 Hz) and 7.78 (2H, d, J=8 Hz). MS, m/z: Calcd, 432.132. 
Found, 432.56 (M). 
Synthesis 30 
2' ,4'-Difluoro-N-(3-(2-hydroxy-1-morpholinoethyl) 
phenyl)biphenyl-4-sulfonamide (ABD792) 
(0893] 
-d--o-F o C) 
F �-� OH 
� I 
� 
# 
(0894] Using a method analogous to Method D, using 2',4'­
difluoro-N-(3-( oxiran-2-yl )pheny I )bipheny 1-4-sulfonamide 
and 1 M morpholine in methanol, a mixture of regioisomers 
was obtained. Reverse-phase HPLC was used to purify the 
mixture and the title compound was obtained as a pale orange 
powder from the mixture of isomers as gave ABD785. 1H
NMR (300 MHz, CDCl3): o 2.75-2.81 (3H, m), 3.30 (lH, m), 
3.60-3.95 (8H, 111), 4.10-4.20 (lH, 111), 6.80-7.10 (3H, 111), 
7.20-7.30 (2H, 111), 7.35-7.45 (2H, m), 7.57 (2H, d, J=8 Hz) 
and 7.91 (2H, d, J=8 Hz). MS, 111/z: Calcd, 474.142. Folllld, 
474.58 (M). 
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Synthesis 31 
(R)-2-(Methylamino )-2-phenylethanol (ABD81 Oe) 
[0895] 
[0896] A solution ofLiAIH4 (1.0 M in THF, 184 mL, 0.184 
mol) was added to a solution of (R)-(-)-phenyloxazolidin-2-
one (15.0 g, 0.092 mol) in THF and then heated at reflux for 
1.5 hours. The mixture was then cooled in an ice bath and 
quenched by portion-wise addition of sodium sulphate 
decahydrate, until bubbling ceased. The mixture was filtered 
through Celite and partitioned between EtOAc (200 mL) and 
water (100 mL). The layers were separated and the aqueous 
phase was extracted with EtOAc (3xl00 mL). After drying 
over MgS04 the solvents were evaporated, giving the title 
compound as a yellow oil, which crystallised on standing to 
give an off white solid (10.3 g, 75%). 
Synthesis 32 
(R)-2-(Methylamino )-2-(3-nitrophenyl)ethyl nitrate 
(ABD810d) 
[0897] 
[0898] Concentrated HNO, (20 mL) was added drop wise to 
concentrated H2S04 (20 mL) while cooling in an ice/metha­
nol bath. The mixture was then cooled to below -20° C. and 
ABD810e (5.00 g, 25.5 mmol) was added portionwise with 
vigorous stirring, maintaining the temperature below -10° C. 
The mixture was stirred at -10° C. for 2 hours, then allowed 
to warm to 10° C. and stirred for a further 30 minutes. The 
mixture was then poured onto ice (150 g) and stirred until the 
ice melted, creating a suspension of a light yellow solid which 
was collected by filtration, washed with water and dried in a 
vacuum desiccator, giving the title compound as a dry, light 
yellow solid (5.0 g, 82%). 
Synthesis 33 
(R)-3-Methyl-4-(3-nitrophenyl)oxazolidin-2-one 
(ABD810c) 
[0899] 
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[0900] Carbonyl diimidazole (5.70 g, 0.032 mol) was 
added to a stirred solution ofABD810d (5.0 g, 0.035 mol) and 
triethylamine (14 mL, 0.103 11101) in DCM (80 mL) and 
heated at 40° C. overnight. Water (50 mL) was added and the 
layers were separated. The DCM layer was washed with 1 M 
HCl (20 mL), water (20 mL) and brine (20 mL) and dried over 
MgS04• The solution was filtered and evaporated to yield a 
light brown glllll. The crude material was purified by dry flash 
chromatography, eluting with 30-40% acetone/hexane to give 
the title compound as a pale yellow-orange glllll which solidi­
fied on standing ( 944 mg, 21 % ) . 
Synthesis 34 
(R)-4-(3-Aminophenyl)-3-methyloxazolidin-2-one 
(ABD810b) 
[0901] 
[0902] A solution of ABD810c (940 mg, 4.23 nunol) in 
IMS (20 mL) was stirred at room temperature and a suspen­
sion of 5% Pd/C (100 mg) in EtOAc (1 mL) was added. A 
balloon of hydrogen was fitted and the mixture was stirred for 
two hours at room temperature and then filtered through celite 
and evaporated to give the target compound as an orange gum 
(814 mg, 99%). 
Synthesis 35 
(R)-2',4'-Difluoro-N-(3-(3-methyl-2-oxooxazolidin-
4-yl)phenyl)biphenyl-4-sulfonamide (ABD81 Oa)
[0903] 
F 
[0904] 2,4-Difluorobiphenyl sulfonyl chloride (1.21 g, 4.23 
11111101) was added to a solution of ABD810b (810 mg, 4.23 
11lll10l) and pyridine (1.7 mL, 21 11lll1ol) in DCM (20 mL) 
while cooling in an ice bath. The reaction mixture was stirred 
at room temperature overnight then diluted with DCM (50 
mL) and 1 M HCl (25 mL). The layers were separated and the 
DCM layer was washed with 1 M HCl (25 mL), water (25 
mL) and brine (25 mL), and dried over MgS04, filtered and 
evaporated. The crude material was purified by flash chroma­
tography, eluting with 30% acetone/hexane to give the title 
compound as a light yellow glllll (1.08 g, 58% ). 
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Synthesis 36 
(R)-2'.4'-Difluoro-N-(3-(2-hydroxy-l-(methylamino) 
ethyl)phenyl)biphenyl-4-sulfonamide (ABD8 l 0) 
[0905] 
[0906] A solution ofLiOH.H20 (960 mg, 23 mmol) in water 
(15 mL) was added to a solution of ABD810a (1.06 g, 2.38 
mmol) in THF (2.5 mL) and MeOH (2.5 mL) at room tem­
perature. The mixture was heated at 65° C. overnight, after
which the organic solvents were removed under reduced pres­
sure and the residue was diluted with water (50 mL), then 
carefully neutralised with 2 M HCl to pH 7. The resulting 
suspension was extracted with EtOAc (3x50 mL) and the 
combined organic phases were washed with brine ( 40 mL) 
and dried over MgS04• Evaporation of the solvents afforded 
the product as a gum, which was re-dissolved in Et20 and
then Et20/hexane and re-evaporated to give the title com­
pound as yellow foam (807 mg, 81 % ). 1 H NMR (300 MHz, 
DMSO-d6): o 1.98 (3H, s), 3.12-3.20 (lH, m), 3.28-3.38 (2H, 
m), 4.83 (lH, s), 6.79 (2H, br t, J=9.5 Hz), 7.04 (lH, s), 7.13 
(lH, t, J=7.5 Hz), 7.19 (lH, td, J=8 Hz, 2 Hz), 7.37 (lH, ddd, 
J=ll.5 Hz, 9 Hz, 2.5 Hz), 7.56 (lH, td, J=9 Hz, 6.5 Hz), 7.64
(2H, d, J=8.5 Hz) and 7.77 (2H, d, J=8.5 Hz). LCMS: (MHt 
=419. 
Synthesis 37 
(S)-2' ,4'-Difluoro-N-(3-(2-hydroxy-1-(methylamino) 
ethyl)phenyl)biphenyl-4-sulfonamide (ABD811) 
[0907] 
[0908] The title compound was prepared using a method 
analogous to that used for ABD810, starting with (S)-4-phe­
nyloxazolidin-2-one. 1H NMR (300 MHz, DMSO-d6): o 1.98
(3H, s), 3.12-3.20 (lH, m), 3.28-3.38 (2H, m), 4.83 (lH, s), 
6.79 (2H, br t, J=9.5 Hz), 7.04 (IH, s), 7.13 (lH, t, J=7.5 Hz), 
7.19 (lH, td, J=8 Hz, 2 Hz), 7.37 (lH, ddd, J=l 1.5 Hz, 9 Hz, 
2.5 Hz), 7.56 (lH, td, J=9 Hz, 6.5 Hz), 7.64 (2H, d, J=8.5 Hz) 
and 7.77 (2H, d, J=8.5 Hz). LCMS: (MHt=419. 
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Synthesis 38 
3-( 4-Bromophenylsulfonamido )benzoyl chloride 
(ABD833d) 
[0909] 
[0910] A suspension of 3-( 4-bromophenylsulfonamido) 
benzoic acid (2.30 g, 6.46 mmol) in DCM ( 50 mL) was stirred 
and cooled under argon to 0° C. Oxalyl chloride ( 67 6 µL, 7 .11
11111101) was then added dropwise via a syringe, followed by 
DMF (50 µL). The resulting solution was then stirred over­
night, allowing the reaction mixture to warm room tempera­
ture. The solution was used without further purification. 
Synthesis 39 
3-( 4-Bromophenylsulfonamido )-N,N-dimethylben­
zamide (ABD833c) 
[0911] 
[0912] A solution of ABD833d (2.42 g, 6.46 nunol) in 
DCM (50 mL) was cooled to 0° C. under argon. Dimethy­
lamine (2 M in THF, 16.15 mL, 32.30 nu11ol) was added 
dropwise via a syringe. Once addition was complete, the 
reaction was allowed to warm to room temperature and stirred 
for an additional 2 hours. After this time, the reaction was 
diluted with DCM (50 mL) and sat. NH4Cl (25 mL). The 
aqueous phase was made acidic (pH 2) with 2 M HCl solution 
and the layers separated. The aqueous phase was then 
extracted with DCM (2x30 mL) and the combined organics 
were washed with water (25 mL), brine (25 mL), dried 
(Na2S04) and filtered. Evaporation and recrystallisation 
(MeOH) gave the title compound as colourless prisms (2.35 
g, 95%). 
Synthesis 40 
4-Bromo-N-(3-( ( dimethylamino )methyl)phenyl)
benzenesulfonamide (ABD833b) 
[0913] 
[0914] ABD833c (500 mg. 1.31 nunol) was dissolved in 
THF (] O mL) under argon (required gentle wam1ing). When 
the temperature had fallen to 30° C., LiAIH4 (1 M in THF,
2.62 mL, 2.62 mmol) was added via syringe over 15 minutes 
and effervescence was observed. After 1 hour the reaction 
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was diluted with THF (10 mL) and cooled to 0° C. Na2S04• 
10H20 (s) was added in portions until effervescence ceased. 
The mixture was filtered through celite and the solids washed 
with EtOAc (4x50 mL) and MeOH (4x50 mL). The com­
bined organics were evaporated to give the title compound as 
a colourless oil (273 mg, 57%). 
Synthesis 41 
4-(N-(3-( (Dimethylamino )methyl )phenyl)sulfamoyl) 
phenylboronic acid (ABD833a) 
[0915] 
[0916] ABD833b (500 mg, 1.36 mmol), bis(pinacolato) 
diboron (518 mg, 2.04 mmol), Pd(dppf)Cl2 (51 mg, 5 mol %) 
and KOAc ( 453 mg, 4.62 mmol) were suspended in DMSO (5 
mL). The reaction was purged with argon in an ultrasonic bath 
for 5 minutes, and then placed in a pre-heated oil bath (90° C.) 
for 1.5 hours. The reaction was then cooled to room tempera­
ture, poured into water ( 50 mL ), made acidic (pH 1) with 2 M 
HCI and then neutralised withNa2C03 (sat. aq.). The mixture
was extracted with EtOAc (4x50 mL) and the combined 
organics were then dried (Na2S04), filtered and the solvent
evaporated. The residue was absorbed onto silica and purified 
by flash chromatography, eluting with 5% 2 M NHjMeOH in 
DCM, to give the title compound as a dark brown solid (708 
mg, quantitative). 
Synthesis 42 
4-(3,5-Dichloropyridin-2-yl)-N-(3-((dimethylamino) 
methyl)phenyl)benzene-sulfonamide (ABD833) 
[0917] 
0 
II H 
Cl rNv( 
[0918] 2-Bromo-2,5-dichloropyridine (236 mg, 1.05 
mmol) and Pd(dppf)Cl2 (37 mg, 5 mol %) were dissolved in 
a freshly prepared solution ofABD833a (approx. 1.27 mmol) 
in DMSO (20 mL), and 2 M Na2C03 solution (1.58 mL, 3.15
mmol) was added. The vessel was sealed and purged with 
argon for 5 minutes while it was placed in an ultrasonic bath. 
The flask was then placed in a pre-heated oil bath (90° C.) for 
I h. After this time the reaction was cooled to room tempera­
ture, filtered and acidified with 2 M HCI. The cmde mixture 
was roughly purified by SCX-2 chromatography (!solute, 2 g) 
and the resulting material was purified further by chromatog­
raphy on Si02 (70 g !solute II cartridge, SP4), eluting with 
4.5-5.5% 2 M NH3/MeOH in DCM, then by reverse-phase 
HPLC. Finally, trituration with 1: 1 v/v Et20:hexane gave the 
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title compound as a colourless powder (23 mg, 5% ). 1 H NMR
(300 MHz, DMSO-d 6): o 2.15 (6H, s), 3.33 (2H, s), 6.98 (IH, 
t, J=2 Hz), 7.03-7.09 (2H, 111), 7.21 (IH, t, J=8 Hz), 7.78 (2H, 
dt, J=8.5 Hz, 2 Hz), 7.83 (2H, dt, J=8.5 Hz, 2 Hz), 7.84 (IH, 
d, J=2 Hz) and 8.54 (IH, d, J=2 Hz). LCMS: (MHt=436; 
(M-Hf=434. 
Synthesis 43 
4-(5-Chloropyrimidin-2-yl)-N-(3-(( dimethylamino) 
methyl)phenyl)benzenesulfonamide (ABD834) 
[0919] 
[0920] ABD833a (250 mg, 0.75 mmol), 2,5-dichloropyri­
midine (133 mg, 0.90 mmol) and Pd( dppf)Cl2 (29 mg, 5 1110! 
%) were suspended in DME (4 mL) and 2 M Na2C03 (1.12 
mL, 2.24 mmol) was then added. The reaction was then 
purged with argon while standing in an ultrasonic bath for 5 
minutes, and placed in a pre-heated oil bath (90° C.) for 1 
hour. The reaction was cooled to room temperature, poured 
into water ( 50 mL) and extracted with EtOAc (3x25 mL). The 
combined organics were washed with water (25 mL) and 
brine (25 mL ), dried (Na2SO 4), filtered and the solvent evapo­
rated. The cmde product was purified by chromatography on 
Si02, eluting with 5% 2 M MeOH/NH3 in DCM and then by
preparative HPLC to give the title compound as a colourless 
solid (31 mg, 10%). 1H NMR (300 MHz, DMSO-d6): o 2.54
(6H, s), 4.12 (2H, br s), 6.90-7.40 (4H, m), 7.90 (2H, d, J=9 
Hz), 8.43 (2H, d, J=9 Hz), 9.04 (2H, s) and 10.61 (IH, br s). 
LCMS: (MHt=403. 
Synthesis 44 
(R)-Methyl 2-(tert-butoxycarbonylamino)-2-(3-(2',4'­
difluoro bipheny 1-4-y lsulfonan1ido )pheny !)acetate 
(ABD854b) 
[0921] 
[0922] (R)-Methyl 2-(3-aminophenyl)-2-(tert-butoxycar­
bonylamino )acetate (385 mg, 1.37 llll11ol) (prepared in an 
analogous fashion to the (S)-isomer ABD855c) and 2',4'­
difluorobiphenylsulfonyl chloride (396 mg, 1.37 mmol) were 
stirred in EtOAc (lOmL) and water ( lO mL) andK2C03 (760 
mg, 5.5 1111110!) was added. The mixture was stirred at room 
temperature for 3 days and then diluted with EtOAc (20 mL) 
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and water (20 mL) and the layers were separated. The aque­
ous phase was extracted with EtOAc (10 mL) and the com­
bined organics were washed with water ( 10 mL) and brine ( 10 
mL) and dried over MgSO 4• After evaporation of the solvents, 
the crude material was purified by colunu1 chromatography 
on Si 02, eluting with 10-50% acetone/hexane, to give the title 
compound as a yellow gum (580 mg, 80%). 
Synthesis 45  
(R)-tert-Butyl 1-(3-(2' ,4'-difluorobiphenyl-4-ylsul­
fonamido) phenyl)- 2-hydroxyethylcarbamate 
(ABD854a) 
[0923] 
[0924] A solution of ABD854b (1.0 g, 1.9 llllllol) in dry 
THF (60 mL) was cooled 1mder argon to 0° C. and LiAIH4 (1 
M in THF, 9.4 mL, 9.4 llllllol) was added by syringe. The 
mixture was stirred at 0° C. for 30 minutes and then allowed
to warm to room temperature and stirred overnight. It was 
then cooled back to 0° C. and Na2S04.10H20 (s) was added
until bubbling ceased. The mixture was diluted with further 
THF ( 60 mL) and stirred for 1 hour at room temperature and 
then filtered. After evaporation of the solvents, the residue 
was purified by chromatography on Si02 (20 g !solute II 
cartridge, SP4), eluting with 30% acetone/hexane to give the 
title compound as an off-white solid (195 mg, 20%). 
Synthesis 46 
(R)-N-(3-(1-Amino-2-hydroxyethyl)phenyl)-2' ,4'­
difluorobiphenyl-4-sulfonamide (ABD854) 
[0925] 
II H 
2 -0-0-F O NH 
F rNifOH 
[0926] A solution of ABD854a (195 mg, 0.37 mmol) in 
DCM (10 mL) was stirred at room temperature and TF A (5 
mL) was added. After 1 hour the solvents were evaporated and 
the residue was re-dissolved in DCM (5 mL) and loaded onto 
an SCX cartridge (2.0 g, (solute II) and eluted with DCM/ 
MeOH (1:1, 2x5 mL) and then 5%-20% 2 M NH/MeOH in 
DCM. The product-containing fractions were combined and
evaporated to afford a yellow gum which was triturated with
Et20/hexane (1: 1) to give the title compound as an off-white
solid (118mg, 79%). 1H NM R (400 MHz, DMSO-d6): 113.18
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(lH, t, 1=9.5 Hz), 3.32-3.37 (lH, m obscured by water peak), 
3.79 (lH, dd, 1=8 Hz, 4.5 Hz), 4.83 (lH, br s), 6.96 (2H, br t, 
1=7 Hz), 7.10 (lH, s), 7.11 (lH, t, 1=8 Hz), 7.18 (lH, td, 1=8 
Hz, 2 Hz), 7.37 (lH, ddd, 1=11.5 Hz, 9 Hz, 2.5 Hz), 7.59 (lH, 
td, 1=8.5 Hz, 6.5 Hz), 7.65 (2H, dd, 1=8.5 Hz, 1.5 Hz) and 7.81 
(2H, d, 1=8.5 Hz). LCMS: (MHt=405. 
[0927] 
Synthesis 47 
(S)-Methyl 2-aniino-2-(3-nitrophenyl)acetate 
(ABD855e) 
�H2 
O,N
'()l(
O
" 
[0928] A mixture of HN03 (30 mL) and H2S04 (30 mL)
was cooled to below -10° C. and a solution of methyl (S)­
phenylglycine hydrochloride (32.0 g, 0.149 nunol) in H2S04 
(30 mL) was added drop wise while stirring. The mixture was 
then stirred at 0° C. for 1 hour before being allowed to wann
to room temperature and stirred for a further 30 minutes. The 
mixture was poured onto ice and then adjusted to pH 9 with 
cone. NH40H, while cooling to maintain the internal tem­
perature <30° C. The mixture was extracted with EtOAc
(4x100 mL) and the combined extracts were washed with 
brine (50 mL) and dried over MgS04. Evaporation of the 
solvent gave the title compound as a dark orange oil (30.3 g, 
97% ), which was used without further purification. 
Synthesis 48 
(S )-Methy I 2-( tert-butoxycarbony !amino)-2-(3-nitro­
pheny l)acetate (ABD855d) 
[0929] 
[0930] A suspension of ABD855e (30.3 g, 0.144 mol) and 
triethylamine (25 mL, 0.18 mol) in DCM (300 mL) was 
stirred at 0° C. and (B0C)20 (40 g, 0.18 nnnol) was added.
The mixture was stirred overnight, allowing it to warm to 
room temperature. TLC indicated that some starting material 
remained, so further (B0C)20 (5 g, 22 llllllol) was added and 
stirring continued a further 3 hours. The mixture was then 
poured into water (200 mL) and the layers were separated. 
The organic phase was washed with 0.5 M HCI (50 mL), 
water (50 mL) and brine (50 mL) and dried over MgS04 • 
After evaporation of the solvents, the crude material was 
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purified by column chromatography on Si02 (0%- 20% 
EtOAc/hexane) and then by trituration with warm hexane 
(3x) to give the title compound as an off-white solid (1 1 g, 
25%). 
Synthesis 49 
(S )-Methy 1 2-(3-aminopheny 1)- 2-( tert-butoxycarbo­
nylamino )acetate (ABD855c) 
[0931] 
[0932] A 1 L autoclave was charged with a solution of 
ABD855d (l l .O g, 37 mmol) in MeOH 150 mL). Pd/C (10%, 
1.0 g) was added as a slurry in EtOAc (5 mL) and the auto­
clave was sealed and charged to 50 bar (-5 MPa) with H2 (g). 
The mixture was stirred at room temperature for 3 hours and 
then filtered through celite. Evaporation of the solvents gave 
the title compound as a dark green oil (10.3 g, quantitative), 
which was used without further purification. 
Synthesis 50 
(S)-Methyl 2-(tert-butoxycarbonylamino )- 2-(3-(2' ,4'­
difluorobiphenyl-4-y lsulfonamido )pheny ])acetate 
(ABD855b) 
[0933] 
[0934] A solution of 2',4'-difluorobiphenylsulfonyl chlo­
ride (2.0 g, 6.9 mmol) in DCM (20 mL) was cooled under 
argon to 0° C. and ABD855c (2.4 g, 8.8 mmol) was added, 
followed by DMAP (1 crystal) and pyridine (2.94 mL, 36.5 
mmol). The solution was stirred overnight, allowing it to 
warm to room temperature, and then diluted with further 
DCM (50 mL) and 1 M HCl (20 mL) and stirred for 30 
minutes. The layers were separated and the DCM was washed 
with 1 M HCl (20 mL), water (20 mL) and brine (20 mL) and 
dried over Na2 S04. Evaporation of the solvents gave the title 
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compound as an orange gum (3 .7 5 g, quantitative) which was 
used without further purification. 
Synthesis 5 1  
(S )-tert-Butyl 1-(3-(2',4'-difluorobiphenyl-4-ylsul­
fonamido )pheny 1)- 2-hydroxyethy lcarbaniate 
(ABD855a) 
[0935] 
[0936] A solution of ABD855b (1.0 g, 1.87 mmol) in dry 
THF (20 mL) was cooled under argon to -10° C. and LiAIH4 
(1 M in THF, 3.75 mL, 3.75 mmol) was added by syringe. The 
solution was stirred for 2 hours, allowing it to wann to room 
temperature and then poured onto 10% NH4Cl (aq., 25 mL). 
The mixture was extracted with EtOAc (3x20 mL) and the 
combined organics were dried over MgS04, filtered and 
evaporated to afford an orange gun1. This was purified by 
colunn1 chromatography on Si02 (20%-30% acetone/hex­
ane) to give the title compound as a yellow gum (659 mg, 
70%). 
Synthesis 5 2  
[0937] (S)-N-(3-(1-Amino- 2-hydroxyethyl)phenyl)- 2', 
4'-difluorobiphenyl-4-sulfonamide (ABD855) 
[0938] ABD855a (100 mg, 0. 20 11111101) was stirred in diox­
ane (10 mL) at room temperature and HCl/dioxane (3 M, 5 
mL) was added. The mixture was stirred at room temperature 
for 2 days and then concentrated under reduced pressure. The 
residue was stirred with Et20 (5 mL) giving a pale brown 
solid which was collected by suction filtration. Trituration 
with further Et20 and then hexane gave the title compound as 
the hydrochloride salt (77 mg, 87% ). 1 H NMR ( 400 MHz, 
DMSO-d6): o 3.50-3. 70 (2H, m), 4. 20 ( lH, m), 5.49 (lH, m), 
7.00 (lH, d, J=8 Hz), 7 .10 (lH, d, J=8 Hz), 7. 14-7.30 (3H, 111), 
7.45-7.55 (lH, 111), 7.60 (lH, 111), 7.65 (2H, d, J=8 Hz), 7.85 
(2H, d, J=8 Hz), 8.35 (2H, br s) and 10.50 (lH, s). LCMS: 
(MHt=405. 
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[0939] 
Synthesis 53 
2-Bromo-1-(3-nitropheny I )ethanone
o,N�
Ut 
[0940] m-Nitroacetophenone (20 g) was dissolved in acetic 
acid (150 mL) 1mder argon. Pyridinium tribromide (38.7 g) 
was added at once; the reaction was allowed to stir at room 
temperature for 1 hour and then quenched with water (250 
mL). The product was filtered and air dried to give the title 
compound (25 g, 84%). 
Synthesis 54 
2-(3-Nitrophenyl)-2-oxoethyl acetate 
[0941] 
�N
 
U tc 
[0942] 2-Bromo-1-(3-nitrophenyl)ethanone (25 g) was dis­
solved in methylethyl ketone (150 mL). NaOAc (12.5 g) was 
added and the mixture stirred for 48 hours. Water (100 mL) 
was added and the reaction mixture extracted with DCM. The 
DCM layer was dried over Na2S04 and concentrated to give 
the title compound (20 g, 87%). 
Synthesis 55 
2-Hydroxy-2-(3-nitrophenyl)ethyl acetate
[0943] 
�N
 
U tc 
[0944] 2-(3-Nitrophenyl)-2-oxoethyl acetate (20 g) was 
dissolved in MeOH (200 mL) and cooled to 0° C. Sodium 
borohydride (6.78 g) was added pinch-wise to the reaction 
mixture and this was stirred for 2 hours at room temperature. 
The reaction was quenched by addition of acetone (10 mL) 
and the mixture concentrated to give a solid. The solid was 
treated with water (100 mL) and extracted with ethyl acetate 
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(3x100 mL). The cmde title compound obtained was used for 
next step without further purification (18 g, 89% ). 
Synthesis 56 
l-(3-Nitrophenyl)ethane-1,2-diol 
[0945] 
O;N� 
u t
[0946] 2-Hydroxy-2-(3-nitrophenyl)ethyl acetate (18 g) 
was dissolved in MeOH (180mL) and cooled to 0° C. K2C03 
(22 g) was added and the reaction stirred at room temperature 
for 2 hours. The mixture was concentrated under vacuum, 
quenched by addition of water (100 mL) and extracted with 
ethyl acetate (2xl00 mL). The EtOAc layer was dried over 
Na2S04 and concentrated to give the cmde title compound 
(13 g, 88%). 
Synthesis 57 
l-(3-Aminophenyl)ethane-1,2-diol 
[0947] 
[0948] 1-(3-Nitrophenyl)ethane-1,2-diol (10 g) was dis­
solved in MeOH (100 ml). 10% Pd/C (1.3 g) was added the 
mixture hydrogenated at 40 psi H2 for 1 hour. The reaction 
mass was filtered through hyflo and concentrated to give the 
cmde title compound ( 10 g, 92% ). 
Synthesis 58 
Benzyl 3-(1,2-dihydroxyethyl )phenylcarbamate 
[0949] 
[0950] 1-(3-Aminophenyl)ethane-l,2-diol (10 g) was dis­
solved in DCM (80 mL). H20 (80 mL) andNa2C03 (10.98 g) 
were added and the mixture cooled to 0° C. Benzylchlorofor­
mate (22 g) was added drop-wise over 20 minutes and the 
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reaction mixture stirred at room temperature overnight. The 
organic phase was separated, dried over Na2S04 and concen­
trated to give a crude product which was purified by column 
chromatography to give the title compound (8 g, 45% ). 
Synthesis 59 
Benzyl 3-(2-(tert-butyldimethylsilyloxy )-1-hydroxy­
ethyl)phenylcarbamate 
[0951] 
[0952] Benzyl 3-(1,2-dihydroxyethyl)phenylcarbamate (8 
g) was dissolved in dry DMF (50 mL) and cooled to 0° C.
Imidazole (2.8 g) and TBSCl (5 g) were added and the mix­
ture was stirred at room temperature for 24 hours. The reac­
tion was quenched by addition of water (100 mL) and 
extracted with EtOAc (2xl00 mL). The organic phase was 
separated, dried over Na2S04 and concentrated to give a
crude product which was purified by column chromatography
to give the title compound (6 g, 60%).
Synthesis 60 
1-(3-(Benzy loxycarbony !amino )phenyl)-2-( tert-bu­
ty ldimethylsily lox y )ethy I methanesulfonate 
[0953] 
H
mOMs 
/N � Cbz 
1 # OTBS 
[0954] Benzyl 3-(2-(tert-butyldimethylsilyloxy)-1-hy­
droxyethyl)phenylcarbamate ( 4 g) was dissolved in dry DCM 
(80 mL) and cooled to 0° C. under an argon atmosphere. 
Triethylamine (5 g) was added, followed by mesyl chloride 
(3.42 g) added drop-wise over a period of 2 hours. The reac­
tion temp was maintained at 0° C. for further 2 hours. The 
reaction was quenched by addition of water, extracted into 
DCM and concentrated under vacuum at a temperature below 
25° C. The crude product (3.5 g) was unstable and was used 
for next step as soon as possible. 
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Synthesis 61 
{ 3-[2-( tert-Butyl-dimethyl-silanyloxy )-1-(2-meth­
oxy-ethylamino )-ethyl]-phenyl }-carbamic acid ben­
zyl ester 
[0955] 
H
m
H
N�
O
'-.. 
N Cbz/ � I # OTBS 
[0956] 1-(3-(Benzyloxycarbonylamino )phenyl)-2-(tert­
butyldimethylsilyloxy)ethyl methanesulfonate (3.5 g) was 
dissolved in dryTHF ( lOmL) and methoxyethylamine (5.4 g) 
was added in a sealed tube and heated to 70° C. for 16 hours. 
Water was added and the reaction mixture extracted with 
DCM (2x20 mL). The organic phase was separated, dried 
over Na2S04 and concentrated to give the crude product, 
which was purified by column chromatography to give the 
title compound (1 g, 30%). 
Synthesis 62 
{ 3-[ 1-[ tert-Butoxycarbony 1-(2-methoxy-ethyl )­
amino ]-2-(tert-butyl-dimethyl-silanyloxy )ethyl]­
phenyl }-carbamic acid benzyl ester 
[0957] 
[0958] { 3-[2-(tert-Butyl-dimethyl-silanyloxy)-1-(2-meth­
oxy-ethylamino )-ethyl]-phenyl }-carbamic acid benzyl ester 
(] g) was dissolved in dry DCM (10 mL) and stirred under 
argon at 0° C. Triethylamine (0.4 g) and (B0C)20 (0.52 g) 
were added and the reaction mixture was stirred at room 
temperature for 2 days. The reaction was quenched by addi­
tion of water and the mixture extracted with DCM. The 
organic phase was separated. dried over Na2S04 and concen­
trated to give a crnde product which was purified by colunm 
chromatography to give the title compound ( 400 mg). 
Synthesis 63 
tert-Butyl 1-(3-aminophenyl)-2-(tert-butyldimethyl­
sily loxy )ethy I( 2-methoxyethy I )carbamate 
[0959] 
[0960] { 3-[ l -[tert-Butoxycarbonyl-(2-methoxy-ethyl)­
amino ]-2-(tert-butyl-dimethyl-silanyloxy )ethyl]-phenyl }­
carbamic acid benzyl ester was added to ethanolic HCI (20 
mL) at 0° C., allowed to warm to room temperature and 
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stirred overnight. The reaction mixture was concentrated to 
give the title compound as a light yellow oil (300 mg). 
Synthesis 64 
tert-Butyl 1-(3-( 4-bromophenylsulfonamido )phenyl)-
2-(tert-butyldimethylsilyloxy)ethyl(2-methoxyethyl) 
carbamate (ABD858b) 
[0961] 
lli S-N 0 
-0-TI 
H
�Boc'-N�O'-.,,, 
il I : 
'ms
[0962] A suspension of tert-butyl 1-(3-aminophenyl)-2-
( tert-buty ldimethy lsily loxy )ethyl (2-methoxyethy l)carbam­
ate (0.5 g, 1.95 mmol) and 4-bromobenzenesulfonyl chloride 
(0.99 g) in chloroform (20 mL) was stirred under nitrogen at 
room temperature. N,N-Diisopropyl ethyl amine (1 mL) was 
added and the mixture was stirred for 16 hours at 60° C. The 
solution was diluted with EtOAc (50 mL), washed with water 
(2x20 mL), 1 M HCl (20 mL) and brine (20 mL) and dried 
over Na2S04. Evaporation of the solvents gave a brown oil 
which was purified by column chromatography (30% EtOAc 
in hexane) to give the title compound as a light yellow oil (0.3 
g). 
Synthesis 65 
tert-Butyl 2-(tert-butyldimethylsilyloxy )-1-(3-(2' ,4'­
difluoro bipheny 1-4-y lsulfonamido )pheny l)ethy 1(2-
methoxyethyl )carbamate (ABD858a) 
[0963] 
[0964] ABD858b (300 mg) and 2,4-difluorophenylboronic 
acid (110 mg) were stirred in DME (8 mL) and 2 M Na2CO, 
( 1.2 mL) was added. The flask was stoppered and flushed with 
N2 (g) for 5 minutes. Pd(dppf)Cl2 (lOmg) was then added, the 
flask placed in an oil bath at 90° C. and stirred for 8 hours. The 
reaction mixture was cooled, filtered over a celite bed and 
diluted with EtOAc (50 mL). The solution was washed with 
water (2x20 mL) and brine (20 mL) and dried over Na2S04 . 
Evaporation of the solvent under reduced pressure gace a 
brown oil which was purified by column chromatography 
(10% EtOAc in hexane) followed by trituration with n-pen­
tane and ether and the title compound obtained as a light 
yellow oil (200 mg). 
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Synthesis 66 
2',4'-Difluoro-N-(3-(2-hydroxy-l-(2-methoxyethy­
lamino )ethy 1 )phenyl )bipheny 1-4-sulfonamide 
(ABD858) 
[0965] 
[0966] ABD858a (200 mg) was added to ethanolic HCl (20 
mL) at 0° C., allowed to warm to room temperature and 
stirred overnight at room temperature. The reaction mixture 
was concentrated to a yellow oil, which was purified by 
column chromatography (20% EtOAc in n-hexane) to give 
the title compound as a stick-y solid (50 mg, 38% yield). 1H 
NMR (300 MHz, DMSO-d6): I\ 3.11 (3H, s), 3.26 (lH, m), 
3.35 (lH, m), 3.54 (2H, m), 3.76 (lH, m), 3.94 (3H, m), 5.17 
(lH, m), 6.44 (lH, s), 6.54 (2H, m), 6.91-7.02 (3H, m), 7.38 
(lH, m), 7.59 (2H, d, J=8.4 Hz) and 7.94 (2H, d, J=8.4 Hz); 
LCMS: (Mt=462. 
Synthesis 67 
N-(3-((Dimethylamino)methyl)phenyl)-4-(pyrimi­
din-2-yl)benzenesulfonamide (ABD860) 
[0967] 
[0968] 4-Bromo-N-(3-(( dimethylamino )methyl)phenyl) 
benzenesulfonamide (273 mg, 0.74 mmol), pyrimidine-5-
boronic acid (lOl mg, 0.81 mmol) and Pd(dppf)Cl2 (29 mg, 5 
mol %) were dissolved in DME (4 mL) and 2M Na2C03 
solution (1.11 mL, 2.22 mmol) was added. The vessel was 
sealed and purged with argon for 5 minutes while it was 
placed in an ultrasonic bath. The flask was then placed in a 
pre-heated oil bath (90° c.) for 1 hour. After this time the 
reaction was cooled to room temperature and absorbed onto 
silica. The material was semi-purified by flash chromatogra­
phy (!solute II, 70 g silica cartridge, SP4) eluting with 4.5-5. 
5% MeOH/NH3 :DCM, followed by reverse-phase HPLC and 
finally by trituration from 1: 1 v/v Et20:hexane to give the title 
compound as a colourless solid (26 mg, 10%). 1H NMR (300 
MHz, DMSO-d6): ll 2.13 (6H, s), 3.32 (2H, s), 6.99 (lH, br s), 
7.06 (2H, d, J=9 Hz), 7.21 (lH, t, J=8 Hz), 7.62 (2H, d, J=8.5 
Hz), 7.89 (2H, d, J=8.5 Hz), 8.92 (2H, s) and 9.25 (lH, s). 
LCMS: (MHt=369; (M-Ht=367. 
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Synthesis 68 
Methyl 2-( tert-butoxycarbonylamino )-2-(3-nitrophe­
nyl)propanoate (ABD862d) 
[0969] 
[0970] A solution ofABD855d (1.0 g, 3.2 mmol) and Mel 
(2.0 mL, 32.2 mmol) in dry THF (15 mL) was stirred under 
argon at 0° C. and KO'Bu (470 mg, 4.2 mmol) was added in 
one portion. The mixture was stirred for 2 days, allowing it to 
warm to room temperature. HPLC analysis indicated that 
significant starting material was still present so a further 
portion ofKO'Bu (35 mg, 0.32 nm1ol) was added and stirring 
continued for an hour, after which a second portion ofKO'Bu 
(70 mg, 0.64 nunol) and Mel (0.36 mL, 6.4 nunol) were 
added and stirring was continued overnight. Saturated NH4Cl 
(aq., 5 mL) was then added and the mixture was extracted 
with EtOAc (3xl O mL ). The combined extracts were washed 
with water (] 0 mL) and brine ( I O mL) and dried over MgSO 4 . 
After evaporation of the solvents, the residue was purified by 
dry flash chromatography on Si02 (5%-20% EtOAc/hexane) 
to afford the title compound as a yellow oil (503 mg, 48%). 
Synthesis 69 
Methyl 2-(3-aminophenyl)-2-(tert-butoxycarbony­
lamino )propanoate (ABD862c) 
[0971] 
[0972] A solution of ABD862d (500 mg, 1.54 mmol) in 
MeOH (10 mL) was stirred at room temperature and Pd/C 
(10%, 50 mg) was added as a slurry in MeOH (1 mL). The 
flask was fitted with a balloon ofH2 (g) and stirred vigorously 
overnight. The mixture was filtered through celite and the 
solvents evaporated to give the title compound as a pale 
yellow-green oil (440 mg, 97%), which was used without 
further purification. 
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Synthesis 70 
Methyl 2-(tert-butoxycarbonylamino )-2-(3-(2',4'­
difluoro bipheny 1-4-y lsulfonamido )phenyl )pro­
panoate (ABD862b) 
[0973] 
[0974] A solution of ABD862c (440 mg, 1.5 mmol) in 
DCM (10 mL) was cooled to 0° C. and then 2',4'-biphenyl­
sulfonyl chloride ( 408 mg, 1.5 nunol) was added, followed by 
pyridine (600 �tL, 585 mg, 7.5 nunol). The mixture was stirred 
for 3 hours, allowing it to warn1 to room temperature, and then 
water (10 mL) and 2 M HCl (10 mL) were added. The layers 
were separated and the aqueous phase was extracted with 
DCM (3x10 mL ). The combined organics were washed with 
1 M HCl (10 mL ), water (10 mL) and brine (10 mL) and dried 
over MgS04• Evaporation of the solvents gave the title com­
pound as an orange gum (800 mg, 97%) which was not 
purified further. 
Synthesis 71 
tert-Butyl 2-(3-(2',4'-difluorobiphenyl-4-ylsulfona­
mido )phenyl )-1-hydroxypropan-2-ylcarbamate 
(ABD862a) 
[0975] 
[0976] A solution ofABD862b (800 mg, 1.46 nunol) in dry 
THF (10 mL) was cooled to -5° C. (ice/MeOH) and LiAIH4 
(1 M in THF, 7.3 mL, 7.3 11111101) was added dropwise. The 
mixture was stirred overnight, allowing it to warm to room 
temperature. It was then cooled back to -5° C. and sat. NH4Cl 
( aq ., 5 mL) was added cautiously, followed by water (20 mL) 
and EtOAc (20 mL) and the mixture was stirred vigorously. 
After filtering through celite. the layers were separated and 
the aqueous phase was extracted with EtOAc (3x 10 mL ). The 
combined organics were washed with water (10 mL) and 
brine ( lOmL) and dried over MgS04.After evaporation ofthe 
solvents, the residue was purified by colunu1 chromatography 
on Si02 (20%-40% acetone/hexane) to give the title com­
pound as a pale yellow gum (330 mg, 44%). 
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Synthesis 72 
N-(3-(2-Amino- l -hydroxypropan-2-yl)phenyl)-2',4'­
difluorobiphenyl-4-sulfonamide (ABD862) 
[0977] 
[0978] A solution of ABD862a (330 mg, 0.64 mmol) in
dioxane (10 mL) was stirred at room temperature and HCl/ 
dioxane ( 4 M, 3 mL) was added. The mixture was stirred at 
room temperature overnight and the solvent was then evapo­
rated under reduced pressure. The resulting yellow gum was 
taken up in MeOH (5 mL) and loaded onto an SCX-2 column 
(2 g).The column was eluted with MeOH (3x5 mL) and then 
15% NH)MeOH, resulting in some purification. The proce­
dure was repeated and the resulting orange gum was triturated 
with Et20 to afford an off-white foam. Final purification by 
reverse-phase preparative HPLC gave the title compound as 
an off-white solid (48 mg, 18%). 1H NMR (300 MHz,
DMSO-d6): o 1.17 (3H, s), 3.27 (2H, s), 4.78 (IH, br s), 
6.88-6.92 (IH, 111), 7 .04-7.10 (2H, 111), 7.14-7 .22 (2H, m), 
7.37 (IH, ddd, J=l 1.5 Hz, 9 Hz, 2 Hz), 7.58 (IH, td, J=9 Hz,
6.5 Hz), 7.61 (2H, dd, J=8.5 Hz, 1.5 Hz) and 7.80 (2H, d, 
J=8.5 Hz). LCMS: (MHj+=419; (M-Ht=417.
Synthesis 73 
4-Bron10-3-methyl-N-(3-sulfamoylphenyl)benzene­
sulfonamide (ABD866a) 
[0979] 
O O 0 -p- 11 H \/j 
Br S-N
v
s......_ 
M I �
NH2 
Me # 
[0980] Method E: 4-Bromo-3-methylbenzenesulfonyl
chloride (1.5 g) was dissolved in DCM (30 mL). 3-Ami­
nobenzenesulfonan1ide (3 g) was added, followed by pyridine 
(5 mL) and the mixture was stirred overnight at room tem­
perature. The mixture was poured into water and acidified 
(HCl). The solid was collected by filtration, dissolved in 
EtOAc and washed with water. The organic phase was col­
lected, dried, most of the solvent removed and the product 
crystallised by addition of petrol. 
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Synthesis 74 
2'-4'-Difluoro-2-methyl-N-(3-sulfamoylphenyl)bi­
phenyl-4-sulfonan1ide (ABD866) 
(0981] 
F 
F 
[0982] Using a method analogous to Method B, using
ABD866a and 2,4-difluorobenzeneboronic acid, the title 
compound was obtained as a brown oil, contaminated with a 
small amount of ABD866a. 
Synthesis 75 
2',3'-Dimethoxy-N-(3-sulfamoylphenyl)biphenyl-4-
sulfonamide (ABD867) 
[0983] 
MeOO-O-OMe 
O O 0 
�-� \(! g 
V
'Nn, 
[0984] Using a method analogous to Method B, using
ABD75l a  and 2,3-dimethoxybenzeneboronic acid, a brown 
oil was obtained. The oil was dissolved in DCM and crystal­
lised by addition of petrol to give the title compound as pale 
brown crystals. 1H NMR (250 MHz, DMSO-d6): o 3.52 (3H,
s), 3.84 (3H, s), 6.92 (IH, m), 7.13 (2H, m), 7.34 (IH, m), 7.45 
(4H, m), 7.66 (3H, m). 7.86 (2H. d. J=7.9 Hz) and 10.77 (IH, 
s ). 
Synthesis 76 
3'-Methoxy-N-(3-sulfamoylphenyl)biphenyl-4-sul­
fonamide (ABD869) 
[0985] 
MeO
b-o-
0 0 0 
�-� V 
11 V'NH, 
[0986] Using a method analogous to Method B, using
ABD751a and 3-methoxybenzeneboronic acid, a brown oil 
was obtained. The oil was dissolved in DCM and crystallised 
by addition of petrol to give the title compmmd as pale brown 
crystals. 13C NMR (DMSO-d6): o 55.2, 112.3, 114.5, 116.4, 
119.6, 121.2, 122.9, 127.5, 127.9, 130.0, 130.3, 138.1, 138.3, 
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139.7, 144.5, 145.1 and 159.8. 1H NMR (DMSO-d6): o 3.80 
(3H, s), 6.98 (lH, d), 7.22-7.47 (7H, m), 7.66 (lH, s) and 7.87 
(4H, m). 
Synthesis 77 
4-Bromo-2-chloro-N-(3-sulfamoylphenyl)benzene­
sulfonamide (ABD870a) 
[0987] 
O O 0 -Q- 11 H \// 
Br S-Nus......_
M I 
� NH2 
Cl # 
[0988] Using a method analogous to Method E. using 
4-bromo-2-chlorobenzenesulfonyl chloride and 3-aminoben­
zenesulfonamide, the title compom1d was obtained as a white
solid.
[0989] 
Synthesis 78 
3-Chloro-N-(3-sulfamoylphenyl)-4'-(trifluo­
romethoxy )biphenyl-4-sulfonamide (ABD870)
[0990] Using a method analogous to Method B, using 
ABD870a and 4-trifluoromethoxybenzeneboronic acid, a 
brown oil was obtained. The oil was purified by colllllln 
chromatography and then pumped under vacuum to give the 
title compound as an amorphous white solid. 1 H NMR 
(DMSO-d6): o 7.30 ( lH, m), 7.40-7.49 (4H, m), 7.63 ( lH, s), 
7.83 (lH, m), 7.89 (2H, d, 1=8.5 Hz), 7.98 (lH, s), 8.16 (lH,
d, 1=8.5 Hz) and 11.17 ( lH, br s ).
Synthesis 79 
4 '-Methy 1-N-(3-sulfamoy !phenyl )bipheny 1-4-sul­
fonamide (ABD871) 
[0991] 
[0992] Using a method analogous to Method B, using 
ABD751a and 4-methylbenzeneboronic acid an off-white 
solid was obtained. The solid was washed with DCM to give 
the title compound as a white solid. 1 H NMR (DMSO-d6): o
2.33 (3H, s), 7.29 (3H, m), 7.44 (4H, m), 7.60 (lH, d, 1=8.2
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Hz), 7.66 ( l H, s) and 7.84 (4H, m). 13C NMR (DMSO-d6): o 
20.7, 116.1, 121.7, 122.3, 126.8, 127.2, 127.4, 129.7, 129.9, 
135.3, 137.6, 138.3, 138.3, 144.5 and 145.1. 
Synthesis 80 
3-Chloro-N-(3-sulfamoylphenyl)-3',5'-bis(trifluo­
romethyl)biphenyl-4-sulfonamide (ABD872)
[0993] 
[0994] Using a method analogous to Method B, using 
ABD870a and 3,5-bis(trifluoromethyl)benzeneboronic acid, 
the title compound was obtained as a white solid. 1 H NMR
(DMSO-d6): 7.32 ( lH, m), 7.43 (4H, m), 7.65 ( l H, s), 8.03 
(lH, d, 1=8.2 Hz), 8.20 (3H, m), 8.46 (2H, s), and 11.19 (br s).
Synthesis 81 
3' ,4 '-Difluoro-N-(3-sulfamoy lpheny 1) bipheny 1-4-
sulfonamide (ABD873) 
[0995] 
F 
F 
[0996] Using a method analogous to Method B, using 
ABD751a and 3,4-difluorobenzeneboronic acid an off-white 
solid was obtained. The solid was washed with DCM to give 
the title compound as a white solid. 13C NMR (DMSO-d6): o
116.1, 116.4, 118.2, 121.6, 122.2, 124.0, 127.3, 127.5, 130.0, 
135.7 (d, 1=3.9 Hz), 138.2, 138.5, 142.3, 145.1, 147.8 (d,
1=14.7 Hz) and 151.7 (d, 1=12.7 Hz). 1H NMR (DMSO-d6): 
o 7.35-7.57 (6H, m), 7.66 (lH, s) and 7.88 (4H, m).
Synthesis 82 
2'-Chloro-N-(3-sulfamoy lpheny 1) bipheny 1-4-sulfona­
mide (ABD874) 
[0997] 
US 2011/0190302 Al 
(0998] Using a method analogous to Method B, using 
ABD75la and 2-chlorobenzeneboronic acid an off-white 
solid was obtained. The solid was washed with DCM to give 
the title compound as a white solid. 13C NMR (DMSO-d6): 6
116.5, 121.0, 122.3, 126.5, 126.7, 127.5, 130.0, 130.2, 130.8, 
131.L 131.3, 138.1, 138.3, 138.6, 143.2 and 145.1. 1H NMR
(DMSO-d6): 6 6.60 (IH, s), 7.42-7.65 (9H, m), 7.63 (2H, d,
J=8.2 Hz) and 7.90 (2H, d, J=6.4 Hz).
(0999] 
Synthesis 83 
2,4-Difluoro-3'-methylbiphenyl (ABD875c) 
F 
F 
Me 
(1000] Using a method analogous to Method B, using 
3-bromotoluene and 2,4-difluorobenzene boronic acid, the
title compound was obtained as a clear oil.
Synthesis 84 
2',4'-Difluoro-3-methylbiphenyl-4-sulfonic acid 
(ABD875b) 
(1001] 
F 
0 
II 
F S-OH
II 
0 
Me 
(1002] ABD875c (2 g) was dissolved in chloroform (30 
mL). Chlorosulfonic acid (2 mL) was added and the mixture 
stirred at room temperature for 5 hours. The chloroform was 
allowed to evaporate in a fume cupboard until separation of a 
dark oil was seen. The chloroform was decanted and the oil 
washed with further chlorofonn. The chlorofonn fractions 
were combined and left to stand, with the solvent intem1it­
tently decanted from any oil that separated. On further stand­
ing the title compound precipitated from the chlorofom1 as 
large white crystals. 
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Synthesis 85 
2',4'-Difluoro-3-methylbiphenyl-4-sulfonyl chloride 
(ABD875a) 
(1003] 
F 
0 
II 
F S-Cl 
II 
0 
Me 
(1004] ABD875b (1.8 g) was refluxed in thionyl chloride 
(20 mL) containing a catalytic quantity ofDMF, for 5 hours. 
The solvents were evaporated with addition of toluene, and 
the title compound obtained as a pale yellow oil. 
Synthesis 86 
2'-4'-Difluoro-3-methyl-N-(3-sulfamoylphenyl)bi­
phenyl-4-sulfonamide (ABD875) 
(1005] 
F 
F 
(1006] Using a method analogous to Method A, using 
ABD875a and 3-aminobenzenesulfonamide, the title com­
pound was obtained as a clear thick oil. 1 H NMR (DMSO-d6): 
6 2.66 (3H, s), 7.20 (IH, m). 7.28 (IH. m), 7.40 (2H, m), 7.42 
(4H, d, J=8.2 Hz), 7.52-7.62 (4H, m), 8.02 (IH, d, J=8.2 Hz) 
and 10.92 (IH, br s). 
Synthesis 87 
N-(3-Sulfamoylphenyl)biphenyl-4-sulfonamide 
(ABD879) 
(1007] 
(1008] Using a method analogous to Method A, using 
biphenyl sulfonyl chloride and 3-aminobenzenesulfonamide, 
the title compound was obtained as a white solid. 1 H NMR
(DMSO-d6): 6 7.34 (IH, d, J=7.6 Hz), 7.43-7.48 (7H, m), 
7.69 (2H, m), 7.70 (IH, d, J=7.3 Hz), 7.88 (4H, m) and 10.79 
(IH, br s). 
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Synthesis 88 
3-( 4-Bromophenylsulfonamido )-2-methylbenzoic 
acid (ABD882d) 
[1009] 
-0-
TI ··
ijl
CH3 0 
Br s-M � 
g I � OH 
# 
[1010] The title compound was prepared using a method 
analogous to Method A, using 4-bromobenzene sulfonyl 
chloride, 3-amino-2-methylbenzoic acid, and a large excess 
of pyridine. The title compound was precipitated on partition 
of the reaction mixture between dilute HCl and DCM. The 
precipitate was collected by filtration, dissolved in ethyl 
acetate and dried. Evaporation of the solvent gave the title 
compound as a pale brown solid. 
Synthesis 89 
3-( 4-Bromophenylsulfonamido )-2-methylbenzoyl 
chloride (ABD882c) 
[1011] 
[1012] ABD880d (4 g) was suspended in toluene (30 mL) 
and refluxed in the presence of thionyl chloride (10 mL) 
overnight. The solvents were evaporated to give the title com­
pound as a pale yellow oil which solidified on standing. 
Synthesis 90 
3-( 4-Bromophenylsulfonamido )-N,N-diethyl-2-me­
thylbenzamide (ABD882b) 
[1013] 
[1014] ABD880c (1 g) was dissolved in THF (20 mL) and 
chilled to 0° C. Diethylamine ( 4 ml) was added and a precipi­
tate formed. The mixture was stirred for a further 4 hours, 
poured into dilute HCl and extracted with ethyl acetate. The 
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organic was washed with water, dried and evaporated to give 
an oil. Trituration with ether gave the title compmmd as a 
white powder. 
Synthesis 91 
3-(2' ,4'-Difluorobiphenyl-4-ylsulfonamido )-N,N­
diethyl-2-methylbenzamide (ABD882a) 
[1015] 
F 
F 
[1016] Using a method analogous to Method B, using 
ABD882b and 2,4-difluorobenzene boronic acid, the title 
compound was obtained as a pale brown solid. 1H NMR
(DMSO-d6): b 0.84 (3H, t, 1=7.0 Hz), 1.07 (3H, t, J=7.0 Hz), 
1.82 (3H, s), 2.81 (lH, m), 2.95 (lH, m), 3.22 (lH, m), 3.58 
(lH, 111), 7.00 (lH, d, J=7.3 Hz), 7.11 (lH, d, 1=7.6 Hz), 7.18 
(lH, d, 1=7.6 Hz), 7.24 (lH, d, J=7.6 Hz), 7.41 (lH, t, J=9.l 
Hz), 7.62 (lH, q, J=8.5 Hz), 7.72 (4H, 111) and 9.83 (lH, s). 
Synthesis 92 
N-(3-((Diethylamino)methyl)-2-methylphenyl)-2',4'­
difluorobiphenyl-4-sulfonamide (ABD882) 
[1017] 
F 
F 
[1018] ABD882a (0.5 g) was dissolved in dry THF and 
stirred at room temperature under N2. LiAIH4 l M in THF (5 
mL) was added and the mixture stirred overnight, by which 
time all of the starting material had been consumed. Saturated 
NH4Cl (20 mL) was added slowly and the mixture extracted 
with ethyl acetate and dried. Purification by column chroma­
tography gave the title compound as a pale brown oil. 13C 
NMR (DMSO-d6): b 11.4, 13.1, 46.1, 55.9, 104.8, 112.3, 
116.0, 123.4 (dd, J=l2.7, 3.9 Hz), 125.6, 127.0, 128.3, 129.5, 
132.2, 134.3, 134.8, 138.3, 139.1, 139.9, 159.2 (dd, 1=250.0, 
12.7 Hz)and 162.3 (dd, 1=248.0, 11.7 Hz). 1H NMR(DMSO­
d6): b 0.88 ( 6H, t, J=7 .0 Hz), 2.00 (3H, s ), 2.95 ( 4H, q, J=7 .0 
Hz), 3.38 (2H, hidden), 6.90 (lH, d, J=7.9 Hz), 7.03 (lH, t, 
J=7.9 Hz), 7.13 (lH, d, J=7.0 Hz), 7.21 (lH, t, J=7.9 Hz), 7.39 
(lH, t, J=9.l Hz), 7.70 (5H, m) and 9.65 (lH, s). 
Biological Methods 
[1019] Initial screening of candidate compounds was per­
formed using in vitro assays to determine potency, metabolic 
stability and solubility in biologically relevant fluids. Potency 
was assessed using a viability assay based on the survival of 
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the 1774 macrophage cell line. Macrophages are closely 
related to osteoclasts and have been used previously as a 
model system for osteoclast survival (see, e.g., Luckman et 
al., 1998). Like osteoclasts, 177 4 macrophages are dependent 
on continued NFKB activation for survival, thereby providing 
a valuable screen for compounds with anti-inflammatory 
activity. Metabolic stability was measured by determining the 
rate of disappearance of compound in the presence of human 
liver microsomal preparations, as quantified by LC-MS/MS. 
Solubility was measured by equilibration of the compound in 
fasted state simulated intestinal fluid (FaSSIF) and quantified 
by HPLC. 
Alamar Blue Macrophage 1774 Viability Assay 
[1020] In vitro potency as anti-inflammatory agents was 
determined for a number of APSAP compounds by incuba­
tion with 177 4 macrophages and subsequent determination of 
cell viability. 
[1021] 1774 cells were plated at 104 cells per well in 100 µL 
aMEM (a Modified Eagle Medium) in 96-well plates and 
grown overnight. The next day, test compounds were added to 
the cultures, and cultures were continued for another 72 
hours. At the end of the culture period, cell survival was 
determined using an Alamar Blue assay as previously 
described (see, e.g., Nociari et al., 1998). 
[1022] Alamar Blue is an oxidation-reduction sensitive 
indicator. The dye itself is in the oxidised state, which is blue 
and non-fluorescent. The dye can accept electrons from 
reducing species, such as NADPH and FADH, to form a 
reduced dye species, which is red and fluorescent. Thus the 
transformation from oxidised form to reduced form can be 
measured by fluorimetric or colourimetric means. For fluo­
rescence measurements, 530-560 11111 excitation and 590 nm 
emission wavelengths are typically used. For colourimetric 
measurements, absorbance at 570 lll11 (reduced form) and 600 
nm (oxidised fom1) is typically measured. A simple calcula­
tion is performed to detennine the relative quantities of the 
two species. 
[1023] A high ratio of the reducing species, NADPH and 
FADH, to the corresponding oxidised species, NADP and 
FAD, is an indicator that cells are proliferating and viable. A 
low ratio indicates cells that are quiescent or non-viable. 
(1024] Briefly, A.lamar Blue (Biosource International) was 
added undiluted to each well (1: 10 v/v, 10 µL). The plate was 
incubated at 37° C. for 3-4 hours and the fluorescence was 
measured at 590 lll11, with a 25 11111 bandwidth. A high reading 
indicated cells with normal viability, and a low reading indi­
cated cells that have been damaged and are no longer prolif­
erating normally. The controls gave a high fluorescence read­
ing, indicating a high number of live, healthy cells. A potent 
test compound gave a low fluorescence reading. 
(1025] The average results for each test compouud 
were expressed as a percent(%) of the average control value. 
[1026] Addition of Compounds. All of the compmmds 
studied were made up as 100 mM solutions in DMSO. These 
stock solutions were then diluted 1000-1 OOOOx in culture 
medium (aMEM). From these 100 �tM or 10 µM solutions, 
convenient quantities (3-33 µL) were added directly to the 
wells so as to give the desired final compound concentration. 
(1027] This assay offers numerous advantages over other 
assays, including MTT assays: it permits a higher throughput; 
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it is more sensitive; it is non-damaging to the cells; it is faster; 
and it generally gives an identical result to MTT assays. 
Aqueous Solubility Measurements 
[1028] Thermodynan1ic aqueous solubility was measured 
by equilibration of a number of APSAP compounds, in the 
solid state, with fasted state simulated intestinal fluide (FaS­
SIF) and quantified by HPLC. Measurement of solubility in 
FaSSIF provides a valuable model for the prediction of drug 
dissolution following oral administration. 
(1029] FaSSIF was prepared as described below: 
[1030] Preparation of blank FaSSIF: NaOH pellets (174 
mg), NaH2P04.2H20 (2.235 g), and NaCl (3.093 g) were 
dissolved in 500 mL of water. The pH was adjusted to 6.5 
using 1 M NaOH solution. 
[1031] Preparation of FaSSIF: Sodi1m1 taurocholate (165 
mg) was dissolved in 25 mL blank FaSSIF. 0.6 mL of a 
solution containing 100 mg/mL lecithin in methylene chlo­
ride was added. The methylene chloride was eliminated under 
vacuum at about 40° C. The vacuum was drawn for 15 min­
utes at 250 mbar, followed by 15 minutes at 100 mbar. T11is 
resulted in a clear, micellar solution, having no perceptible 
odour of methylene chloride. After cooling to room tempera­
ture, the solution was then adjusted to 100 mL with blank 
FaSSIF. 
(1032] Aqueous solubility was determined by suspending 
separately sufficient compouud in the FaSSIF to give a maxi­
mum final concentration of � 10 mg/mL of the parent free­
form of the compound. The suspension was equilibrated at 
25° C. for 24 hours, and then the pH was measured. The 
suspension was then filtered through a glass fibre C filter into 
a 96-well plate. The filtrate was then diluted by a factor of 
100. Quantification was made by HPLC with reference to a
standard solution of compouud at approximately 0.1 mg/mL
in DMSO. Different volumes of the standard, diluted and
undiluted sample solutions were injected. The solubility was
calculated using the peak areas determined by integration of
the peak found at the same retention time as the principal peak
in the standard injection. Detection conditions are shown in
the table below. Analysis was performed on an Agilent
HPl lOO series system equipped with a diode array detector
and using ChemStation software vB.02.01-SRl .
TABLE 1 
HPLC Method Parameters for Solubility Measmements 
Type of method: 
Column: 
Colurrm 
Temperature(' C.): 
Standard Injections 
Test Injections 
Detection: Wa,•eler,gth, 
Bandwidth (nm): 
Flow Rate (mL/min): 
Phase A: 
Phase B: 
Timetable: 
Reverse phase with gradient elution 
Phenomenex Luna, C18 (2) 5 µm 50 x 4.6 mm 
25 
1,2,3,5, 7, 10 
1, 2, 3, 10, 20, 50 
260, 80 
0.1% TFA in water 
0.085% TFA in acetonitrile 
Time(min) % Phase A 
0.0 95 
1.0 80 
2.3 5 
3.3 
3.5 95 
4.4 95 
% Phase B 
5 
20 
95 
95 
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Human Liver Microsomal Stability Assay 
[1033] Metabolic stability of APSAP derivatives was mea­
sured by detennination of the rate of compound disappear­
ance when incubated in the presence of human liver 
microsomes. Liver microsomes are prepared from the endo­
plasmic reticulum of hepatocytes and are the primary source 
of the most important enzymes (cytochrome P450) involved 
in drng metabolism. Study of drng stability in the presence of 
liver microsomes is accepted as a valuable model permitting 
rapid prediction of in viva drng stability. 
Protocol Sunmrnry: 
[1034] Human liver microsomcs were obtained from a 
commercial source. Test compounds (3 µM) were incubated 
with pooled liver microsomes (male and female). Samples 
were incubated for a 45 minute period and removed at 5 time 
points and test compounds were analysed by LC-MS/MS. 
[1035] Microsomes (final protein concentration 0.5 
mg/mL), 0.1 M phosphate buffer pH 7.4, and test compound 
(final concentration 3 µM; diluted from 10 mM stock solution 
to give a final DMSO concentrationof 0.25%) were incubated 
at 37° C. prior to the addition ofNADPH (final concentration 
1 mM) to initiate the reaction. The final incubation volume 
was 25 µL. A control incubation was included for each com­
pound tested, where 0.1 M phosphate buffer pH 7.4 was 
added instead ofNADPH. The control compounds testoster­
one and 7-hydroxycoumarin were included in each experi­
ment and all incubations were perfonned singularly for each 
compound. 
[1036] Each compound was incubated for 0, 5, 15, 30, and 
45 minutes. The control (minus NADPH) was incubated for 
45 minutes only. The reactions were stopped by the addition 
of 50 µL methanol containing internal standard at the appro­
priate time points. The incubation plates were centrifoged at 
2500 rpm for 20 minutes at 4 ° C. to precipitate the protein. 
Quantitative Analysis: 
[1037] Following protein precipitation, the sample super­
natants were combined in cassettes of up to 4 compounds and 
analysed using standard LC-MS/MS conditions. 
Data Analysis: 
[1038] From a plot of the natural logaritlun of the peak area 
ratio (i.e., the ratio of compound peak area:internal standard 
peak area) against time, the gradient of the line was deter­
mined. Subsequently, half-life and intrinsic clearance were 
calculated using the equations below: 
Eliminated rate constant(k)=(-gradientJ. 
Halflife(t1d(minJ=0.063/k. 
Intrinsic Clearance(CL;"')(µL/min/million cells)=(Vx 
0.693)/tl/2. 
wherein V=Incnbation volnme(µL/mg microsomal 
protein). 
Pharmacokinctics Studies 
[1039] Absorption and metabolic stability were studied 
using an in viva pham1acokinctics assay. Drng levels were 
assessed using ultra-performance LC/TOF-MS. 
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(1040] Three male Sprague-Dawley rats, 200-300 g, were 
dosed per route. Test compmmd was administered either 
orally or intravenously ( dose level of 1 mg/kg body weight). 
Test compound was formulated in 50:50 tetraethylene glycol: 
PBS for both routes. Animals were given free access to food 
throughout the study. On the day prior to dosing, the carotid 
artery was cannulated for sample collection and for the intra­
venous study, the jugular vein was cannulatcd to enable dos­
ing. 
(1041] Blood samples were taken from the carotid artery at 
the following time points and placed in heparinised tubes: 
Oral dosing-predose. 0.25. 0.5, 1, 2, 4. 8 and 24 hours post 
dose. 
IV dosing-predose, 0.08, 0.25, 0.5, 1, 2, 4 and 8 hours post 
dose. 
(1042] After the final time point, the animals were sacri­
ficed by an overdose of anaesthetic. 
[1043] Blood samples were centrifoged to obtain plasma, 
which was transferred to a separate container and frozen at 
-20° c.
Sample Preparation: 
(1044] Samples were thawed at room temperature and pre­
pared by protein precipitation with acetonitrile in the ratio 1 :2 
with plasma, followed by centrifogation for 10 minutes at 
16, lOOxg (Eppendorf 5415D, Eppendorf AG, Hamburg, Ger­
many). The supematants were collected for analysis. The 
standard samples were prepared similarly. after spiking blank 
rat plasma samples to study compound concentrations at 1, 2, 
5, 10, 20, 50, 100, 200, 500 and 1000 ng/mL. In addition, 
extra samples were prepared from 0-1 hour i.v. samples by 
diluting 1/20 with 50% aqueous acetonitrile to avoid exceed­
ing the linear range of the analytical method. 
Analytical Methods: 
(1045] A Waters Acquity liquid ultra-perfomrnnce chro­
matographic system (Waters Corp., Milford, Mass., USA) 
with autosampler, vacuum degasser and colllllln oven was 
used. The analytical cohmm used for all compounds was a 
Waters BEH C18, (2.lx50 mm, 1.7 �nn, Waters Corp, Mil­
ford, Mass., USA) together with a 0.2 µ111 on-line filter before 
the colllllln. The eluents were 0.1 % acetic acid (A, pH 3.2) 
and methanol (B). Gradient elution from 5% to 60% B in two 
minutes was employed, followed by one minute gradient to 
90% B and column equilibration. The flow rate was 0.5 
mL/min and the colllllln oven temperature was 35° C. The 
flow was directed to the MS via Water Acquity photo-diode­
array (PDA) detector. LC/TOF-MS data were recorded with a 
Micromass LCT Premier XE time-of-flight (TOF) mass spec­
trometer (Micromass Ltd., Manchester, England) equipped 
with a LockSpray electrospray ionization source. A positive 
ionization mode of electro spray was used for all compounds. 
The mass range of m/z 100-900 was acquired. The W-option 
of the reflector was used, and the DRE (dynamic range 
enhancement) option was set to on. The mass spectrometer 
and HPLC system were operated under Micromass MassL­
ynx 4.1 software. Leucine enkephalin ([M+Ht m/z 556. 
2771) was used as a lock mass compound for accurate mass 
measurements and was delivered into the LockSpray probe 
with a syringe pmnp. Masslynx 4.1 software was used for 
controlling the instrnmentation and for data processing. 
Calculations: 
[1046] The pharmacokinetic parameters for the test com­
pounds were calculated by WinNonlin Pro (Pharsight Corp, 
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C A) using standard noncompartmental methods. The elimi­
nation phase half-life (t!/2) was calculated by least -squares 
regression analysis of the terminal linear part of the log con­
centration-time curve. The area under the plasma concentra­
tion-time curve (AUC) was determined by use of the linear 
trapezoidal rule up to the last measurable concentration and 
thereafter by extrapolation of the tenninal elimination phase 
to infinity. The tentative oral bioavailability (F) was calcu­
lated by dividing the AUC (0-24 hours) after p.o. administra­
tion by the AUC (0-8 hours) a±ter i.v. administration, i.e., 
F=AUC(p.o.)/AUC(i.v), and reported as percentages(%). 
Biological Data 
Biological Study 1 
[1047] The biological activity of a nmnber ofAPSAP com­
pmmds was determined and compared with the biological 
activity ofa range of structurally related compounds using the 
assays described previously. 
[1048] IC50 values were detem1ined for several APSAP 
compounds, as well as several reference compounds, using 
the Alamar Blue macrophage J77 4 viability assay described 
above. The results are smnmarised in the following tables. 
TABLE2 A 
Alamar Blue Macrophage J774 Viability Assay Data 
(Reference Compounds) 
Compound R''2 RX4 Q R ICso(µM) 
ABD527 F F 5-CH20H 6-Me 0.08 
ABD565 F F 5-CHpH 4-CH20H 0.15 
ABD585 F F 5-CH20H 2-0H 0.20 
ABD456 F F 5-CH20H 0.25 
ABD575 F Cl 5-CH20H 0.40 
ABD455 Cl Cl 5-CH20H 0.50 
ABD446 Br H 5-CH20H 2.5 
ABD466 F F 4-CH20H 3.0 
ABD612 Cl Cl 5-COOH >50
TABLE2B 
Alamar Blue Macrophage J774 Viability Assay Data 
Compound R'2 R·'4 
ABD707 Cl Cl 
ABD708 Cl Cl 
ABD709 Cl Cl 
ABD766 Cl Cl 
Q 6 5 
II --cxQ
�-� \ )4 o 2 I 3 
Q R IC5o(r1M) 
5-C(MehOH 0.09 
5-CH(Me)OH 0.18 
5-C( cycloprop-1,1-di-yl)OH 0.38 
5-CH(CF3)0H 0.71 
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TABLE2C 
Alamar Blue Macrophage J774 Viability Assay Data 
R:'2 
0 6 5 
II -co
RX4 g-� \ 1 4
R 
Compound RD RX4 Q R IC50 (µM) 
ABD788 F F 5-CH2NH2 1.00 
ABD724 Cl Cl 5-CH2NMe2 0.30 
ABD783 F F 5-CH(OH)CH2NHMe 1.18 
ABD784 F F 5-CH(OH)CH2NMe2 1.43 
ABD785 F F 5-CH(OH)CHTmorpholino 4.71 
ABD789 F F 5-CH(NHMe )CH20H 0.14 
ABD791 F F 5-CH(NMe2)CH20H 0.57 
ABD792 F F 5-CH(morpholino )CH20H >30 
ABD810 F F 5-CH(R-NHMe)CH20H 1.02 
ABD811 F F 5-CH(S-NHMe)CH20H 0.35 
ABD854 F F 5-CH(R-NH2)CH20H 1.35 
ABD855 F F 5-CH(S-NH2)CHpH 0.86 
ABD862 F F 5-CH(NH2)(CH3)CH20H 2.43
ABD751 Cl Cl 5-S02NH2 0.87 
[1049] These data demonstrate that it is possible to modify 
the benzyl alcohol (i.e., where Q is -CH20H), by way of 
further substitution on the methylene group, optionally with 
extension of the methylene group to an ethylene group; by 
replacement of the alcohol with an amine; or by a combina­
tion of these; without a loss of potency. The data also dem­
onstrate that this replacement is neither trivial nor predictable 
and can lead either to an increase or a decrease in potency. 
Biological Study 2 
[ 1050] The metabolic stability of a number of APSAP com­
pounds was determined and compared with the metabolic 
stability of a range of structurally related compounds using 
the assays described previously. 
[1051] Biological half-life values (tl/2) were determined 
for several APSAP compom1ds, as well as several reference 
compounds, using the human liver microsomal stability assay 
described above. The results are su111l11arised in the following 
tables. 
Compound 
ABD446 
ABD455 
ABD456 
ABD466 
ABD527 
ABD565 
TABLE3A 
Human Liver Microsomal Stability Data 
(Reference Compow1ds) 
RX2 RX4 Q R 
H Br 
Cl Cl 
F F 5-CH20H 
F F 4-CH20H 
F F 6-Me 
F F 4-CH20H 
Tw(min) 
42 
28 
30 
2 
20 
14 
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Compound 
ABD575 
ABD585 
ABD625 
ABD628 
ABD630 
ABD612 
ABD746 
R'f4 
Compound 
ABD707 
ABD708 
ABD709 
ABD766 
Compound 
ABD788 
ABD724 
ABD728 
ABD730 
ABD783 
ABD784 
ABD785 
ABD789 
ABD791 
ABD792 
ABD855 
ABD751 
TABLE 3 A-continued 
Human Liver Microsomal Stability Data 
(Reference Compounds I 
RX2 RX4 
F Cl 
F F 
Cl Cl 
F F 
H Br 
Cl Cl 
Cl Cl 
O 6 5 
II --cxQ�-� \ )4
o 2 I 3 
Q (min) 
5-CH20H 
5-CH20H 2-0H 38 5-CH2CH20H 13 5-CH2CH20H 18 5-CH2CH20H 43 5-COOH Stable 
5-COCH3 11 
TABLE3B 
Human Liver Microsomal StabiliJ:Y Data 
R;a 
0 6 5 
II -coII-� \ )4
o 2 I 3 R 
Rx2 RX4 Q R T 1/2(min) 
Cl Cl 5-C(MehOH 12 
Cl Cl 5-CH(Me)OH 6 
Cl Cl -C( cycloprop-1,1-di-yl)OH 18 
Cl Cl 5-CH(CF3)0H 16 
TABLE3C 
Hrnnan Liver Microsomal StabiliJ:Y Data 
Rn RX4 
F F 
Cl Cl 
Cl Cl 
Cl Cl 
F F 
F F 
F F 
F F 
F F 
F F 
F F 
Cl Cl 
O 6 5 
II --cxQ�-� \ )4
o 2 I 3 
(min) 
60 
5-CONH2 34 5-CONMe2 15 5-CH(OH)CH2NHMe Stable 5-CH(OH)CH2NMe2 5-CH(OH)CH2-morpholino 5-CH(NHMe )CH pH Stable 
5-CH(NMe)2)CH20H 27 5-CH(morpholino )CH20H 2 5-CH(S-NH2JCH20H 289 5-S02NH2 46 
[1052] These data demonstrate that it is possible to modify 
the benzyl alcohol (i.e., where Q is ----CH20H), by way of 
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farther substitution on the methylene group, optionally with 
extension of the methylene group to an ethylene group; by 
replacement of the alcohol with an amine; or by a combina­
tion of these; without a loss of metabolic stability. The data 
also demonstrate that this replacement is neither trivial nor 
predictable and can lead either to an increase or a decrease in 
metabolic stability. Furthermore, the data show the excep­
tional stability imparted by the groups-CH(OH)CH2NHMe 
( e.g., as fmmd in ABD783) and----CH(NHR)CH20H ( e.g., as 
found in ABD789 and ABD855). 
Biological Study 3 
[1053] The solubility of a munber of APSAP compounds 
was determined and compared with the solubility of a range 
of structurally related compounds using the assays described 
previously. 
[1054] Solubility in the biological model fasted state simu­
lated intestinal fluid (FaSSIF) was determined for several 
APSAP compounds, as well as several reference compounds, 
using the aqueous solubility assay described above. The 
results are smnmarised in the following tables. 
TABLE4A 
Data 
RX2 
Compound RX2 RX4 Q 
ABD446 H Br 5-CH20H ABD455 Cl Cl 5-CH20H ABD456 F F 5-CH20H 
ABD466 F F 4-CH20H 0.04 ABD527 F F 5-CH20H 6-Me 0.04 ABD565 F F 5-CH20H 4-CH20H 0.03 ABD575 F Cl 5-CHpH 0.07 
ABD585 F F 5-CH20H 2-0H 0.07 ABD630 H Br 5-CH2CH20H 0.06 ABD615 Cl Cl 5-COOH 0.13 
ABD746 Cl Cl 5-COCH3 0.008 
TABLE4B 
Agueous SolubiliJ:Y Data 
RX2 
0 6 5 
II -coRX4 II-� \ )4 
o 2 I 3 R 
Solubility 
Compound R¥2 RX4 Q R (mg/mL) 
ABD707 Cl Cl 0.14 
ABD708 Cl Cl 0.10 
ABD766 Cl Cl 0.02 
ABD709 Cl Cl 5-C( cycloprop-1. 1-di-yl)OH 0.07 
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Compound R'2 
ABD788 F 
ABD724 Cl 
ABD728 Cl 
ABD730 Cl 
ABD783 F 
ABD784 F 
ABD785 F 
ABD789 F 
ABD791 F 
ABD792 F 
ABD855 F 
ABD751 Cl 
TABLE 4C 
Agueous Solubility Data 
R·';i Q 
F 5-CH2NH2 
Cl 5-CH2NMe2 
Cl 5-CONH2 
Cl 5-CONMe2 
F 5-CH(OH)CH2NHMe 
F 5-CH(OHJCH2NMe2 
F 5-CH(OH)CHrmorpholino 
F 5-CH(NHMe )CH20H 
F 5-CH(NMe2)CH20H
F 5-CH(m01pholino)CH20H 
F 5-CH(S-NH2)CH20H 
Cl 5-S02NH2 
0.02 
0.02 
0.37 
0.21 
0.52 
3.0 
4.4 
4.1 
0.04 
[1055] These data demonstrate that it is possible to modify 
the benzyl alcohol (i.e., where Q is --CH20H), by way of 
further substitution on the methylene group, optionally with 
extension of the methylene group to an ethylene group; by 
replacement of the alcohol with an amine; or by a combina­
tion of these; without a loss of aqueous solubility. The data 
also demonstrate that this replacement is neither trivial nor 
predictable and can lead either to an increase or a decrease in 
aqueous solubility. Furthermore, the data show the excep­
tional aqueous solubility imparted by the groups --CH(OH) 
CH2NHMe (e.g., as found in ABD783), --CH(NHMe) 
CH20H (e.g., as found in ABD789), --CH(NMe2)CH20H 
(e.g. as found in ABD791) and-CH(NH2)CH20H (e.g., as 
found in ABD855). 
Biological Study 4 
[1056] The oral absorption of the APSAP compound, 
ABD789, was determined in a rat model as described previ­
ously. 
ABD789 
[1057] Serum levels of ABD789, following oral or intrave­
nous dosage (1 mg/kg) (see FIGS. l and2 respectively), were 
investigated in viva in rats using an ultra-performance 
LC/TOF-MS detection system. as described previously. The 
pharmacokinetic data are summarised in the following table. 
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Bioavailability F % 
AUC (ng/mL/min) 
T1/2 (hJ 
TABLES 
Pharmacokinetic data 
ABD789 
(lmgikg) 
38 
p.a. i.v.
1500 11900 
3.17 0.81 
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Reference Compound 
ABD455 
(2.5 mg/kg) 
p.a. i.v. 
1.2 
0.8 
9 
0.53 
[1058] The data show that ABD789 is well absorbed fol­
lowing oral administration with a bioavailability (F) of 38% 
and an extended half life of 7 .67 hour, and is superior to the 
reference compound ABD455 (see FIGS. 3 and 4 and Table 
5). Thus, the APSAP compound, ABD789, demonstrates the 
properties required for an orally active drug. 
[1059] The foregoing has described the principles, pre­
ferred embodiments, and modes of operation of the present 
invention. However, the invention should not be construed as 
limited to the particular embodiments discussed. Instead, the 
above-described embodiments should be regarded as illustra­
tive rather than restrictive, and it should be appreciated that 
variations may be made in those embodiments by workers 
skilled in the art without departing from the scope of the 
present invention. 
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234. A componnd selected from compmmds of the follow­
ing formula, and pharmaceutically acceptable salts thereof: 
wherein: 
-A is:
-Ar is independently phenyl, pyridinyl, or pyrimidinyl;
p is independently an integer from Oto 3; 
q is independently an integer from Oto 3; 
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-R'N is independently -H or saturated
C 1_4alk-yl; 
-RS! is independently -H or saturated
C 1_4alkyl; 
RS2 is independently H or saturated
C 1_4alkyl; 
-RS3 is independently -H or saturated
C 1_4alkyl;
-R'4 is independently -H or saturated
C 1_4alk-yl;
-Q is independently:
either: 
each -R IN is independently -H or -R eN; 
each -R2N is independently-H or -R eN; and 
each -R eN is saturated aliphatic C1_4alkyl; 
or: 
aliphatic 
aliphatic 
aliphatic 
aliphatic 
aliphatic 
-NRLvR2N is independently azetidino, pyrrolidino, imi­
dazolidino, pyrazolidino, piperidino, piperazino, mor­
pholino, thiomorpholino, azepino, or diazepino, each
optionally substituted with one or more groups selected
from saturated aliphatic C 1_4alkyl;
is independently -H, -Re, or , and 
-R 2A is independently -H, -Re, or -RF;
or and together fonn a saturated aliphatic 
C2_4alkylene group; 
-R3A is independently-Re, -RF, or -RJ; and
-R4A is independently -H, , or -RF; 
or -R3A and -R4A together form a saturated aliphatic 
C2_4alk')'lene group; 
-RsA is independently-Re or -RF; and 
-R 6A is independently -Re, or -RF;
or -RsA and -R6A together fom1 a saturated aliphatic 
C2_4alk-ylene group; 
-RIB is independently-II, -Re, or -RF; and
-R 2B is independently -H, -Re, or -RF;
or -RIB and together form a saturated aliphatic 
C2_4alkylene group; 
-R3B is independently -Re, -RF, ---OH, or
---OR0· and
-R4B is i�dependently -H. -Re. or -RF;
or -R3B and -R4B together form a saturated aliphatic 
C2_4alk-ylene group; 
-RsB is independently-H, or -RF; and 
-R6B is independently , or-RF; 
or -RsB and -R6B together fom1 a saturated aliphatic 
C2_4alkylene group; 
each-Re is saturated aliphatic C 1_4alk-yl; 
each -RF is saturated aliphatic C 1_iluoroalk-yl; 
-R0 is saturated aliphatic C 1_4alk-yl;
-RJ is independently -NH2, -NHR
JN1
, -NRJNI 2, or
-NRJN2RJN3;
each -R.JN1 is independently -RJ1, -R.12-0H,
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each -R.11 is saturated aliphatic C 1_4alk')'l; 
each -R.12 - is saturated aliphatic C2_4alk-ylene; 
-NRJN2RJN3 is independently azetidino, pyrrolidino, imi-
dazolidino, pyrazolidino, piperidino, piperazino, mor­
pholino, thiomorpholino. azepino, or diazepino, each
optionally substituted with one or more groups selected
from saturated aliphatic C1_4alk-yl;
each -Rx is independently --Cl, -Br, -I, -Rxx, 
---OH, -ORxx, -SH, -SRxx, --CF3, ---OCF3, 
-SCF3, -NH2, -NHR
=, -NRxx2, -NR
rrR22,
--C(=O)R1::\ -OC(=O)Rn·, --C(=O)OH,
--C(=O)ORi:'.Y, -C(=O)NH2, -C(=O)NHR
=. 
--C(=O)NR=2, -C(=O)NR
rrR22, -OC(=O) 
NH2, ---OC(=O)NHR
u, -OC(=O)NR
x\, ---OC 
(=0)NR1TR22, -NHC(=O)R=, -NR=C(=O) 
R=, -NHC(=O)OR=, -NRuC(=O)OR
x,·, 
-NHC(=O)NH2, -NHC(=O)NHR
xY, -NHC 
(=O)NR=2, -NHC(=O)NR
rrR22, -NR=C(=O)
NH2, -NR
i:'.YC(=O)NHR=, -NR=C(=O)NR=2,
-NR=C(=O)NRrrR22, --CN, -N02, -S(=O)
2NH2, -S(=0)2NHR
1:'.Y, -S(=0)2NR
=
2, -S(=O) 
2NR
rrR22, -S(=O)R=, -S(=0)2R
xY, ---OS(=O) 
2R
=, -S(=O\OH. or -S(=0) 20R
=; 
each -R= is independently saturated aliphatic C 1_6alkyl, 
phenyl, or benzyl, wherein said phenyl and benzyl are 
optionally substituted with one or more groups selected 
from: --Cl, -Br, ---OCF 3, -R
xi:'.Y, 
---OH, ---ORxrr, or , wherein each -R= is 
independently saturated aliphatic C 1_4alkyl; and each 
-NR rrRzz is independently azetidino, pyrrolidino,
imidazolidino, pyrazolidino, piperidino, piperazino,
morpholino, thiomorpholino, azepino, or diazepino,
each optionally substituted with one or more groups
independently selected from saturated aliphatic
C 1_4alkyl.
235. A compound according to claim 234, wherein -Ar is 
phenyl. 
236. A compound according to claim 234, wherein -A is:
wherein: 
-R'Y2 is independently -H or -R'Y25;
-Rx4 is independently -H or -Rx4s;
-R:r:2s is -Rx . and
-Rx4sis
237. A compound according to claim 234, wherein -A is:
wherein: 
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-Rx2s is -Rx; and
-Rx4s is -Rx.
238. A compound according to claim 237, wherein:
each -R"" is independently -F, -Cl, -Br, -I, -Ru,
-DH, -OR,u, -SH, -SR,u, -OCF3, -SCF3, -NH2, -NHR'LY, -NRx\, -NRrrR22,
--C(=O)R,cr, -DC(=O)R=, -C(=O)OH, 
--C(=O)OR=, -C(=O)NH2, --C(=O)NHRxx, 
--C(=O)NR=2, --C(=O)NRn-R22, -N02,
-S(=0) 2NH2, -S(=0)2NHR=, -S(=0)2NR=2,or-S(=0)2NRnTR22; and
each-NR rrR22 is independently pyrrolidino, piperidino, 
piperazino, or morpholino, each optionally substituted 
with one or more groups selected from saturated ali­
phatic C1_4alkyl. 
239. A compound according to claim 237, wherein:
is independently Cl, Br, RxA,
-0Rx1, -SRxA, -CF3, or -DCF3 , wherein each-R'':4 is saturated aliphatic C1 _4alk-yl; and
is independently -Br, , 
-DR't:4, -SRxA, -CF3, or wherein each -RxA is saturated aliphatic C1 _4alkyl.
240. A compound according to claim 237, wherein:
-RX2s is independently -F or -Cl; and
is independently -F or --Cl. 
241. A compound according to claim 240, wherein the
leading phenylene group: 
is: 
wherein: 
-Rxci is independently -H or -Rxcc; and
-Rxc2 is-H;
or: 
is-H;and 
-R'Yc2 is independently-H or -Rxcc;
or: 
-Rxci is -H; and
is 
wherein each -R'YCc is independently 
ccc; 
wherein each-Rxccc is independently -Me or -Et. 
242. A compound according to claim 241, wherein:
either:
each -R lN is independently -H or -R cN;
each -R2N is independently-H or -R cN; and
each -R cN is saturated aliphatic C1_4alkyl;
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or: 
-NR1NR2iv is independently piperidino, piperazino, or
morpholino, each optionally substituted with one or
more groups selected from saturated aliphatic C1_4alk-yl;is independently H or , 
-R 24 is independently -H or -R c; 
-R3A is independently -R c or -RJ;
-R4A is independently-H or -R c;
-R54 is-Rc·
-RGA is indep�ndently -H or -R c;
-R !B is independently -H or -R c.is independently -H , 
-R3B is independently -H, -R c, -OH, or -OR 0;
-R4B is independently-H or -R c;
-R5B is independently-H or -R c;
-R GB is independently -H or -R c;
each is saturated aliphatic C1 _4alkyl; -RO is saturated aliphatic C1_4alk-yl;is independently -NH2, -NHRIN1, -NRIN1 2, or -NRIN2RIN3;
each is , 
each-RJ1 is saturated aliphatic C1 _4alkyl; -NRIN2R.IN3 is independently piperidino, piperazino, or
morpholino, each optionally substituted with one or
more groups selected from saturated aliphatic C1_4alkyl.
243. A compound according to claim 241, wherein:
either:
each -R IN is independently -H or -R cN;
each -R 2N is independently -H or -R cN;
each -R cN is saturated aliphatic C1_4alkyl;or:
-NR1NR2N is independently piperidino, piperazino, or
morpholino, each optionally substituted with one or
more groups selected from saturated aliphatic C1_4alkyl;-R1A is-H;
is 
-R3A is
-R4A is
-R5A is
-RGA is indep�ndently -H or -R c;
is 
-R2B is
is independently -OH or -OR 0;
-R4B is-H;
is-H; 
-R6B is-H;
each -R c is saturated aliphatic C1 _4alkyl;
is saturated aliphatic C1_4alk-yl; 
is independently -NH2, -NHRIN1, -NR""'1 2, or -NRIN2R.IN3;
each -RIN1 is -RJ1; 
each -RJ1 is saturated aliphatic C1 _4alk-yl; 
-NRJ7\'2RJ7\s is independently piperidino, piperazino, or
morpholino, each optionally substituted with one or
more groups selected from saturated aliphatic C 1_4alkyl.
244. A compound according to claim 243, wherein -Q is
independently: 
r-r r r-rB rB /RJN 
C-C-OH, C-C-N , 
I I I I \ R4A R2A R4B R2B R2N 
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-continued
t
O R !N 
t
RSB R!N 
II I I 1 
S-N , or C-N . 
g \2N i6B \2N 
245. A compound according to claim 243, wherein -Q isindependently: 
trA rA or ti·JB rB /R!N 
C-C-OH C-C-N 
I I I I \ 
R4A R2A R4B R2B R2N 
246. A compound according to claim 245, whereinis-H. 
247. A compound according to claim 246, wherein:-R51 is-H;is 
is-H;and 
-R54 is-H.
248. A compound according to claim 234, wherein:
-Ais:
is independently -F or -Cl; 
-Rx4 is independently -F or -Cl;
the leading phenylene group:
is: 
wherein: 
-Rxci is independently-H or -Rxcc; and
is 
or: 
-Rxci is -H; and
is independently -H or -Rxcc; 
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249. A compound according to claim 248, wherein:-Rx2 is-F;is -Rxc1 is-H'-Rxcz is -H'. and-RJ is indepe�dently-NH 2 , -NHMe, or -NMe2 .
250. A compound according to claim 234, wherein:-Ais:
-Rx2 is independently -F or --Cl;-Rx4 is independently -F or --Cl;the leading phenylene group:
is: 
wherein: -Rxci is independently -H or -Rxcc; and-R"c2is-H;or: -Rxci is -H' andis indei,endently -H or -Rxcc; 
US 2011/0190302 Al 
or:
-Rxci is -H; and
is
each -Rxcc is -Rxccc;
each is -Me;
-RsN is-H or -Me;
-Rs1 is-H;
is-H;
-Rs3 is-H;
-Rs4 is-H;
-Q is:
-R1B is
is 
-R3B is independently -OH or -OR 0;
-R4B is-H;
each is independently -H or -R cN; and
each -R 2N is independently -H or -R cN_ 
251. A compound according to claim 250, wherein:
-Rx2 is 
-Rx4is 
is-H;
is
-R3B is -OH; and
each -R cw is -Me.
252. A compound according to claim 234, wherein:
-Ais:
-R"':l is independently -F or -Cl;
is independently -F or -Cl;
the leading phenylene group:
is:
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wherein:
-Rxci is independently -H or -Rxcc; and
-Rxc2 is-H;
or:
-R"n is -H- and 
-Rxc2 is inde�endently -H or -Rxcc;
or:
is and
-Rxc2 is
each -Rxcc is -Rxccc;
each-Rxccc is -Me;
is-H or-Me;
-R'1 is
-RS2 is-H;
-Rs3 is-H;
is
-Q is:
-R1N is independently-H or-Rew; and
R2N is independently Hor RcN_ 
253. A compound according to claim 252, wherein:
-R IN is -H- and
-Rm is-H'.
254. A compound according to claim 234, wherein:
-Ais:
-Rx2 is independently -F or �l;
-R"4 is independently -F or �1;
the leading phenylene group:
is:
wherein:
is independently H or
-Rxc2is-H;
or:
-R"c1 is -H; and
is independently -H or -Rxcc;
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or: 
is and 
-
R'YC2 is -H;
xcc· Rxccc.each-R is-
each is -Me; 
-RsN is-H or -Me;
is 
-Rs2 is-H;
-Rs3is-H;
is 
-Q is:
�
R5B RIN. 
I ; 
, 
C-N 
I \ 2N R6B R 
-RsB is-H;
-R6B is-H;
-R IN is independently -H or -R 
cN; and
RCN -R 2N is independently -H or - ·
255. A compound according to claim 254, wherem:
-Rxc1 is
-Rxc2 is -H; and
each -R cw is -Me.
256 A compound according to claim 1, selected from the 
1 
·: 
pounds and phamrnceutically acceptable salts fol owmg corn 
thereof: 
Cl 
Cl 
Cl 
(ABD707) 
0� 
II H 
S-N 
II � OH, 
o I
# 
(ABD708) 
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Cl 
Cl 
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-continued
(ABD723) 
II H 
r
N
l)
( 
(ABD751) 
(ABD758) 
0 0 0 
�-�vV( 
II "¾ NH2, 
o I 
# 
(ABD760) -0-0-Cl 
O o o 
F 
� I ' 
�-�uY(o
# 
(ABD766) 
Cl �-�
 Cl II "'l OH, 
o I
# 
Cl 
� H
ef
CF3 
S-N
II � OH. 
o I
# 
Cl 
Cl 
(ABD709) 
0� 
II H 
S-N
II � OH. 
o I
# 
(ABD782) -0-0-F 
� 
H
�
OH 
NH2,S-N "¾ F 
� I 
# 
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-continued (ABD783) 
-0-0-F O OH F 
�
-� �
'-...
, o I
# 
(ABD784) 
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-continued (ABD792J 
F 
(0) 
F-o-o-, f ' �-� N OH, -
II I - 0 
# 
Cl (ABD805) 
0 0 0 -0--0-F o OH I F �-� N
'-,. 
Cl 
� I 
# 
�-�vY( II � NH2,o I 
# 
(ABD785) 
(ABD788) F 
F 
(ABD789) -0-0-F '-...NH F II "¾ �-� OH, o I
# (ABD790J -0-0-F LM
�
NH2 OH.F II "¾ o I 
# (ABD791) F '-,. / 
F r< n �-� N OH, 
--v---c;_ - g I 
# 
(ABD810) 
(ABD811J 
(ABD829) F 
0 II H 
F rNvu/ 
(ABD830) F 
F-0-Q-, f ' �-�vN�,- II I H - 0 
(ABD831) F 
F n n L�
Y"Y"
N� �- -�v�,
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-continued
(ABD832) 
(ABD833) Cl 
-0-o-�-�VN/· Cl II I I N 0 
# 
(ABD834) 
(ABD850) 
rl' §'. t�
�
'-..
NH 
OH, Cl-<c/-c;� i � 
# 
(ABD851) 
(ABD852) 
(ABD853) -O-o-c1 LMT'--Nir OH. Cl II � o I 
# 
(ABD854) 
71 
Aug. 4, 2011 
-continued
(ABD855) 
F 
F-0--0-i-M�oH 
(ABD857) 
M
F 
F\ O NHEt 
F�-j \-# J-M701! 
(ABD858) -0--0-F 
O HN
�OMe, 
II H 
OH F i-Nif 
F 
F 
Me 
(ABD859) 
�H2 
II H 
� OH 
r
N
� 
(ABD860) 
(ABD862) -0--0-F O NH2 
II H 
OH F 
r
N
if 
• 
F 
(ABD866) 
F 
0 0 0 
�-Mu'V( 
II � NH2, o I 
# 
(ABD867) 
MeOO-O-OMe 
O O 0 
�-� 'V( 
II u NH2. o I 
# 
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-continued
(ABD869) 
(ABD871) 
O O 0 -0-0-11 H \# 
Me S-Nvs....._
g I 
NH2, 
# 
F 
F 
F 
(ABD872) 
0 O 0 
c, j-*liY(m,, 
(ABD873) 
rlCI #'). 
LM \/ 
L;-U'-il V 
'mr,
(ABD875) 
F 
O O 0 
M
, 
[-*liY(NH,
(ABD879) 
O O 0 0-0-�-� V 
il 
V
'mr,
72 
Aug. 4, 2011 
-continued
(ABD880) 
,-0-0-I-Mlf N�, 
F 
(ABD881) 
F 
0 
M
, J-MuNM,, 
(ABD882) 
257. A pharmaceutical composition comprising a com­
pound according to claim 234 and a pharmaceutically accept­
able carrier, diluent, or excipient. 
258. A method of treatment of a disorder in a patient in need
of said treatment, comprising administering a therapeutically 
effective amount of a compound according to claim 234 to 
said patient, wherein said disorder is: 
an inflammatory disorder or an autoimmune disorder; 
a disorder associated with inflammation and/or activation 
of the immune system; 
a disorder mediated by excessive and/or inappropriate and/ 
or prolonged activation of the immune system; 
inflammation; 
a disorder associated with inflammation or activation of the 
immune system; 
rheumatoid arthritis; 
psoriasis; 
psoriatic arthritis; 
chronic obstructive pulmonary disease (COPD); 
atherosclerosis; 
ankylosing spondylitis; 
inflanmiatory bowel disease; 
an immune response leading to organ or graft rejection 
following transplant; 
a tumour which over expresses TNFa, IL-1, RANKL, or 
NFKB or in which inhibition ofTNF a, IL-1, RANKL, or 
NFKB facilitates or improves the action of cytotoxic 
tumouricidal agents; 
a haematological malignancy; 
US 2011/0190302 Al 
a haematological malignancy associated with activation of 
NFKB, with aberrant NFKB signalling, or with inflam­
mation; 
multiple myeloma, leukaemia, or lymphoma (e.g., non­
Hodgkin Lymphoma; 
multiple myeloma, leukaemia, or lymphoma ( e.g., non­
Hodgkin Lymphoma associated with activation of 
NFKB, with aberrant NFKB signalling, or with inflam­
mation; 
a solid tumour cancer; 
a solid tumour cancer associated with activation ofNFKB, 
with aberrant NFKB signalling, or with inflammation; 
cancer of the bladder, breast cancer (female and/or male), 
colon cancer, kidney cancer, lung cancer, pancreatic 
cancer, prostate cancer, brain cancer, skin cancer, thy­
roid cancer, or melanoma; 
cancer of the bladder, breast cancer (female and/or male), 
colon cancer, kidney cancer, lung cancer, pancreatic 
cancer, prostate cancer, brain cancer, skin cancer, thy­
roid cancer, or melanoma associated with activation of 
NFKB, with aberrant NFKB signalling, or with inflam­
mation; 
T-cell lymphoblastic lymphoma, mantle cell lymphoma, or
acute lymphoblastic leukemia;
a haematological malignancy associated with inactivation 
or impairment of caspase induction or with aberrant 
caspase signalling; 
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T-cell lymphoblastic lymphoma, mantle cell lymphoma, or
acute lymphoblastic leukemia associated with inactiva­
tion or impainnent of caspase induction or with aberrant
caspase signalling;
renal cell carcinoma, breast cancer (female and/or male), 
gastric cancer, prostate cancer, colon cancer, or basal 
cell ameloblastoma; 
a solid tumour cancer associated with inactivation or 
impainnent of caspase induction or with aberrant 
caspase signalling; 
renal cell carcinoma, breast cancer (female and/or male), 
gastric cancer, prostate cancer, colon cancer, or basal 
cell ameloblastoma associated with inactivation or 
impainnent of caspase induction or with aberrant 
caspase signalling; 
bone loss; 
joint destrnction; 
bone loss associated with rheumatoid arthritis, osteoporo­
sis, cancer-associated bone disease, or Paget's disease of 
bone; 
rheumatoid arthritis, osteoporosis, cancer-associated bone 
disease. or Paget's disease of bone; 
neoplasia of bones; or 
aseptic loosening of prosthetic implants. 
* * * * *
